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COMBATING MALIGNANT MELANOMA WITH THE MULTIFACETED SOY-DERIVED 
PEPTIDE LUNASIN 
Christopher P. Shidal 
April 24, 2017 
Lunasin is a 44 amino acid peptide that has been shown to have cancer chemopreventative and 
chemotherapeutic properties. This study investigated the potential utility of Lunasin as a chemotherapeutic 
in melanomas.  Studies showed that Lunasin had little activity against established melanoma cell lines 
using adherent culture methods; however, Lunasin’s in vitro activity was significantly higher in non-
adherent colony-forming assays and oncosphere formation. These results led to the investigation of whether 
or not Lunasin has selective effects on cancer initiating cells (CIC) that are known to be present in 
melanomas. It was revealed that Lunasin selectively inhibited the proliferation of high-ALDH expressing 
CICs, and prevented oncosphere formation. In vitro results were extended into mouse xenograft studies 
using parental cells and isolated CICs.  Lunasin significantly inhibited tumor growth in both cases, with the 
highest inhibition being observed in tumors initiated by CICs while achieving an excellent safety profile. 
Lunasin reduced the invasive potential of CICs in vitro and in an in vivo experimental metastasis model.  
Mechanistic studies revealed that Lunasin may disrupt integrin signaling by inhibiting phosphorylations of 
the intracellular kinase FAK as well as altering the PI3K/AKT axis.  Additionally, it was demonstrated that 
histone acetylation in H3 and H4 core histone are significantly altered in CICs treated with Lunasin.  While 
histone acetylation is potentially involved in Lunasin’s anticancer activity, the effects seen in these studies 
are mainly integrin-driven.  These studies demonstrate that Lunasin has activity against putative CICs, and 
that Lunasin has potential utility as a therapeutic in treating malignant melanomas. 
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND AND RATIONALE FOR THIS STUDY 
Lunasin as an Anticancer Agent 
 Consumption of high amounts of soy is prevalent in many Eastern cultures and has been linked by 
epidemiological studies to lower incidence of certain types of cancer [1-3].  Several components of soy 
have been attributed with its chemopreventative and chemotherapeutic properties including isoflavones [4], 
protease inhibitors [5], and bioactive peptides [6].  In combination, these components may work in a 
concerted effort to reduce carcinogenesis through several mechanisms of action.  For example, genistein, a 
well-studied soy isoflavone, has been acknowledged to assert its anticancer effects through a variety of 
mechanisms including cell cycle arrest and induction of differentiation [7].  Bowman Birk Inhibitors (BBI) 
present in soy isolates perform an import action in the uptake and stability of bioactive peptides [8].  
Lunasin, a 44 amino acid peptide encoded by the 2S Albumin gene in soy, has been reported to have 
several activities which may drive its anticancer effects; previous reports have shown that Lunasin 
functions as a histone acetyltransferase inhibitor [9] as well as an integrin antagonist [10].  With these 
studies in mind, using soy intake as a functional food seemingly has promising health benefits in preventing 
carcinogenesis.  Additionally, investigating diet as a potential anticancer agent would appear an 
encouraging avenue for future therapeutic-based studies.  This dissertation will specifically investigate the 
utility of the soy-derived peptide Lunasin as a chemotherapeutic agent against malignant melanomas. 
Lunasin is a soy-derived peptide that has demonstrated anticancer, anti-inflammatory, antioxidant, 
and immunomodulatory activity [11-14].  Lunasin has been reported as a 43 amino acid fragment present in 
processed 2S albumin protein [15]; however, the Davis lab recently identified a native 44 amino acid 
sequence of Lunasin isolated from defatted soy flour consisting of the sequence: 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDDN [16].  This 44 amino acid 
sequence was verified by subsequent studies by Serra et. al.  [17].  Lunasin has been proposed to have three 
distinct domains that are responsible for its therapeutic and chemopreventive activity: an RGD sequence 
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involved in internalization of the peptide via integrin binding, a poly-aspartic acid tail that binds 
lysine residues present in H3 and H4 histone tails, and a hypothesized chromatin binding domain [9, 18].  
Limited studies have described the direct chemotherapeutic effects of Lunasin against cancer as it is 
generally defined as a chemopreventive agent based on earlier studies by De Lumen and coworkers [9, 19-
22].  Thus, many questions remain about the number of cancer types sensitive to Lunasin, the possible 
mechanisms of Lunasin’s anticancer effects, and to what extent Lunasin is involved with the tight 
correlation of soy consumption with a protective effect against certain cancer types [23-25]. 
Lunasin has been found to inhibit transformation induced by multiple carcinogens and viral 
oncogenes [9, 19, 26-28].  Moreover, studies in the Davis lab indicate Lunasin is able to inhibit 
transformation of mouse fibroblast cells induced by carcinogens present in cigarette smoke including 
cadmium and nicotine-derived nitrosamine ketones (unpublished data).  The most discussed mechanism of 
action of Lunasin is the inhibition of histone acetyltransferases (HATs) and modulation of histone 
acetylation (Figure 1).  The acetylation of core histones initiates the unwinding of tightly packed DNA 
from the nucleosome complex allowing for transcription of target genes.  HAT inhibition alters normal 
acetylation patterns leading to hypoacetylation of histone tails, repressing transcription and can account for 
global cellular effects including proliferation, cell cycling, and apoptosis [29-31].    Although some 
evidence supports HAT inhibition as Lunasin’s primary mechanism of action, to date, there have been no 
functional studies to support this hypothesis.  Moreover, as new principal mechanisms of Lunasin action 
are still being discovered, it is not clear in the different experimental systems that have been studied 
whether histone acetylation is involved in all cases.    
 Studies in the Davis lab confirm a significant antiproliferative effect of Lunasin on non-small cell 
lung cancer (NSCLC), an effect which is mediated by disrupting cell cycle signaling [32].  Previous studies 
have suggested that Lunasin reduces cyclin-dependent kinase (CDK) levels, and may promote aspirin-
induced apoptosis in breast cancer models [33, 34].  Additionally, Lunasin was reported to induce apoptosis 
and alter expression of matrix adhesion proteins in metastatic colon cancer [35].  Lunasin was recently 
shown to suppress FAK/ERK/NF-κB signaling in human colon cancer as well as potentiate the 
antiproliferative and antimetastatic effects of oxaliplatin [36].  
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 Sadly, many plant-derived compounds (e.g. curcumin) are quickly metabolized or excreted resulting in 
poor bioavailability; however, Lunasin is active and bioavailable in humans consuming physiologically 
relevant amounts of soy [37].  In this study, volunteers were orally dosed with Lunasin (155.5 mg/day) in 
50 grams (g) soy protein for 5 consecutive days.  De Mejia et al. revealed Lunasin is   
orally bioavailable; however, incomplete gastrointestinal (GI) absorption resulted in a low concentration 
(71.0 ng/mL or approximately 14 nM) of Lunasin in plasma samples [37].  
 
 
Figure 1: Proposed mechanism in which Lunasin decreases histone acetylation.  The poly-aspartic acid 
tail of the Lunasin peptide may inhibit binding of HATs to lysine residues on core histone H3 and H4 tails.  
This effect disrupts the normal cycles of histone acetylation/deacetylation and subsequently represses 
transcription of target genes.  Transcriptional machinery is unable to initiate transcription when chromatin 
is tightly wound around the nucleosome complex (top).  Histone acetylation allows for the unwinding of 




  Prior studies suggest that Lunasin interacts with a specific subset of integrin subunits, as 
supported by a 2012 study by De Mejia and coworkers [12].  Furthermore, recent studies suggest that 
internalization of Lunasin is mediated by αvβ3 integrins via clathrin and caveolin-mediated endocytosis 
[38].  Proximity ligation assays (PLA) verify that the specific integrin subunits αv, α5, β1 and β3 network 
with the Lunasin peptide [10].  In normal cells, integrins mediate cell-cell and cell-matrix adhesions by 
recognizing binding motifs (i.e. RGD) as well as cooperating with growth factor receptors to induce 
proliferative and survival signaling [39, 40].  The ubiquitous activity of integrin signaling provides an 
interesting target for cancer prevention and treatment because many of these pathways are deregulated in 
cancer and result in uncontrolled proliferation and metastasis.  More specifically, this dissertation aimed to 
elucidate the effects of Lunasin on downstream pathways associated with integrin signaling and how 
disrupting these pathways can therapeutically benefit melanoma patients. 
Perhaps the most intriguing aspect of the Lunasin peptide is the fact that it has been shown to have 
immunomodulatory properties as well as those previously mentioned.  Having a therapeutic with several 
mechanisms may lower the possibility of chemoresistance due to the upregulation of pathways associated 
with the inhibition of oncogenic pathways caused by chemotherapeutic agents as seen in B-Raf targeted 
therapies (i.e. vemurafenib).  In one study, Lunasin was shown to increase antigen specific T cells when 
mice were challenged with allergen, while also suppressing inflammatory cytokines through NF-ĸB 
inhibition [41].  A subsequent study demonstrated that Lunasin provided a significant advantage in 
dendritic cell activation and maturation and conferred an enhanced immune response to viral challenge in a 
similar murine model [42].  Relevant to melanoma, Lunasin in combination with cytokines (IL-2 and IL-
12) synergistically enhanced NK cell-mediated cytotoxicity leading to significantly improved tumoricidal 
activity both in vitro and in vivo [13].  Lunasin, when introduced into a host, induces an immune response 
as indicated by the use of multiple antibodies raised in both rabbit and mouse models [16]; thus, Lunasin 
could be considered an antigenic peptide.  Perhaps, the introduction of an immunogenic peptide such as 
Lunasin promotes the mobilization of cells involved in innate immunity (NK cells, etc.) in order to combat 
tumor-associated molecules; though, this hypothesis is only speculator at this point, and subsequent studies 
on the precise mechanisms of Lunasin’s immunomodulatory functions are necessary.   
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Studies utilizing Lunasin have demonstrated its significant benefit in several cancer models; 
however, specific mechanisms of action and their induced response in cancer cells is only beginning to 
become clear.  Without functional studies to investigate the precise activity of mechanisms such as integrin 
antagonism or histone acetylation, it is difficult to target the exact cause of Lunasin’s anticancer activity.  
This dissertation aims to explore the functional domains of the Lunasin peptide while also expanding the 
knowledge of its chemotherapeutic potential in preclinical models of human melanoma with a strong 
emphasis on understanding the interactions between Lunasin’s RGD domain and integrin subunits on the 
extracellular matrix (ECM). 
 
Integrins as a targeted therapy in melanoma patients 
Integrins are vital to many cellular processes, and remain an important and underexplored target 
for cancer therapies (Figure 2).  Recent studies utilizing RGD peptides have shown targeting of integrins as 
a viable treatment alternative in melanoma therapy by inhibiting tumor angiogenesis, growth, and 
metastasis [43-45].  Integrins are heterodimeric membrane proteins primarily implicated in cell adhesion 
and migration [46, 47]; yet, integrins have also been reported to be intimately involved in cell growth, 
differentiation, and survival [48, 49].  Integrin heterodimers are composed of a single α-subunits and a 
single β-subunits, of which there are 18 and 8 variations, respectively.  These α- and β-subunits comprise 
the 24 heterodimeric proteins known in humans [50], and make integrin signaling flexible yet highly 
intricate [51].  Furthermore, integrin expression profiles in vitro can vary largely depending upon the type 
of adhesion (adherent cells versus cells in suspension) [52], and can result in recruitment of very different 
subsets of proteins.  Proteins attracted to different adhesion structures (e.g. paxillin) can produce diverse 
yet specific signaling cascades.   
By categorizing NSCLC lines based on integrin expression profiles, studies have associated 
explicit integrin subunits with Lunasin sensitivity [10].  Moreover, it was shown that Lunasin exerts its 
anticancer effects in NSCLC by reducing activating phosphorylations of v-akt murine thymoma viral 
oncogene homolog 1 (AKT), focal adhesion kinase (FAK), and interactions of β-subunits with integrin-
linked kinase (ILK), thereby altering signaling pathways downstream of integrin-ligand binding [10].   
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In melanoma models, the integrin αvβ3 is currently the predominant target for therapeutic 
applications of integrin antagonists.  Integrin αvβ3 is expressed at low levels in non-transformed epithelial 
cells relative to melanoma cells [53], as αvβ3 expression has been related to metastatic potential and 
dissemination of melanoma neoplasms to a metastatic phenotype [54, 55].  Crosstalk between integrins and 
growth factor receptors has been well documented [56, 57].  Enhanced cancer cell survival has been 
attributed to a number of interactions between integrin signaling and other pathways including increased 
BCL-2 expression, PI3K-AKT activation, or NF-κB signaling [58-60].  This dissertation proposed that in 
melanoma models, similar to recent findings in NSCLC [10], Lunasin binds αvβ3 integrins through its 
RGD domain and inhibits proproliferative and prosurvival signaling.   
 
 
Figure 2: Integrin-associated signaling pathways and the cellular effects associated with integrin 
signal transduction.  Integrin signaling is ubiquitous in that several intracellular kinases (and their effector 
proteins) are involved in signal transduction.  These transduction pathways elicit various cellular effects 
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including proliferation, differentiation, and migration, to name a few.  Specific kinases highlighted in this 
dissertation are enclosed in red boxes. 
 
Certain integrins have specific roles in melanoma;  for instance, it has been shown that α4β1, a 
homing molecule on leukocytes that binds VCAM-1, is absent on melanocytes, yet present in melanoma 
cultures [61].  Consequently, α4β1 may help melanomas mimic hematopoietic cells by enabling melanoma 
migration into tissues that expressing VCAM-1 [62].  Other integrins implicated in melanoma are α3β1 and 
α5β1, which were elevated in metastatic melanoma tissue.  Furthermore, α1β1, α2β1 and α6β1 integrin 
subunits were found to be reduced in metastatic versus primary melanoma [61].  However, roles of 
integrins in CICs are somewhat ambiguous.  Recent studies show that integrin subunits may be a viable 
marker for CICs and may be responsible for stem cell pool maintenance and differentiation mediated by 
FAK [63, 64], but the specific functions of integrins in CICs when compared to non-CICs have yet to be 
elucidated.  CICs are proposed to be more tumorigenic based on properties such as chemoresistance, 
immune evasion, and self-renewal capabilities [65, 66].  Whether integrins, through mechanical adhesion or 
signal transduction mechanisms, play a central role in these cellular processes is a major focus of this 
dissertation. 
Cilengitide, a cyclic RGD (cRGD) peptide, has been used to treat glioblastoma and is the first 
integrin inhibitor to be used in Phase III clinical trials [67].  Unfortunately, cilengitide had minimal clinical 
efficacy as a single agent in treating malignant melanoma [68].  Clinicians noted a significant decrease of 
αVβ3 expression in cilengitide-treated melanoma patients.  Interestingly, the sole responder to cilengitide 
treatment had no tumoral αVβ3 expression.  Additional clinical trials utilizing integrin-targeted therapeutics 
in combination with standard treatments have yielded disappointing results [69, 70]; despite promising 
preclinical data [71-73].  Despite not obtaining a significant difference, the treatment arm combining 
standard-of-care chemotherapy and anti-integrin targeted therapy trended toward improved overall survival 
in addition to having a favorable kinetic profile [69].  Furthermore, targeting of integrin subunits explicitly 
expressed on cancer cells may represent a dynamic solution to reducing off-site, adverse side effects 
generally seen with traditional chemotherapy.  Using integrin antagonists to suppress angiogenesis as well 
as integrin-associated signaling cascades may prove useful in the future as novel therapeutic strategies that 
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do not simply target the bulk of rapidly proliferating tumor cells.  The multiple modes of action of Lunasin 
may provide a substantial boost in antitumor efficacy over more traditional integrin-targeted therapies. 
 
Melanoma and the presence of melanoma stem cells 
Skin cancers account for nearly half of all diagnosed cancer cases in the United States and have 
increased in frequency over the last thirty years [74].  Melanoma is estimated to account for 76,000 new 
cancer cases in 2014 [75].  Despite being less frequent than other skin cancers, nearly 75% of skin cancer 
deaths are attributed to melanoma [75].  Even more unnerving, NCI’s Surveillance, Epidemiology, and End 
Results (SEER) program estimates cases of melanoma have nearly tripled in the past thirty years increasing 
from 7.9 (per 100,000) in 1975 to 22.7 in 2011, while 5-year survival rates remain constant.  Early 
detection and diagnosis is paramount for overall survival with 5-year survival rates of 98%, 62%, and 16% 
for localized, regional, and distant diseases, respectively [75].  Epidemiological studies have shown that the 
single greatest risk factor for melanomagenesis is UV exposure [76]; however, heredity has been reported 
to be involved in up to 12% of melanoma cases [77].  Classification of melanomas (reviewed in [78]) relies 
on a staging system which incorporates tumor thickness, presence of ulcerations, mitotic rate, and the 
existence of metastasis.  If diagnosed at an early stage, melanoma is a highly curable disease; however, 
progression from the radial to vertical growth phase indicates the ability to invade surrounding tissues and 
potential for metastatic dissemination [79]. 
Continued research of melanoma has provided several “cracks in the armor” of metastatic 
melanoma leading to the development of several targeted therapies that aim to inhibit proliferation, 
metastasis, and angiogenesis of primary and secondary tumors.  One such targeted therapy is vemurafenib, 
which decreases melanoma cell viability and proliferation resulting in tumor regression and increasing 
overall mean survival time [80, 81].  Vemurafenib targets a mutated form of the B-Raf protein found in 
approximately 60% of melanomas in which a V600E substitution leads to constitutive Raf signaling within 
the mitogen-activated protein kinase (MAPK) cascade [82].  In the majority of patients harboring this 
mutation, mean survival time has been improved with vemurafenib; however, after initial tumor regression, 
many patients experience recurrence of tumors that are vemurafenib-resistant [83-85].   Conferred 
resistance to vemurafenib may occur through a number of mechanisms including, but not limited to, 
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feedback activation of epithelial growth factor receptor (EGFR), upregulation of other Raf proteins, or 
upregulation of N-Ras [85-87].   
One explanation for the reformation of palpable tumors with chemoresistance is the presence of 
CICs within the bulk tumor population.  The presence of CICs and their origin have become a topic of 
debate [88-92].  According to the cancer stem cell theory, a subset of cells within the tumor population 
have properties that resemble physiological stem cells including the ability to self-renew while also giving 
rise to daughter cells that differentiate to reform heterogeneous tumor populations [88] (Figure 3).  The 
present study will show that CICs exist within established melanoma cell lines at a relatively high rate, and 
that this subset of cells displays enhanced tumorigenicity and invasiveness.   
 
 
Figure 3: Stochastic model compared to the cancer stem cell model. The stochastic model of 
tumorigenesis argues that all individual cells within a tumor population have the intrinsic ability to form a 
tumor.  The cancer stem cell hypothesis states that only a subset of tumor cells have the capacity for 
reforming heterogeneous tumor populations.  The cancer stem cell hypothesis has recently become a topic 
of debate.  While several models seem to appropriately fit the cancer stem cell hypothesis, several 
researchers have provided evidence suggesting some models do not follow this model. 
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Discovery of melanoma cells with stem cell-like plasticity was initially found in patient tumors 
overexpressing CD20 and CD133 [93, 94].  CD20 is a membrane-spanning surface molecule generally 
found on B lymphocytes; per se, it is the molecular target for therapeutic monoclonal antibodies (e.g. 
rituximab) for treatment of select leukemias and lymphomas.  CD133 (prominin-1) is a membrane-
spanning protein of no known function that is classified as a marker for primitive hematopoietic and neural 
stem cells.  These subsets of cells were found to have properties of stem cells as well as enhanced ability to 
form palpable tumors in immunodeficient mice.  Ensuing studies verify ATP-binding cassette sub-family B 
member 5 (ABCB5), a drug transporter playing a key role in chemoresistance, and Low-Affinity Nerve 
Growth Factor Receptor  (LNGFR/CD271),  a member of the tumor necrosis factor (TNF) receptor family 
involved in survival and differentiation of neurons, as viable CIC biomarkers [66, 95]. However, scientists 
are slow to embrace this concept for a number of valid reasons.  One concern remains the standardization 
of techniques for identifying and propagating cancer stem cells.  Serial dilution and transplantation of CICs 
into NOD/SCID mice has long been the gold standard for determining stem cell populations; however, 
spheroid assays in addition to genetic lineage tracing provide in vitro assays for CIC classification [89].   
To make matters more complicated, some evidence supports plasticity of differentiated cancer 
cells in a breast cancer model [96].  By reverting to a dedifferentiated phenotype, stem-like cells arise de 
novo in response to environmental cues [96].   These data support the theory of bidirectional movement 
between stem and non-stem compartments, and have serious implications on the plasticity of cells in cancer 
models as well as subsequent therapeutic strategies.  The phenomenon of “phenotype switching” has also 
been reported in melanomas [97].  The hypothesis proposed by Hoek and his coworkers suggests that cells 
within a tumor may be able to undergo a change between invasive and proliferative phenotypes depending 
on environmental cues and genetic alterations.  Additional publications have aimed to refute the claim that 
melanoma “fits” the cancer stem cell theory.  Quintana et. al. recently reported that nearly 1 in every 4 
melanoma cells may be able to produce a palpable tumor in vivo; however, the percentage of tumorigenic 
melanoma cells was highly variable depending upon the immune status of the host animal [98].  This report 
questions whether or not cancer stems cells are a rare subpopulation despite the fact that the rarity of CSCs, 
according to the CSC theory, has yet to be truly defined [99, 100].   
11 
 
Although populations of stem cell-like cells are recognized in melanoma cell lines, the frequency 
of these cells is highly variable, ranging from less than 1% up to nearly 25% [66, 98].  The incidence of 
cancer stem cells seems dependent upon the in vivo model, the biomarker used for identification, and the 
tumor microenvironment [62, 101].  Conflicting reports indicate that tumor samples enriched for CIC 
markers have enhanced tumor forming capacity.  Quintana [98] showed tumorigenic cells are 
phenotypically heterogeneous in melanomas, as significant in vivo tumor growth was marginal based on 
select CIC biomarkers.  Despite these findings, numerous studies report superior tumor forming capabilities 
of cells enriched for melanoma stem cell biomarkers including ABCB5 [102], CD133 [94], CD271 [95], 
and ALDH (aldehyde dehydrogenase) [103].   
 ALDH is a family of detoxifying enzymes responsible for metabolism of certain alkylating agents 
such as cyclophosphamide.  Enrichment for melanoma initiating cells by intracellular ALDH staining 
(protocol reviewed in [104]) has come with mixed reviews; however, most evidence supports ALDH as a 
CIC biomarker [103, 105-107].  ALDH expression has also successfully been used to detect CICs in breast 
and colon cancer models [108, 109].  The use of ALDH as a biomarker is based on its involvement in 
vitamin A metabolism [110].  ALDH has also been researched as a therapeutic target in human melanomas 
and its inhibition has been shown to decrease melanoma cell tumorigenicity and metastasis [111], 
indicating a primary role in melanomagenesis and progression.  Interestingly, ALDH-high cells may also 
serve a role as an adjuvant in vaccine-based therapies for melanoma [112].   
 Throughout this dissertation, ALDH-high fractions of cells derived from several melanoma lines 
were utilized to assess the effects of Lunasin on melanoma CICs compared to “bulk” tumor cells with the 
ALDH-low phenotype.  The complex mechanisms underlying the contributions of ALDH in CIC function 
have yet to be fully elucidated.  While the work presented in this dissertation does not immediately delve 
into these intricacies regarding ALDH function in CICs, it will serve as a foundation for using ALDH as a 
CIC biomarker and supports the notion that ALDH-high cells harbor a highly tumorigenic and invasive 
population of melanoma cells.  In order to indisputably determine whether melanomas follow a hierarchal 
or stochastic model of tumorigenesis, additional research must be conducted using a standardized and well 
defined classification and identification system for CSCs.  Simply collecting cells based on a single 
biomarker will most likely not suffice, but long-term propagation in an in vivo system may help categorize 
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subsets of tumors cells in terms of tumorigenic capacity and self-renewal.  Data presented throughout this 
dissertation and how it relates to what is currently known about the CSC theory (Reviewed in [113]) will be 
discussed in subsequent chapters of this work. 
 
Traditional approaches to treating melanomas and future perspectives 
 It is becoming clear that late-stage and recurrent melanoma may be due to the presence of 
melanoma stem cells which repopulate the heterogeneity of melanoma tumor tissues throughout the body.  
An emerging issue in treatment strategies involving late-stage cancers is the fact that traditional 
chemotherapeutic agents (e.g. alkylating agents) can actually expand the CIC compartment while 
simultaneously causing an initial regression of the primary tumor [114-116].  Recent studies have found 
that several traditional chemotherapies, including many used in the treatment of malignant melanomas, can 
increase the number of cells in the CIC compartment [117-120].  In addition to selecting for CICs, these 
chemotherapeutic regimens can increase genetic instability leading to phenotypic abnormalities such as 
increased invasiveness or enhanced tumorigenicity [121]. Therefore, the strategy of using differentiation-
inducing agents to reduced CIC populations prior to, in combination with, or immediately following 
therapeutic intervention is an emerging area of research [122].   
 The standard protocol for treating melanoma has largely depended on the stage at diagnosis; early 
melanomas (stage I and II) can generally be surgically resected without fear of recurrence [123, 124].  
However, late stage (stage III and IV) melanomas are treated much more aggressively and traditional 
treatment usually includes surgical resection, radiation, chemotherapy, or a combination of these therapies 
[123, 124].  Dacarbazine, temazolomide, cisplatin, and paclitaxel have primarily been used as the 
chemotherapeutic arm of traditional treatment strategies [125-127].  While these therapies have been shown 
to induce apoptosis in many melanomas and provide relief in the form of an initial tumor regression, many 
patients will experience recurrence and subsequent metastasis of chemoresistant tumor populations within 
months of treatment; patients with stage IV melanomas given the standardized treatment of care (i.e. 
dacarbazine) had median overall survival times ranging from 5.6 – 7.8 months and a response rate of only 7 
– 12% [83, 128-131].  These facts, taken in conjunction with the high cytotoxicity and ongoing list of 
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adverse effects of traditional anticancer pharmacologics, make it very clear to see why the demand for 
efficacious yet safe treatment options are needed. 
 The past decade has seen the implementation of several novel strategies for the treatment of late 
stage melanomas including targeted therapy (e.g. vemurafenib) [132] and immunotherapies, which consist 
of several subcategories including adoptive cell transfer [133], oncolytic viral therapy [134], and 
checkpoint blockade (e.g. nivolumab) [135].  Due to the strong immunogenicity of melanomas [136], the 
use of immunotherapies for modulating melanoma progression has received strong interest from 
researchers and pharmaceutical companies and will likely be a major focus moving forward.  While 
immunotherapies have shown great promise in clinical trials [137-139], the fact that these drugs are just 
now being implemented clinically raises the question as to whether these agents can sustain improved 
patient responses and increased overall survival rates.  Therefore, the continual development of novel 
antimelanoma drugs is necessary to combat this particularly deadly and inherently common disease.  With 
respect to Lunasin, a particularly intriguing aspect of the recent development and approval of 
immunotherapies is the fact that Lunasin has been shown to enhance components of both innate and 
adaptive immunity [13, 41, 42].  While strategies dedicated to eliciting cell-mediated immune responses 
seem to be receiving heightened interest, inducing an overall immune response by activating several 
constituents of the immune system may provide a more robust antitumor effect.  At the very least, it will be 
interesting to see what the future holds for immunomodulatory therapies, and whether or not they become a 
mainstay in anticancer treatments. 
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1.2 SPECIFIC AIMS AND GOALS OF THE DISSERTATION 
Overall Goals 
 The principle goal of this dissertation is to expand upon the existing knowledge that Lunasin has 
significant anticancer activity.  Initial data from the Davis lab indicated that Lunasin may have potential 
utility against NSCLC.  The hypothesis of this dissertation extends upon previous studies in the Davis lab 
to suggest that Lunasin may have potential clinical utility against melanoma.  Malignant melanoma cell 
lines derived from both human and murine origins were used to investigate the functional effects on cancer 
cells when they are treated with Lunasin, and additionally, to demonstrate through preclinical studies that 
these effects could provide a potential therapeutic benefit in clinical applications.  Initially, it was observed 
that Lunasin had a modest effect in vitro; however, these effects were more robust in vivo.  The importance 
of CICs in melanoma mortality [140] led to the question as to whether or not Lunasin might have a 
selective effect on this population of cells.  This was especially important due to the problematic and 
challenging nature of melanoma recurrence and chemoresistance due to the presence of CICs [140].  A 
principle goal of this study was to characterize the effects of Lunasin on melanoma cells through analysis 
of proliferative, apoptotic, differentiation, and senescence markers.  Previously described mechanisms of 
Lunasin’s anticancer activity including alterations in histone acetylation and integrin signaling were 
investigated to reveal which mechanism(s) was responsible for the effects seen in melanoma models.  The 
driving hypothesis of this study is that Lunasin decreases tumorigenicity and proliferation of melanoma cell 
lines by inhibiting integrin signal transduction. 
 Recent findings in NSCLC [10] indicated that Lunasin’s interaction with integrins comprised a 
significant portion of its anticancer activity; therefore, those studies were used as a stepping stone to further 
explore melanoma as a model to discover novel functions of the Lunasin peptide.  Because of the central 
role of both CICs and integrins in metastatic dissemination [62], it was imperative to assess whether 
Lunasin, through its changes in integrin signal transduction and selective targeting of CICs, would 
significantly suppress metastatic outgrowth in a murine model of metastasis.  In terms of clinical relevance, 
the use of Lunasin as an adjuvant in combination with the commonly prescribed B-Raf inhibitor 
vemurafenib was utilized to assess any additional gain in therapeutic benefit.  Taken together, it was 
expected that these findings would advance Lunasin as a potential drug candidate for further development, 
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not only in malignant melanoma, but in malignant diseases in which the presence of CICs has the potential 
to cause patient relapse. 
Specific Aims 
1. Identify the mechanisms in which Lunasin exerts its anticancer effects in melanoma 
Sub Aim A. Assess the ability of Lunasin to reduce populations expressing CIC and stem-associated 
markers 
Sub Aim B. Characterize the effects of Lunasin on CICs through analysis of proliferative, apoptotic, and 
differentiation markers 
Lunasin’s effects on melanoma had yet to be documented prior to the Davis lab’s initial study 
[141]; however, the recent findings in NSCLC would suggest that these effects are conserved throughout 
many different cancer cell types.  It was revealed that NSCLC proliferation was significantly inhibited 
when cancer cells were treated with Lunasin, and additionally, that this effect was differentially dependent 
upon expression of specific integrin subunits [10].  These results would suggest that integrin signaling is 
strongly linked to the initial results which demonstrated that Lunasin diminished the ability of cells to form 
colonies in soft agar as well as had a very modest effect on melanoma cells in proliferation assays.  Firstly, 
this dissertation aimed to identify and characterize the effects that Lunasin had on parental melanoma cells 
through assessment of markers for proliferation, apoptosis, differentiation, and senescence.  Secondly, this 
work planned to identify whether or not Lunasin had a significant effect on biomarkers for melanoma CICs 
including ALDH, CD271, and CD133.  Categorizing these effects as described would justify subsequent 
aims geared toward elucidating specific mechanisms of Lunasin in melanoma CICs. 
2. Evaluate the interaction between Lunasin and integrin subunits 
Sub Aim A. Specify the explicit integrin subunits interacting with Lunasin and identify the downstream 
mediators of integrin signal transduction 
Sub Aim B. Mutate the Lunasin peptide to discriminate the effects caused by histone acetyltransferase 
inhibition and integrin antagonism 
Sub Aim C. Genome-wide microarray analysis to discover Lunasin associated gene targets 
Recent work in the Davis laboratory has focused on using NSCLC as a model to investigate the 
specific mechanisms in which Lunasin exerts its effects on cancer cells.  It was observed that in NSCLC, 
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integrin signaling was significantly suppressed in cells treated with Lunasin.  Using these results as a 
stepping stone, it was next investigated if these effects were conserved in models of melanoma.  Therefore, 
this dissertation proposed to investigate the interactions between RGD-recognizing integrin subunits and 
the Lunasin peptide as well as assessed the downstream effects through integrin-associated intracellular 
kinases (e.g. FAK) caused by this interaction.  Because Lunasin has been reported to have significant 
effects on global histone acetylation patterns [142], it was next asked whether these effects could be driven 
by alterations in chromatin structure (via histone acetylation) compared to suppressed integrin signaling.  
Using synthesized peptides with mutated activity domains, this study aimed to test whether the RGD 
domain or the poly-aspartic acid tail were necessary for Lunasin’s activity in melanoma.   
Integrin signal transduction has been linked to several oncogenic signaling pathways [143]; for 
example, integrins have been shown to cooperate with the MAPK signaling cascade [144].  The ubiquitous 
nature of integrin-mediated signaling makes it difficult to accurately pinpoint precise mechanisms involved 
in Lunasin’s activity.  Thus, a genome-wide microarray screen was employed in order to distinguish any 
signaling pathways that may overlap with either integrin signal transduction or histone acetylation causing 
the effects observed in previous studies.  Using Lunasin as a tool to probe for novel therapeutic targets or 
identify connected hubs of proteins associated with these targets may allow researchers to explore this 
multifaceted peptide as a viable treatment option for malignant melanoma. 
3. Investigate the antimetastatic effects of Lunasin 
Metastatic dissemination due to circulating tumor cells that have undergone epithelial to 
mesenchymal transition (EMT) is the foremost reason for poor prognosis due to the high mortality rates 
caused by secondary tumor growth [145].  Prevention of initial metastatic seeding and sequential 
colonization of distant tissues is at the forefront of several clinical trials, and remains a major focus for 
oncologists and researchers [146, 147].  Even after metastatic outgrowth from the primary tumor, shrinkage 
of these initial lesions and prevention of metastatic spread can successfully improve overall patient 
survival.  Therefore, it was next investigated whether or not Lunasin could provide any antimetastatic 
benefit in a syngenic model of experimental metastasis.  These data, if supportive of the proposed 
hypothesis, could potentially provide significant clinical implications for the development of Lunasin as an 
adjuvant therapy in malignant diseases. 
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CHAPTER 2: EXPERIMENTAL PROCEDURES AND METHODOLOGY 
2.1 Lunasin Isolation and Purification 
 Lunasin was isolated from “white flake,” a product resulting from the flaking and defatting of 
soybeans via hexane extraction.  The extraction and purification was scaled and performed by Kentucky 
BioProcessing (KBP) as previously described [16].  Briefly, Lunasin was extracted from defatted soy flour 
in a 12.5: 1 ratio of extraction buffer (20 mM sodium phosphate/150 mM NaCl/20 mM ascorbic acid/10 
mM sodium metabisulfite, pH 7.4) to soy flour.  This solution was mixed for one hour at room temperature.  
A diatomite filter aid (Advanced Minerals Corporation) was added to the solution after mixing, and the 
mixture was then passed through a filter press (ErtelAlsop, 1 μm filter pads).  The filter cake was dried and 
once again washed with extraction buffer, and the resulting mixture was added to the initial extract.  Anion 
exchange chromatography was performed at Kentucky BioProcessing using a 20x13 cm Q-Sepharose FF 
column on a Pharmacia 10 mm BioProcess System Skid after both column and skid were sanitized with 1 
N NaOH and preconditioned with equilibration buffer (20 mM sodium phosphate/150 mM NaCl, pH 7.4).    
Clarified extracted was applied to the column for a residence time of approximately 3 min, and washed 
with 14.8 CV (column volumes) of equilibration buffer.  Lunasin was eluted using a linear gradient of 
sodium chloride (0.29 – 0.48 M, pH = 7.4), and the Lunasin-containing fractions were filtered through a 0.2 
μm capsule filter.  Dithiothreitol (DTT) was added to the fraction containing Lunasin to a final 
concentration of 2 mM, and the mixture was mixed at room temperature for one hour.  DTT-containing 
fractions were then subjected to ultrafiltration using 30 kDa polyethersulfone membranes and a Sartorious 
Sartocon Slice unit (Sartorious Stedium Biotech).  The final step in the purification process utilized 
reverse-phase chromatography (RPC) using a 10x9.2 cm Source RPC column on an AKTA pilot system 
(GE Healthcare).  Fractions were applied to the column with a residence time of precisely 2.5 min. and 
subsequently washed with equilibration buffer followed by a step elution process using 20% up to 100% 
elution buffer (17 mM sodium phosphate/127.5 mM NaCl/15% n-propanol/pH 7.4) in which the 100% 
buffer was the Lunasin-containing fraction.  This fraction was concentrated using a 0.5 m2 2 kDa cellulose 
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cassette (Sarorious Stedium Biotech).  RPC elution buffer was replaced with 50 mM sodium phosphate (pH 
7.4) via diafiltration, and passed through a 0.2 μm filter.  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) analysis indicate these Lunasin preparations have >99% purity (Figure 4).  
Subsequent experiments utilizing Lunasin as a treatment used these stock preparations, which had been 
diluted to a final concentration of 4.7 mg/mL of Lunasin (in 50 mM sodium phosphate) in 10 mL sterile 
glass vials and stored at 4˚ C. 
 
 
Figure 4: SDS-PAGE analysis of lunasin purified from soybean white flake. A total of 5 μg total 
protein was subjected to SDS-PAGE using a 15% gel (BioRad) followed by staining with Coomassie 
Brilliant Blue (BioRad). Labels indicate migration of SeeBlue Plus2 (Life Technologies) protein standards. 
 
2.2 Cell Culture and Reagents 
 B16-F10, SKMEL-28, and A375 cell lines were obtained from American Type Culture Collection 
(Rockville, MD), and further authenticated by short tandem repeat profiling (Promega).  Cells were 
monitored for mycoplasma contamination every 6 months.  All cell lines were grown in Dulbecco’s 
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Modified Eagles Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), Penicillin (100 
U/mL), and Streptomycin (100 μg/mL).  Cells were incubated at 37 °C at 5% CO2 and sub-cultured every 
72 h.  ALDH+ cells were purified by fluorescence-activated cell sorting (FACS) and were grown in 
DMEM/F-12 serum-free media containing 1x N-2 Supplement (Gibco) 10 ng/mL basic fibroblast growth 
factor (Gibco), and 10 ng/mL epidermal growth factor (Gibco).  For soft agar assays, DMEM media 
(Invitrogen) powder was reconstituted in ultrapure water (500 mL) and supplemented with 20% FBS, 
Penicillin (200 U/mL), and Streptomycin(200 μg/mL).  Vemurafenib (a selective B-Raf inhibitor) was 
obtained from Selleck Chemicals (PLX4032, RG7204).  Vemurafenib was dissolved in dimethyl sulfoxide 
(DMSO) at a stock concentration of 1 mM and stored at -20˚C until use.  The A375R cell line was created 
in the Davis lab to mimic acquired vemurafenib resistance.  A375R cells are derived from A375 melanoma 
cells which were cultured in 1 μM vemurafenib for 4 weeks.  The resulting cell phenotype had decreased 
sensitivity to vemurafenib compared to parental A375 cells. 
2.3 Proliferation Assays 
Manufacturer protocols were followed to determine the effects of Lunasin on melanoma cell 
proliferation (Promega Cell titer-96 Aqueous Reagent).  Initial seeding densities were standardized at 7.5x 
103 cells/cm2 in 100 μL culture media.  Briefly, cells were plated and incubated at 37˚C, 5% CO2 for 4 h.  
Media were drained from each well and replaced with media containing varying concentrations of vehicle, 
Lunasin, or vemurafenib.  Treatment media were replaced every 24 h during the 72 h treatment period.  
After 72 h of treatment, wells were drained of expired media and refilled with 100 μL of fresh media.  20 
μL of  [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) reagent was added to each well and the plate was incubated for 2-3 h.  Absorbance was read at 490 
nm on a plate reader (Biotek Instruments).  Average absorbance of media containing no cells (i.e. 
background absorbance) was subtracted from all absorbance values.  Absorbance values were then 
normalized to control and expressed as percent control ± s.d. 
2.4 Soft Agar Colony Forming Assay 
 A lower, cell-free layer of 0.5% Bacto agar and cell culture media (1:1 suspension) was plated in 
6-well tissue culture plates and allowed to solidify at room temperature in a laminar flow cabinet. An upper 
layer of 0.35% agar and culture media (1:1) containing 1000 melanoma cells plus vehicle, Lunasin or 
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vemurafenib was plated over the solid lower layer. Plates were incubated at 37 °C and 5% CO2 for 10–18 
days until colonies grew to approximately 100 μm in diameter. After seeding, plates were fed with culture 
media containing vehicle (PB) or Lunasin twice weekly. Plates were stained with crystal violet solution 
(0.005%; Sigma-Aldrich), photographed, and scanned (1000 dpi; EPSO Expression 1680 scanner). Average 
colony size and total colony area for each sample were analyzed using Image-J software (National 
Institutes of Health). 
 2.5 ALDEFLUOR Staining 
 The ALDH positive population was identified using a commercial kit (ALDEFLUOR™, Stem 
Cell Technologies) according to manufacturer’s directions. A375, SKMEL-28, and B16-F10 cells were 
grown to approximately 80% confluence in DMEM cell culture medium and treated with Lunasin for 24 h. 
Cells (1 × 106 cells/mL) were washed and resuspended in ALDEFLUOR™ Assay Buffer. ALDEFLUOR™ 
reagent (5 µL/mL) was added to the cell suspension. The sample was mixed, and a portion was added to a 
fresh tube containing the N,N-diethylaminobenzaldehyde (DEAB) inhibitor. Another portion was placed in 
a fresh tube for staining with 10 μg/mL propidium iodide (PI). Samples were incubated in 37 °C for 45 min 
and mixed occasionally by inversion. Flow cytometry was performed using FACS Calibur (BD 
Biosciences).  A representative histogram showing SKMEL-28 melanoma cells stained with ALDEFLUOR 
reagent is presented in Figure 5. 
2.6 Flow Cytometry (Apoptosis) 
Annexin V binding assays were conducted using FITC conjugated antibodies against 
phosphatidylserine (BD Bioscience) and propidium iodide to measure rates of apoptosis and cell death.  
Cells were harvested and resuspended in 1x binding buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 mM 
CaCl2) at a concentration of 1x106 cells per mL.  Briefly, 1x105 melanoma cells were incubated with 100 
μM Lunasin for 24 h.  After the 24 h treatment, cells were harvested using enzyme-free dissociation media 
(TrypLE, Life Technologies), counted, and subjected to staining.  Cells were suspended in 0.5 mL binding 
buffer and stained with 5 μL PI, 5 μL Annexin antibody, or both for 15 min at room temperature.  Gates 
were set based on controls (unstained, PI only, Annexin only), and compensation controls were performed 
in FlowJo V10 (FlowJo, LLC).  1x104 events were collected per run on a FACS Calibur flow cytometer 
(BD Biosciences).  
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  For identifying ALDHhigh cells, melanoma cells were assayed for high ALDH activity as 
described above (Section 2.5). ALDHhigh and ALDHlow melanoma cells were sorted using a MoFlo cell 
sorter (Beckman Coulter) or a FACS Aria II with FACS Diva software (BD Biosciences).  Sorted 
ALDHhigh cells (1 × 103 cells/mL) were plated in low-attachment 6-well plates (Corning) in DMEM/F-12 
serum-free media. Cells were either treated with Lunasin (100 μM) or vehicle and labelled with Annexin V 





Figure 5:  SKMEL-28 cells stained with ALDEFLUOR reagent +/- DEAB.  SKMEL-28 melanoma 
cells were grown in adherent culture, harvested, and stained for ALDH activity.  This histogram represents 
a typical ALDH staining profile for the SKMEL-28 cell line run on a MoFlo cell sorter, and shows 




2.7 Flow Cytometry (Cell Cycle) 
Cell cycle analysis was performed on synchronized melanoma cells; cells were serum starved for 
72 h and then released by addition of 10% FBS culture media containing Lunasin or vehicle for 24 h.  
1x106 cells were harvested and resuspended in 200 μL of PBS.  Cells were slowly added to 4 mL ice cold 
70% ethanol for overnight fixation at -20˚C.  After fixation, cells were spun down at 300 xg for 10 min and 
resuspended in 0.5 mL of PI master mix (40 μg/mL PI, 100 μg/mL DNase in PBS) and incubated at 37˚C 
for 30 min prior to flow analysis using a BD FACS Calibur.  Resulting data were analyzed using FlowJo 
V10 cell cycle analysis tool. 
2.8 Fluorescence-assisted Cell Sorting  
Cell sorting was performed on a Beckman MoFlo or BD Aria II instrument equipped with a 20 
milliwatt blue argon laser (488 nm) using the ALDEFLUORTM kit as previously described (Section 2.5).  
ALDHhigh and ALDHlow fractions were detected using a FITC filter set (530/30 emission) on FL-1 (FITC) 
channel and collected for subsequent in vitro and in vivo experiments.  Sorted cells were confirmed to be 
positively stained for ALDH by fluorescent microscopy on a Nikon NiE microscope (Nikon) under a 488 
nm laser and GFP (530/20) filter set.  Batch sorting reports derived from Aria II FACS equipment are 
provided to represent typical staining profiles for A375 (Figure 6) and B16-F10 (Figure 7) melanoma cell 
lines.  Melanoma cells which do not express ALDH (i.e. ALDH-negative) are captured in the left gate (set 
by the DEAB control), and those staining for high ALDH activity are captured in the gate to the right.  
Cells which express intermediate (i.e. between the left and right gate) levels of ALDH represent an ALDH-
positive population that did not demonstrate a one log shift in fluorescence, and thus, were not isolated in 
our ALDHhigh sorted fractions. 
2.9 Formation of Multicellular Oncospheres 
B16-F10, A375 and SKMEL-28 melanoma cells were sorted for ALDH activity as described 
above.  ALDHhigh cells were sorted using a MoFlo flow cytometer (Beckman Coulter) or a FACS Aria II 
(BD Biosciences). Gates were set based upon DEAB controls for each cell line and reflected at least a one-
log shift between negatively and positively stained cells.  Sorted cells were cultured in low-adherent T-25 
flasks (Corning) in DMEM/F-12 serum-free media at a density of 1 × 103 cells/mL.  Cultures were grown 
for up to 14 days and treated with fresh media containing either Lunasin (100 μM) or vehicle twice per 
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week. Oncospheres (>100 μm) were harvested and passed through a 70 μm nylon filter (BD Biosciences) to 
remove single cells and small cell clumps. Spheres were imaged and analyzed using Image-J software 
[148].  
 
Figure 6: Batch report for A375 melanoma cells stained with ALDEFLUOR reagent. Parental A375 
cell lines were subjected to FACS after being stained with ALDEFLUOR reagent.  DEAB was used as a 
negative control in order to set appropriate gates for ALDH-negative cells (A). ALDHhigh cells reflect at 
least a one log shift in fluorescence intensity (B).  Sorted cells were analyzed and isolated using a BD Aria 
II FACS and batch reports were generated using FACS Diva software. 
 
2.10 In vivo Xenograft Model 
 Male athymic nude mice (Jackson #002019) were used at 6-8 weeks of age. All mice were 
handled in accordance with the Association for Assessment and Accreditation of Laboratory Animals Care 
international guidelines with the approval of the appropriate Institutional Animal Care and Use Committees 
at the University of Louisville (protocol #12091) and Indiana University, Bloomington (Protocol # 14-019-
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4). Mice were injected subcutaneously (s.c.) with 2.5 × 106 A375 cells in phosphate buffered saline (PBS; 
100 μL) on the right hind flank. Mice received daily intraperitoneal (i.p.) injections of either Lunasin (30 
mg/kg) or vehicle (PB) starting the same day that cells were implanted and repeated until mice were 
sacrificed.  Noticeable tumor formation was observed approximately 14 days post-injection and measured 
every other day thereafter.  Experimental endpoint was set at tumor volumes exceeding 20 mm in diameter 
(~ 2 cm2 total area) or upon ulceration of tumor tissues.  At endpoint, mice were sacrificed, and organs and 
whole blood samples were taken for subsequent analyses. 
Figure 7: Batch report for B16-F10 melanoma cells stained with ALDEFLUOR reagent. Parental 
B16-F10 cell lines were subjected to FACS after being stained with ALDEFLUOR reagent.  DEAB was 
used as a negative control in order to set appropriate gates for ALDH-negative cells (A). ALDHhigh cells 
reflect at least a one log shift in fluorescence intensity (B).  Sorted cells were analyzed and isolated using a 
BD Aria II FACS and batch reports were generated using FACS Diva software. 
 
 To test the in vivo properties of CICs, ALDHhigh A375 cells were sorted as described above. 
ALDHhigh cells were suspended in Hank’s Balanced Salt Solution (HBSS) +calcium +magnesium 
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(Invitrogen) and mixed at a ratio of 1:1 with Matrigel (growth factor reduced, without phenol red; BD 
Biosciences). A total of 100 μL of this Matrigel-cell suspension containing 1x104 melanoma cells was 
implanted s.c. on the dorsal side of the athymic nude mice. Tumor size was monitored thrice weekly until 
animals were sacrificed due to tumor burden. Tumor volume [V = L × W2 × (π / 6)] was determined by 
measuring the greatest linear dimensions in length (L) and width (W). 
2.11 SDS-PAGE and Immunoblot 
 Cultured cells were treated with 100 μM Lunasin or vehicle and harvested by using enzyme free 
dissociation buffer (TrypLE, Gibco) to minimize protein degradation.  Cells were pelleted by centrifugation 
at 300 xg and resuspended in appropriate amounts of RIPA buffer (250 mM Tris-HCl, pH 7.5, 5 mM 
EDTA, 750 mM NaCl, 0.5% Lauryl sulfate, 2.5% Deoxycholic acid, 5% Igepal CA-630, Protease inhibitor 
cocktail containing 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), pepstatin A, bestatin, leupeptin, 
aprotinin and trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)-butane (E-64) (Sigma-Aldrich).  Protein 
concentrations of cell lysates were determined by a bicinchoninic acid (BCA) assay (Thermo Fisher 
Scientific, Waltham, MA).  Total protein ranging from 20 - 40 μg were loaded in 10% polyacrylamide gels 
(BioRad, Hercules, CA) and resolved at 100 volts for 1 h.  The protein was then transferred to a 
polyvinylidene difluoride (PVDF) membrane (BioRad) at 350 milliamps (mA) for 1 h.  Membranes were 
stained with Ponceau S (BioRad) to ensure equal loading and transfer of protein into the membrane.  In 
some cases, PVDF membranes were then cut into halves, leaving two duplicate membranes that were 
subsequently probed for various proteins.  In some cases, images of immunoblots presented in this 
dissertation represent chemiluminescent signal resulting from these duplicate membranes.  Individual 
PVDF membranes were blocked with 5% bovine serum albumin (BSA) or non-fat dry milk for 1 h.  After 
several washing steps in Tris Buffered Saline with 0.1% Tween (TTBS), primary antibodies were incubated 
with the PVDF membrane at 4˚C overnight with constant agitation.  Lysates were probed with antibodies 
that recognize human Microphthalmia-associated transcription factor (MITF, Cell Signaling #12590), 
Tyrosinase (EMD Millipore #05-647), poly ADP ribose polymerase (PARP, Santa Cruz #sc-7150), 
Caspase-3 (Santa Cruz #sc-56055), NANOG (EMD Millipore #MABD24), β-Actin (Santa Cruz #sc-
47778), phosphorylated AKT (Cell Signaling #9916S), phosphorylated FAK (Cell Signaling #9330S), 
phosphorylated ERK 1/2 (Cell Signaling #4094), H3K9 (EMD Millipore #07-352), H4K12 (EMD 
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Millipore #04-119), H4K8 (EMD Millipore #07-328), and H3K14 (EMD Millipore #07-353) diluted in 
TTBS at 1:1000 – 1:2000 v/v.  After three washes in TTBS, secondary antibodies at 1:10,000 dilutions 
(Cell Signaling) were incubated with the membrane for 1 h at RT.  Electrochemiluminescent (ECL) 
substrate and enhancer solutions (Thermo Fisher) were allowed to activate horseradish peroxidase (HRP) 
signal on membrane for 2-3 min; Chemiluminescence was developed on x-ray film and/or detected using a 
ChemiDoc station (BioRad).  In some cases, membranes were stripped using a harsh stripping buffer (0.5 
M Tris HCL, pH = 6.8, 10% SDS, 1% 2-mercaptoethanol).  Briefly, PVDF membranes were allowed to 
incubate in an appropriate amount of stripping buffer in a dry incubator (Thermo Fisher) for approximately 
20 min at 50˚ C under constant agitation.  After removal of the antibodies, membranes were washed in 
TTBS at least 5 times for a minimum of 5 min per wash.  To ensure removal of all primary and secondary 
antibodies, ECL substrate was applied to the stripped membrane as described above.  After a 2-3 min 
incubation with ECL substrate, membranes were reimaged to confirm the efficient removal of all 
antibodies.  In some cases, a second incubation with stripping buffer was necessary to remove all bands 
from previously imaged membranes.  Efficiently stripped membranes were blocked in an appropriate 
blocking buffer as described above, and subsequently probed using a different primary antibody.  All band 
densities, including the loading control (β-Actin), were normalized to vehicle-treated cells and are shown 
above the appropriate representative protein band.   
2.12 Non-steroidal anti-inflammatory drug (NSAID) Toxicological Panel and Complete Blood Count 
(CBC) 
 Whole blood was drawn from athymic nude mice by cardiac puncture immediately following CO2 
asphyxiation and collected in serum separator tubes (BD Biosciences) or EDTA coated collection tubes 
(BD Biosciences).  Aliquots of whole blood (25 μL) were collected in EDTA coated tubes and sent to the 
Research Resources Center (RRC) at the University of Louisville for CBC analysis.  After 1 h post-
collection, whole blood collected in serum separator tubes were centrifuged for 10 min at 10,000 xg.  250 
μL of serum was removed from each sample, collected in a 1.5 mL Eppendorf tube, and send to the RRC 
facility for NSAID toxicological analysis. Liver damage was assessed by levels of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALKP).  Kidney damage was assessed 
by level of blood urea nitrogen (BUN) and creatinine (CREA). 
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2.13 In vivo Limiting Dilution Assay and ALDH Activity in Primary Tumors 
 In order to determine the viability of using ALDH as a practical biomarker for identifying CICs, in 
vivo limiting dilution assays were employed.  A375 melanoma cells were isolated by FACS based on 
ALDHhigh and ALDHlow activity as described above (Section 2.5).  These cells were counted and assessed 
for high viability (> 95%) by trypan blue exclusion assays.  Cells were resuspended in HBSS and mixed in 
a 1:1 ratio of Matrigel as previously described in this chapter (Section 2.10).  Dilutions of 100, 1,000, and 
10,000 cells were s.c. injected into the hind flanks of athymic nude mice in a total volume of 100 μL.  
Tumor growth initiated by both ALDHhigh and ALDHlow cells was observed for each dilution group.  Upon 
experimental endpoint, tumors were excised, and subjected to collagenase treatment to dissociate primary 
tumors to single cell suspensions.  After resection, tumor tissues were minced using a scalpel and incubated 
at 37˚ C with dissociation media (DMEM/F12 containing 1 mg/ mL collagenase, 20 μg/ mL DNase, and 
1% penicillin/streptomycin) for up to 4 h.  Samples were strained using a 70 μm nylon filter to remove 
aggregates of tumor tissue and collect single cells into a 15 mL conical tube.  Samples from ALDHhigh and 
ALDHlow tumors were pooled before analysis of ALDH activity.  Samples from each group were counted 
and assessed for viability by trypan blue exclusion assays, and subjected to staining for ALDH activity as 
previously described.  In order to discriminate mouse from human cells, all samples were labelled with a 
human-specific antibody against CD147 (BioLegend).  Positively-gated CD147 cells were then analyzed 
for ALDH activity by ALDEFLUORTM staining as previously described. 
2.14 β-Galactosidase Staining 
 Senescence-associated (SA) β-Galactosidase staining (Cell Signaling) was utilized to assess the 
degree of cellular senescence induced by Lunasin treatment; vemurafenib was used as an experimental 
control.  Melanoma cells were plated at 1x105 cells per well in 6-well culture plates (Corning) and treated 
with vehicle (PB), 100 μM Lunasin, or 1 μM vemurafenib for up to 24 h.  Treated cells were washed twice 
with PBS, and incubated with 1x fixative solution for 15 min at RT.  Cells were again washed twice with 
PBS and incubated with 1x staining solution (pH 6.0) overnight in a dry incubator at 37˚ C.  Staining was 
analyzed and imaged using an EVOS light microscope.  A total of 500 cells were counted from 5 
independent fields and averaged for the total number of stained (blue) cells.  The mean number of 
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positively stained cells was averaged from three independent experiments and represented as a percentage ± 
s.d. 
2.15 Liquid Overlay Generation of Multicellular Tumor Spheres 
 Cell culture plates (96-well, Corning) were coated with 100 μL per well of a 1:1 mixture of 
warmed DMEM culture media and cell culture-grade agarose (1.5% final concentration) and allowed to air 
dry at RT.  1x103 A375 and A375R melanoma cells were plated in 100 μL of DMEM culture media 
containing vehicle, 100 μM Lunasin, 1 μM vemurafenib, or a combination of vemurafenib and Lunasin.  
Cells were allowed to grow in an incubator at 37˚C and 5% CO2 for up to 96 h.  Tumor sphere 
measurements were taken after the formation of multicellular spheres (~72 - 96 h), and measured for up to 
an additional 96 h after sphere formation using ImageJ software (National Institutes of Health, NIH).  
Tumor sphere diameters were measured and plotted as mean sphere diameter ± s.d. 
2.16 Microarray 
 Parental A375 cells and A375 ALDHhigh cells from three independent cultures were treated with 
vehicle or 100 μM Lunasin for 72 h in adherent and nonadherent conditions, respectively.  After treatment, 
cells were harvested, homogenized, and RNA was extracted using the RNeasy Mini Kit (Qiagen) 
complemented with the QIAshredder kit (Qiagen).  RNA concentration was quantitated using a Nanodrop 
1000 system (Thermo Fisher) and quality was analyzed by an Expert 2100 BioAnalyzer (Agilent).  All 
RNA used had RNA integrity numbers (RIN) of 8 or greater.  cDNA was generated using the Ovation Pico 
WTA V2 system (NuGen), and analyzed for integrity on the Bioanalyzer.  Fragmentation and labeling of 5 
μg total DNA was carried out using an Encore Biotin Module (NuGen) which is optimized for use with 
Affymetrix gene chips.  Hybridization and raw data analysis were carried out by staff at the University of 
Louisville Microarray Core (Louisville, KY).  Gene expression and analysis were performed using 
MetaCore software (Thomson Reuters) with a fold-change cut-off of 1.3 (p < 0.05). 
2.17 Immunofluorescence Microscopy 
 A375 cells were plated in DMEM culture media at a density of 1 x 104 cells per well in an 8-
chambered microscope slide.  Cells were allowed to adhere for 4 h before removal of media and 
replacement with media containing vehicle (PB) or 100 μM Lunasin.  Cells were allowed to incubate with 
treatment media for up to 24 h.  Cells were washed with PBS, fixed with 4% paraformaldehyde, and 
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permeabilized with 0.1% Triton X-100.  Cells were incubated at -20˚C in 100% methanol before blocking 
with 1% bovine serum albumin.  Cells were incubated with anti-Lunasin (1:1000) rabbit polyclonal 
antibody [16] and anti-αV (1:100) mouse monoclonal antibody (Santa Cruz #376156) in blocking solution.  
Following overnight incubation, cells were washed and incubated with appropriate secondary antibodies 
conjugated to AlexaFluor-488 or AlexaFluor-647 fluorophores (Jackson ImmunoResearch).  After 
washing, mounting media containing DAPI (Thermo Fisher) was dropped onto slides, and a cover slip was 
sealed on top of the slide using clear fingernail polish prior to fluorescent analysis.  Images were taken on a 
Nikon NiE upright microscope using Nikon Elements software (Nikon). 
 For Lunasin uptake experiments, the same protocol was followed; however, time points were 
standardized at 0, 5, 10, 30, and 60 min post-treatment.  Additionally, A375 melanoma cells were treated 
with both Lunasin containing the native (RGD) sequence as well as a mutated (RAD) peptide at a 
concentration of 100 μM.  Melanoma cells were again fixed and labelled with Lunasin monoclonal 
antibody, counterstained with DAPI, and imaged on a Nikon NiE fluorescent microscope using Nikon 
Elements software. 
2.18 Proximity ligation assay (PLA) 
 A375 ALDHhigh cells were isolated by FACS as described in Section 2.5.  Following isolation, 
ALDHhigh cells were treated for 24 h with 100 μM Lunasin.  Treated cells were washed twice with PBS, 
plated on glass coverslips coated with poly-lysine (Sigma), and allowed to air dry in a biological safety 
cabinet.  Coverslips were washed twice with PBS for 5 min per wash and fixed in 4% paraformaldehyde 
(PFA) for 10 min.  Coverslips were then washed three times with PBS for 5 min per wash and 
permeabilized using 0.5% Triton X-100 in PBS for 10 min.  After permeabilization, cells were washed 
three times with TTBS for 5 min per wash, and blocked in 1% BSA in TTBS.  Cells were incubated 
overnight at 4˚C with appropriate antibody combinations against Lunasin [16], phosphorylated focal 
adhesion kinase (FAK, Abcam #ab4803), integrin-linked kinase (ILK, Cell Signaling #3862), and integrin 
αV (Cell Signaling #4711), β1 (Abcam #ab134179), and β3 (Millipore #AB2984) subunits as described [10].  
Antibodies were then labelled using the Duolink in situ red starter kit (Sigma) following the recommended 
manufacturer’s protocol, and subsequently imaged on a Nikon NiE upright microscope with Nikon 
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Elements software.  Exposure settings were kept consistent throughout image collection.  Fluorescence 
analysis of the resulting images representing a single layer was analyzed using ImageJ software (NIH).   
2.19 Transwell invasion assay 
 A375 and B16-F10 cells were plated in 6-well culture plates at a density of 1x105 cells per well in 
2 mL of DMEM culture media.  After 4 h, the media were removed and replaced with media containing 
vehicle or 100 μM Lunasin for 24 h.  After treatment, cells were washed once with PBS, and harvested with 
TrypLE dissociation media (Gibco).  Cells were counted and viability was assessed by trypan blue 
exclusion assay; > 95% viability was observed for all samples.  Cells were replated at a density of 1x105 
viable cells in serum-free DMEM culture media containing vehicle or Lunasin into a transwell Boyden 
chamber (pore size = 8 μm) coated with Matrigel basement membrane (Corning).  The bottom chamber 
was filled with DMEM culture media containing 10% FBS to promote invasion from the top chamber.  
After 24 h at 37˚C, cells were removed from the top chamber by using a cotton-tipped swab, and cells 
adhered on the bottom layer of the insert were fixed in 100% methanol and stained in a 1% Toluidine Blue 
in 1% borax solution.  After several washes in distilled water, membranes were allowed to air dry, mounted 
onto slides with mounting solution, covered, and sealed with a 60 mm cover slip and clear fingernail polish.  
A total of 5 fields per insert were counted and averaged to obtain the average number of cells per field. 
2.20 Murine model of experimental metastasis 
 All mice were handled in accordance with the Association for Assessment and Accreditation of 
Laboratory Animals Care international guidelines with the approval of the appropriate Institutional Animal 
Care and Use Committees at Indiana University, Bloomington (Protocol # 14–019–4).  B16-F10 cells (2.5 
x 105 ) were suspended in 100 μL phosphate buffered saline (PBS) and injected intravenously (i.v.) into 4-6 
week old, female C57Bl/6 mice (Harlan) via the lateral tail vein.  Immediately following transplantation of 
melanoma cells, mice were dosed with Lunasin (30 mg / kg) or vehicle by intraperitoneal (i.p.) injection.  
Mice received daily i.p. injections of Lunasin or vehicle until the end of the experiment 18 days post-
transplantation of cells.  Upon sacrificing the mice, lungs were resected and imaged using a Leica M205 






 After fixation in 10% formalin, lungs were transferred to 70% ethanol and stored overnight at 
room temperature.  Tissues were dehydrated through a series of graded alcohols, and infiltrated with 
paraffin (Electron Microscopy Sciences).  Tissues were embedded in paraffin and sectioned (thickness = 7 
μm) on a microtome.  Sections were transferred to SuperFrost Plus slides (Fisher) and allowed to dry 
overnight on a slide warmer (Fisher).  Paraffin removal was initiated by several washes in xylene, and 
followed by rehydration of the tissues in a series of graded alcohols.  Tissues were stained in hematoxylin 
and eosin (H&E) solutions followed by a clearing solution of xylene.  After staining, PermountTM mounting 
medium (Fisher) was applied to each slide and covered with a 60 mm cover slip (Fisher).  Slides were 
allowed to dry at room temperature overnight and then placed in a drying oven until completely dry.  
Images of H&E stained slides were taken using a Leica M205 Stereoscope (Leica) as well as an EVOS 
light microscope (Life Technologies).  Macrometastases were counted under 4.32x magnification on the 
Leica M205 Stereoscope.  Micrometastases were counted from H&E stained non-sequential sections (n = 
5) from each tissue sample using an EVOS light microscope.  Images were subsequently analyzed for total 
tumor area using ImageJ software (NIH). 
2.22 Differentiation of ALDHhigh cells 
 ALDHhigh and ALDHlow cells were isolated from A375 and SKMEL-28 cell lines as described 
above.  These cells were counted, assessed for viability by trypan blue exclusion, and plated into 6-well cell 
culture plates at a density of 1x105 cells per well in fresh DMEM culture media.  Cells were allowed to 
grow in standard growth conditions in an incubator for up to 7 days.  ALDH activity was assessed on day 3 
and on day 7 and subsequent analysis was performed to assess the proportion of cells remaining in the 
ALDHhigh compartment using methods previously described in Section 2.5.  Analysis was performed using 
FlowJo V10 software using gates set upon a DEAB negative control. 
2.23 Statistical Analysis 
 GraphPad Prism 5.0 software (GraphPad Prism Software, Inc., La Jolla, CA) was used for all 
statistical analyses. For all in vitro studies, two-group comparisons between control and test samples were 
done by two-tailed student’s t-tests and represent data from three independent experiments. For 
experiments in which a significant difference was observed, p-values are provided above the statistically 
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significant (from control group) treatment group.  If statistical significance is observed between 
experimental groups, an asterisk will be used to denote significance between the indicated treatment 
groups.  P-values between groups which were not determined to be statistically significant are not provided 
in their respective figures.  For the in vivo tumor measurement studies, group comparisons were done using 
two-way ANOVA. For all tests, statistical significance was assumed when p < 0.05.  In vitro results are 
shown as means ± s.d.  In vivo experiments were analyzed using GraphPad Prism ANOVA analysis tool 
are shown as means ± s.e.m.  Mean tumor volumes for individual days were compared by unpaired 
student’s t test (p<0.05) to determine significance between control and treatment groups.  Experimental 
metastasis data were analyzed for significance using two-tailed student’s t-tests.  Interactions between 
Lunasin and vemurafenib were determined to be antagonistic (< 1), additive (1), or synergistic (> 1) by 
calculating the Drewinko Index (DI).  All samples were normalized to appropriate controls and applied to 
the formula DI = �𝑆𝑆𝑆𝑆
1�(𝑆𝑆𝑆𝑆2)
𝑆𝑆𝑆𝑆3
 in which SF1 is equal to the surviving fraction of drug1, SF2 is equal to the 
surviving fraction of drug2, and SF3 is equal to the surviving fraction of the combination of drug1 and drug2.  
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CHAPTER 3: LUNASIN IS A NOVEL THERPEUTIC TARGETING MELANOMA STEM CELLS 
3.1 INTRODUCTION 
 Nearly 20% of all Americans will develop some form of skin cancer during their lifetime [149].  
Annual treatment costs for skin cancers are estimated at $8.1 billion; approximately $4.8 billion and $3.3 
billion for non-melanoma and melanoma skin cancers, respectively [150].  Although less frequent than 
non-melanoma skin cancers, rates of melanoma are steadily rising and account for nearly all skin cancer-
associated deaths [74].  Recurrent disease is the major cause of morbidity and mortality associated with 
melanoma. Although significant progress has been made in preventing or delaying disease, additional non-
toxic approaches are needed to reduce the risk of recurrence. Studies in preclinical models of 
carcinogenesis have shown that an enrichment of melanoma CICs is likely to occur after conventional 
chemotherapeutic regimens, implicating CICs in treatment resistance and cancer recurrence [151-154].  
Thus, successful elimination of CICs, along with the proliferating bulk tumor melanoma cells could be an 
effective therapeutic strategy to achieve higher rates of complete remission, especially in patients with late 
stage melanoma. 
Melanoma CICs have been shown to represent about 1–25% of all tumor cells and can form 
tumors by injection of a single cell [98].  Identification of a universal biomarker for CICs remains a major 
research focus [155]; however, most markers appear to be model specific. Melanoma cells with stem cell-
like plasticity were initially discovered in patient tumors that overexpressed CD20 [93] and CD133 [94]. 
These subsets of cells displayed characteristics of stem cells and an enhanced ability to form palpable 
tumors in immunodeficient mice. Ensuing studies have identified ABCB5 [66] and CD271 [95] as potential 
melanoma CIC biomarkers. More recently, melanoma cells expressing Aldehyde Dehydrogenase (ALDH) 
have been shown to display stem cell-like properties with enhanced in vivo tumorigenic capacity [103].  
Other studies utilizing solid tumor models of the colon [108], breast [109], and lung [156] provide further 
evidence for utilizing expression levels of ALDH as a CIC marker.  This hypothesis is supported by data 
showing ALDH1 expression correlates with poor prognosis in breast [157], ovarian [158], and lung [159]
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cancers, and that ALDH is critical in the development and differentiation of hematopoietic stem cells [160, 
161] by modulating retinoid signaling through the conversion of vitamin A (retinol) to retinoic acid [162], a 
ligand for downstream nuclear receptors retinoic acid receptor (RAR) and retinoid X receptor (RXR) [163]. 
Lunasin has three putative functional domains including an aspartic acid tail, an RGD domain, and 
a chromatin-binding helical domain [15, 16].  Lunasin has been shown to exhibit robust chemopreventive 
and chemotherapeutic activities [9, 11-14].  Lunasin has chemotherapeutic activity both in vitro and in vivo 
in various cancer models, including colon [35, 36, 164] and breast [34] cancer.  Previous studies have 
established a novel functional role for Lunasin in decreasing proliferation of NSCLC cells by suppressing 
integrin signaling through αvβ3 [10, 165]. This finding is consistent with results from previous studies that 
demonstrated that Lunasin is internalized via αvβ3 integrin [12, 38].  When compared to melanoma cells, 
the expression of αvβ3 integrins are lower in non-transformed epithelial cells [53]; the expression levels of 
αvβ3 correlate with the metastatic potential and the conversion of melanoma neoplasms to a metastatic 
phenotype [55].   
In light of recent studies that clearly link integrin-matrix interactions to cancer cell survival [166] 
(including the maintenance and survival of CICs through integrin-FAK signaling [64, 167-174]), it seemed 
logical to ask whether Lunasin can target melanoma CICs and, if yes, is this anti-CIC activity critical for its 
in vivo antitumorigenic effects.  This dissertation will aim to show, for the first time, that Lunasin 
specifically targets ALDHhigh CICs in human melanoma cell lines. Lunasin treatment decreases the 
expression of surrogate CIC markers in vitro and reduces their in vivo tumorigenicity. Lunasin treatment 
significantly reduces formation of CIC-enriched melanoma oncospheres and more importantly, induces 
expression of melanocyte-associated differentiation markers while suppressing stem-associated factors. 
Taken together, these results delineate the ability of Lunasin to regulate melanoma CIC properties and 
provide a compelling argument for developing Lunasin as a therapeutic agent to reduce melanoma 
recurrence.  
3.2 MATERIALS AND METHODS 
Isolation and purification of Lunasin 
 Isolation and purification of Lunasin was performed as described in Section 2.1.  These Lunasin 




 ALDH activity was assessed using the ALDEFLUOR kit (StemCell Technologies) as described in 
Section 2.5.  FACS was performed to isolate fractions of cells based on ALDH activity as previously 
described in Section 2.5. 
Annexin V binding assays  
Apoptosis was assessed using a commercially available Annexin V binding assay (BD 
Biosciences) as described in Section 2.6.  
Melanoma oncosphere culture 
Generation of melanoma oncospheres from sorted cells was performed as described in Section 2.9. 
Xenograft experiments 
 Subcutaneous xenograft models to assess tumor growth characteristics of parental and ALDHhigh 
melanoma cells were utilized as described in Section 2.10. 
In vivo limiting dilution assay 
 In order to investigate the tumorigenic properties and frequency of CICs in ALDH-sorted 
compartments, A375 cells were subjected to FACS as described in Section 2.5.  These cells were then 
injected s.c. at various dilutions in order to determine the extent of their tumorigenic potential as outlined in 
Section 2.10. 
Immunoblot analysis 
 Lysate preparation, SDS-PAGE, and immunoblot analysis were performed as outlined in Section 
2.11. 
Toxicological analysis 
 Kidney and liver function as well as complete blood analysis were evaluated by NSAID 
toxicological and CBC panels as previously described in Section 2.12. 
SA β-Galactosidase staining 
 A375 ALDHhigh cells were isolated by FACS and subsequently treated with vehicle, Lunasin, or 





Liquid overlay generation of multicellular tumor spheres 
 Liquid overlay was used to help characterize the interaction between vemurafenib and Lunasin as 
described in Section 2.15. 
Statistical analysis  
 Statistical analysis of data presented in Chapter 3 was performed as described in Section 2.23. 
 
3.3 RESULTS 
 Lunasin inhibits anchorage-independent growth in human melanoma cell lines 
 Previous studies of NSCLC demonstrated that Lunasin had a modest or no effect on most cell 
lines when grown under standard adherent culture conditions whereas all cell lines tested were sensitive 
under non-adherent conditions [165].  It was found that this was also the case with human melanoma cell 
lines. A375 and SKMEL-28 cells did not show any decrease in proliferation when treated with a 
concentration range of 10 to 100 µM over three days when assayed using a standard MTS-based assay 
(Figure 8).  Additionally, no indication of apoptosis in parental A375 or SKMEL-28 melanoma cells was 
observed (Figure 9) when cells were treated with Lunasin and subjected to labelling using an Annexin V 
binding assay (Figure 9A-D).  No significant induction of cleaved caspase 3 or PARP was observed 
following treatment with Lunasin for 24 h in either cell line (Figure 9E).  However, A375 and SKMEL-28 
melanoma cells exhibited a significant dose-dependent decrease in colony formation in soft agar assays 
upon exposure to Lunasin (Figure 10). When compared to cells treated with vehicle alone; colony 
formation by A375 cells was reduced by 37% upon treatment with Lunasin (100 µM) (Figure 10A, 10B, 
and 10E), while Lunasin-treated SKMEL-28 cells exhibited a 23% inhibition of colony formation (Figure 
10C, 10D and 10F). The size of colonies formed by single melanoma cells was also decreased upon 
exposure to Lunasin (Figure 10A–D). These results establish that Lunasin inhibits anchorage-independent 
growth of melanoma in vitro and provides the first demonstration that Lunasin may offer potential 
therapeutic effects on human melanoma cells.  
Lunasin inhibits tumor growth of melanoma cells in vivo 
 To evaluate whether the inhibition of in vitro anchorage-independent growth of melanoma cells 
can be recapitulated in vivo, tumor xenografts were generated by s.c. implantation of A375 cells in athymic 
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nude mice. Tumor cell implantation was followed by concurrent and subsequent daily i.p. injections of 
Lunasin (30 mg/kg body weight).  Dosing was determined by a combination of previous in vivo 
experiments [175] with the objective of obtaining a significant host response while minimizing toxicity, 
and established dosing regimens for previously established biologics (e.g. cilengitide).  While no 
significant reduction in palpable tumor formation was observed, a significant reduction in the tumor growth 
rate was observed in the Lunasin-treated mice when compared to mice injected with vehicle alone 
(Figure 10G). Tumors were measured at 14 days after initial implantation; however, it was observed that 
mice in the Lunasin-treated group displayed tumors that were significantly smaller (< 50 mm3) and difficult 
to measure due to their small size and lack of depth. Mice treated with Lunasin over a 34 day period 
exhibited significant reductions in tumor volume (55%) and total tumor mass (46%) when compared to 
those measured in the vehicle-treated mice (Figure 10G and 10H).  This model established that Lunasin 
was biologically active in athymic nude mice, and its anticancer effects persists in vivo. 
 
 
Figure 8: Lunasin did not have an antiproliferative effect on A375 or SKMEL-28 melanoma cells in 
adherent culture.  Parental A375 (A) and SKMEL-28 (B) cells were plated and treated with vehicle or 
varying concentrations of Lunasin for up to 72 h.  It was observed that Lunasin treatment caused no 
significant antiproliferative effect on these cell lines when utilizing the MTS/MTT tetrazolium-based 
proliferation assay in an adherent format.  These data are consistent with the modest effects observed when 
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several NSCLC, breast, and colon cancer cell lines were treated with Lunasin at similar concentrations.  
Graphs were generated using data gathered from three independent experiments, and statistical analysis 
was performed by student’s t-test.  P-values of less than 0.05 were considered statistically significant. 
 
 
Figure 9:  Lunasin did not induce apoptosis in parental melanoma cell lines. A375 (A, C) and 
SKMEL-28 (B, D) cell lines were treated with Lunasin (100 μM) for 24 h, and subsequently analyzed for 
apoptosis. No significant induction of apoptosis or necrosis was observed with Lunasin treatments.  These 
results were corroborated by findings that Lunasin did not increase levels of cleaved PARP and active 
Caspase 3 when assessed by immunoblot analysis (E).  Data were gathered from three independent 
experiments, and analyzed using FlowJo V10.  Statistical significance between control and Lunasin 
treatment groups was determined by student’s t-test (p < 0.05).   
Lunasin reduces the melanoma CIC subpopulation in established cell lines 
  ALDH is an intracellular enzyme highly expressed by stem-like cells [176] and recent studies 
suggest that high ALDH activity is a property of CICs in human melanoma [103]. To measure ALDH 
activity in melanoma cells, ALDEFLUOR reagent was used.  ALDEFLUOR is a commercially available 
molecule that freely diffuses into cells and is a substrate for the ALDH enzyme. ALDH cleaves 
ALDEFLUOR and yields a fluorescent product that can no longer diffuse across the cell membrane. ALDH 
activity within the cells is then assayed by incubating cells with a fluorescent ALDH substrate followed by 
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flow cytometry. For this assay, ALDHhigh CICs were identified by comparing the fluorescence in a test 
sample to that in a control sample containing DEAB, a specific inhibitor of ALDH. These data demonstrate 
that treatment of A375 melanoma cells with Lunasin (100 µM) for 24 h significantly reduced the size of the 
ALDHhigh CIC subpopulation (Figure 11A – 11C). Similarly, SKMEL-28 ALDHhigh subpopulations were 
reduced after a 24 h treatment with Lunasin (Figure 11D- 11F).  Immunofluorescence analyses for the 
ALDH marker expression corroborated the findings that Lunasin treatment dramatically diminished the 
ALDH expression levels in both A375 and SKMEL-28 melanoma cells and significantly reduced the 
ALDHhigh subpopulation (Figure 11A–11F). 
 
Figure 10:   In vitro efficacy of Lunasin in malignant melanomas. Representative images of colonies 
grown in soft agar for vehicle-treated (A, C) and Lunasin-treated (B, D) A375 (A,B) and SKMEL-28 (C,D) 
cells (magnification at 40x). Scale bars on images represent 100 μm.  Anchorage-independent growth 
conditions sensitized melanoma cells to Lunasin resulting in a significant decrease in colony formation in 
A375 (E) and SKMEL-28 (F) cells. Statistical significance between treatment groups is denoted by an 
asterisks (*) and p-values are provided for each significant difference. Two asterisks (**) signifies a 
difference between 30 μM and 100 μM Lunasin treatment groups.  Data are presented as mean ± s.d. from 
three independent experiments. For xenograft studies, 2.5 X 10
6
 A375 cells were injected s.c. into nude 
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mice and subsequently treated with vehicle (PB) (n = 8) or Lunasin (n = 10) for a total of 34 d.  Lunasin 
reduced tumor volume by 55% (G) and wet tumor weight by 46% (H).  Lunasin-treated mice differed 
significantly in tumor volume (p < 0.001) from control treated mice as assessed by GraphPad ANOVA 
analysis.  The corresponding reductions in wet tumor weights were determined to be significant by 
unpaired student’s t-test (p = 0.003) and statistical significance is denoted by an asterisk.  In vivo data are 
presented as mean ± s.e.m. 
 
 
Figure 11:  Lunasin depleted populations of cells displaying high ALDH activity.  A375 and SKMEL-
28 cells showed a substantial decrease in ALDH positive populations when treated with Lunasin for 24 h.  
DEAB was used as a negative control, and served as a tool for gating ALDH negative populations.  
Representative flow cytometry plots and corresponding fluorescent microscopy images were taken 24 h 
post-treatment and provided for DEAB (A, D), control (B, E), and Lunasin-treated (C,F) groups.  Lunasin 
reduced the number ALDH
high 
cells in A375 and SKMEL-28 cell lines when compared to vehicle-treated 
cells (G).  Statistical significance was determined from three independent experiments and assessed by 
student t-test (p < 0.05). Fluorescence microscopy images were taken at 40x magnification.  Data are 
presented as mean ± S.D and represent data gathered from three independent experiments.  Statistical 
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analyses were performed using student’s t-test with p-values of less than 0.05 being considered statistically 
significant. 
Lunasin suppresses the functional properties of melanoma CICs 
 CICs are characterized by having stem cell-like properties, including the ability to self-renew. 
Oncosphere formation assays have been widely used to measure the functional activity of CICs, and 
previous studies have indicated that the ALDHhigh melanoma cells represent the CIC-enriched compartment 
[103]. To determine the effects of Lunasin on melanoma CIC functional properties, clonogenic and sphere 
formation assays were performed using isolated ALDHhigh A375 and SKMEL-28 melanoma cells. Stringent 
assay conditions in which spheres (floating) and colonies (formed in soft agar) are all of clonal origin were 
first established. Under these conditions, Lunasin treatment (100 µM), when compared to control vehicle 
treatment, significantly inhibited sphere establishment in ALDHhigh A375 melanoma cells and in ALDHhigh 
SKMEL-28 melanoma cells (Figure 12A-C). Similarly, when compared to vehicle-treated cells, Lunasin-
treatment at both 30 µM and 100 µM drug doses significantly affected colony forming ability in purified 
ALDHhigh A375 melanoma cells (Figure 12D, 12E, and 12H) as well as in ALDHhigh SKMEL-28 cells 
(Figure 12F, 12G, and 12I). Collectively, these results indicate that treatment with Lunasin negatively 
regulates melanoma CIC functional properties in vitro.  In these assays, it was demonstrated that Lunasin 
functionally represses the clonogenic ability of melanoma CICs by inhibiting their potential to form 
oncospheres in non-adherent conditions as well as self-renewal capacity when suspended in soft agar. 
Lunasin limits in vivo growth of tumors initiated by melanoma CIC-enriched ALDHhigh cells 
 It was further investigated if the anti-CIC activity of Lunasin in melanoma cells in vitro translated 
into better therapeutic efficacy against in vivo melanoma CIC-initiated tumor growth. ALDHhigh A375 cells 
isolated from the parental line were subcutaneously injected into the dorsal side of nude mice and 
subsequently treated via the intraperitoneal route with 30 mg/kg of Lunasin or vehicle control as described 
in Section 2.5. All mice eventually formed palpable tumors regardless of treatment group; however, a 
significant reduction in the tumor growth rate was observed in the Lunasin-treated group when compared to 
that in vehicle treated mice (Figure 13A and B). Notably, tumor volumes in Lunasin-treated mice were 
reduced by 73% (p < 0.001; Figure 13A) upon experimental endpoint (i.e. 38 days post-transplantation). 
Also, wet weights of tumors isolated from Lunasin-treated groups were reduced by 67% when compared to 
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tumor weights from vehicle-treated mice (p < 0.001; Figure 13B) upon experimental endpoint.  
Additionally, a significant lag time until palpable tumors (> 50 mm3) were formed was observed in the 
Lunasin-treated group when compared to vehicle-treated animals. 
 It was evaluated if any toxicological effects are associated with chronic Lunasin treatment.  Mice 
receiving Lunasin treatment did not display significantly altered liver enzymes or creatinine levels when 
compared to the control group; however, significantly lower BUN levels were observed in Lunasin-treated 
mice (Figure 14A-B).  Additionally, CBC analysis showed no significant difference in blood cell counts 
between vehicle-treated and Lunasin-treated mice (Figure 14C-E).  These studies indicate that melanoma 
CICs were very sensitive to Lunasin treatment in vivo, and that this treatment regimen resulted in minimal 
toxicity. 
 
Figure 12: Lunasin reduced self-renewal capacity and oncosphere formation of CICs.  ALDH
high
 
populations of melanoma cells were plated in low adherent culture for 21 d and treated with vehicle or 
Lunasin twice weekly.  Representative images taken at 7 d (A) and 21 d (B) illustrate the ability of Lunasin 
to disrupt sphere formation of A375 ALDHhigh melanoma cells. Lunasin treatment decreased sphere 
formation by 81% and 55% in A375 ALDHhigh and SKMEL-28 ALDHhigh cell lines, respectively (C).  
ALDH
high
 melanoma cells showed increased sensitivity to Lunasin versus their parental counterparts when 
treated in soft agar.  Lunasin-treated ALDHhigh cells derived from A375 and SKMEL-28 lines demonstrated 
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a decreased ability to form colonies in soft agar.  Representative images for A375 and SKMEL-28 colonies 
treated with vehicle (D, F) or Lunasin (E, G) illustrate the morphological differences between treatment 
groups. The number of colonies formed by Lunasin-treated cells were decreased in size and density in 
ALDHhigh fractions of A375 (H) and SKMEL-28 (I) cell lines.  Significance (p < 0.05) was determined 
from three independent experiments and assessed by student’s t-test (p < 0.05).  Scale bars on images 
represent 100 μm.  All representative images were taken at 40x magnification. Data are presented as mean 
± s.d.  
 





 cells and subsequently dosed with 30 mg/kg of Lunasin or vehicle every day for 38 
d.  Upon endpoint, average tumor volumes in Lunasin-treated mice (n = 9) were significantly lower 
compared to mean tumor volume in vehicle-treated mice (n = 8) (A).  Upon resection of tumor tissues, wet 
tumor weights were determined (B). Statistical significance between mean tumor volumes of control and 
treatment groups was determined using GraphPad ANOVA analysis tool (p < 0.05).  Wet tumor weights 
determined at experimental endpoint were determined to be statistically significant by student’s t-tests, and 





Figure 14:  Long-term Lunasin treatment did not induce toxic side effects. Nude mice were treated 
with Lunasin (30 mg/kg) for several weeks. Upon experimental endpoint, blood serum and whole blood 
fractions derived from mice in the Lunasin and control groups (n = 17) were analyzed for liver (A), kidney 
(B) and CBC (C-E) toxicity, respectively. A significant decrease in BUN was observed in Lunasin-treated 
mice.  Liver and kidney function did not appear to be affected by long-term Lunasin treatment.  Statistical 
significance between Lunasin and control groups was determined by student’s t-test (p < 0.05). 
 
Limiting dilution assays demonstrate differential growth patterns between ALDHhigh and ALDHlow 
phenotypes 
 To assess in vivo tumorigenicity of ALDH-sorted populations derived from A375 melanoma cells, 
varying concentrations of cells were injected into nude mice (Figure 15).  All mice injected with ALDHlow 
cells produced tumors when injected with 1x103 and 1x104 cells; however, only 2/3 mice injected with 
1x102 ALDHlow cells produced tumors.  All mice transplanted with ALDHhigh cells produced palpable 
tumors (9/9).  Although the sample size in these experiments was not large enough to produce a statistical 
significance in tumor formation, a significant difference in tumor growth curves between ALDHhigh and 
ALDHlow cells was observed (Figure 15A-C) when tumor growth rates were analyzed by GraphPad 
ANOVA analysis tool as described in Section 2.5.  When 1x102 ALDHhigh cells were injected into mice, 
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tumors formed quicker and had higher proliferation rates when compared to tumors initiated by ALDHlow 
cells (p < 0.007).  Despite this statistically significant difference, these results were potentially driven by 
one large tumor produced in the ALDHhigh group.  Conversely, ALDHlow cells had higher proliferative 
capacity when compared to ALDHhigh cells when 1x104 cells were transplanted (p < 0.001).  The 
intermediate dilution of 1x103 cells produced no observable differences in tumor growth (p = 0.98).  
Representative images demonstrate the differences in final tumor size between tumors initiated by 
ALDHhigh and ALDHlow cells (Figure 15D-F). 
Tumors initiated by ALDHhigh cells had a higher propensity to stay in the ALDHhigh compartment 
when compared to tumors initiated by ALDHlow cells 
 With the observable differences in tumor growth rates from limiting dilution assays, it was next 
investigated whether or not the proportion of ALDHhigh cells would significantly vary between tumors 
initiated by ALDHhigh and ALDHlow phenotypes (Figure 15G).  In order to discriminate between human 
melanoma cells with elevated ALDH activity and mouse cells which may also have intrinsic ALDH 
activity, human cells were selected for by using a human-specific PE-conjugated antibody against CD147 
(top).  This allowed for the gating and analysis of ALDH activity in only A375-derived cells (bottom).  
Cells dissociated from tumors initiated by ALDHhigh melanoma cells had a population with high ALDH 
activity which represented 6.24% of PE+ cells.  In ALDHlow initiated tumors, high ALDH activity was seen 
in only 1.25% of PE+ cells.  These data raise several questions as to the function and responses of 
melanoma CICs to the surrounding microenvironment, and whether bulk tumor cells play a major role in 
the differentiation and self-renewal of these stem-like cells. 
 In vitro, a small population of cells with low ALDH activity derived from both A375 and 
SKMEL-28 melanoma cell lines had the intrinsic capability to (de)differentiate to form ALDHhigh cells 
(Figure 16).  ALDHhigh and ALDHlow cells were monitored for up to a week in serum-free stem cell media 
in low-adherent culture conditions following FACS.  After 3d and 7d in culture, cells were stained with 
ALDEFLUOR reagent and reanalyzed for the percentage of cells displaying high ALDH activity.  Samples 
derived from A375 (Figure 16A) and SKMEL-28 (Figure 16B) showed a significant portion of ALDHhigh 
cells had differentiated into the ALDHlow compartment.  Unexpectedly, it was also observed that some cells 
isolated in the ALDHlow compartment had the ability to undergo a phenotype switch into the ALDHhigh 
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compartment.  Whether this phenomenon is due to the high plasticity and heterogeneity of melanoma cells, 
a byproduct of using cultured cell lines, or the fact that these studies used a singular marker to define a 
complex hierarchy of cells has yet to be determined.  Additional studies to define the cellular hierarchy and 
differential capacity to differentiate and dedifferentiate between melanoma stem cells and bulk tumor cells 
are necessary to 1) determine if melanoma truly fits the model proposed by the cancer stem cell theory, 2) 
determine if cultured cell lines truly represent the heterogeneity of primary melanoma tissues, and 3) 
determine if ALDH is a practical biomarker for potential CIC identification. 
CIC markers are heterogeneously expressed in different melanoma cell lines 
 Although ALDH was used as a surrogate marker for identification and isolation of melanoma 
CICs, this study aims to investigate whether or not other potential biomarkers for CICs were present in the 
melanoma cell lines used.  Flow cytometry was used to assessed the level of expression of several cancer 
stem cell biomarkers reported for melanomas and for other cancer models including CD44/CD24, CD133, 
and CD271 (Figure 17).  These data indicate that both A375 and SKMEL-28 cells have a highly abundant 
population of cells with a CD44+/CD24- phenotype (Figure 17A).  Conversely, both cells lines failed to 
show populations of cells that were labelled with a CD133 antibody (Figure 17B).   Differential expression 
of CD271 was observed between A375 (93%) and SKMEL-28 (28.1%) cell lines suggesting that 





Figure 15: Limiting dilution assays demonstrate the high tumorigenicity of A375 ALDHhigh cells.  
Xenografted A375 ALDHhigh and ALDHlow melanoma cells were observed for differences in tumor 
proliferation and tumorigenicity when injected into nude mice at decreasing dilutions (A-C).  ALDHhigh 
cells produced tumors in all mice injected (9/9 total), and were tumorigenic with cell dilutions down to 100 
cells.  ALDHlow cells also displayed high tumorigenicity yet, only produced 2/3 tumors in nude mice when 
injected with 100 cells.  Tumor growth rates were also dilution-dependent; ALDHlow cells proliferated 
much more quickly at a lower cell dilution (1x104), but less rapidly at higher concentrations (1x102) when 
compared to ALDHhigh cells.  No significant difference was observed between growth curves at the 
intermediate dilution (1x103).  NT = no tumor.  Statistical analyses were performed using GraphPad 
ANOVA analysis tool with statistical significance considered when p < 0.05.  Representative images of 
tumors derived from both ALDH-sorted groups in dilutions of 1x104 (D), 1x103 (E), and 1x102 (F) are 
shown to illustrate the differential growth patterns of tumors initiated by each phenotype (zoom = 4.32x).  
Tumors initiated by 1x102 ALDHlow and ALDHhigh melanoma cells were dissociated, counted, and pooled to 
generate samples subsequently analyzed for ALDH activity. ALDHhigh and ALDHlow cells of human origin 
(i.e. A375 melanoma cells) were labelled with an anti-CD147 antibody (G, top). PE+ cells were analyzed 
for ALDH activity; Tumor cells derived from the ALDHhigh phenotype had a higher proportion of cells 
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remaining in the ALDHhigh compartment (6.25%) when compared to tumors initiated by ALDHlow 
melanoma cells (1.26%) (G, bottom). 
Lunasin induces expression of differentiation markers in melanoma CICs 
 To test if the Lunasin-induced decrease in CIC function is due to induction of apoptotic cell death 
in the isolated CICs, cell viability and apoptosis assays (Annexin V/PI staining) were performed following 
Lunasin treatment on isolated ALDHhigh cells. Interestingly, these assays failed to detect any significant 
reduction in cell viability with Lunasin treatment in ALDHhigh CICs obtained from either A375 or SKMEL-
28 cell lines when compared to that in vehicle-treated ALDHhigh CICs (Figure 18A and 18B). Consistent 
with these results, there was no apparent difference in the protein expression of apoptotic signaling 
mediators, PARP and Caspase-3 in vehicle and Lunasin-treated ALDHhigh CICs from both A375 and 
SKMEL-28 melanoma cell lines (Figure 18C).  Caspase-3 is cleaved (i.e. activated) in response to 
activation of the apoptotic cascade and in turn, cleaves PARP to carry out cellular deconstruction.  Thus, 
the absence of active Caspase-3 and cleaved PARP in Lunasin-treated samples indicates that apoptosis was 
not induced.   
 Recent studies established that reduced expression of MITF yielded G1-arrested cells with an 
invasive stem cell-like phenotype, whereas high MITF expression generated either proliferating cells or 
cells with a differentiated pigment-producing phenotype depending on the status of MITF’s post-
translational modifications [177, 178]. Other studies provide supportive evidence to this claim and show 
that TGF-β signaling can mediate MITF expression, which is critical for the generation and maintenance of 
melanoma stem cells [179]. In accordance with these reported studies, the authors observed a reduced 
expression of MITF in CIC-enriched ALDHhigh A375 and SKMEL-28 cells in comparison to MITF 




Figure 16: Differentiation of ALDHhigh cells derived from A375 and SKMEL-28 melanoma lines.  
Sorted melanoma cells were replated in normal culture media and cultured in 6-well culture dishes for up to 
7 d.  Cells were assayed for ALDH activity at day 3 (top) and day 7 (bottom).  After sorting,  ALDHhigh 
cells represented a significantly smaller proportion of cells in both A375 (A) and SKMEL-28 (B) after only 
3 days in culture and ALDHhigh populations further decreased in both cell lines at day 7.  Interestingly, it 
was observed that a small population of ALDHlow cells had the capacity to revert back to an ALDHhigh 
phenotype in both cell lines. 
 
 Whether or not Lunasin treatment can modulate MITF expression in CICs and thereby, trigger a 
phenotypic switch in CICs that will ultimately drive the Lunasin exposed melanoma CICs towards 
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differentiation was next investigated. To test this hypothesis, ALDHhigh cells isolated from A375 and 
SKMEL-28 melanoma lines were cultured in the presence or absence of Lunasin (100 µM) for 24 h under 
serum-free, non-adherent culture conditions. Lunasin-treated and vehicle-treated cultures were then 
analyzed for MITF protein expression as well as for the expression of its downstream differentiation-
associated protein, Tyrosinase. It was observed that Lunasin treatment increased the expression of MITF 
and Tyrosinase proteins in A375- and SKMEL-28-derived ALDHhigh cells compared to vehicle-treated 
controls (Figure 19B). Additionally, Lunasin-treated ALDHhigh cells from both A375 and SKMEL-28 
melanoma lines showed reduced expression of the stem-associated transcription factor, NANOG (Figure 
19C). Taken together, these experiments provide substantial experimental evidence to support the notion 
that Lunasin treatment negatively influenced melanoma CICs’ tumorigenicity and self-renewal abilities by 
regulating MITF signaling, one of the key drivers in inducing a differentiated phenotype in melanoma 
CICs, as well as suppressing levels of the key stemness factor Nanog.  
Lunasin did not induce a significant senescent response in ALDHhigh melanoma cells 
 A375 melanoma cells were sorted based on ALDH activity.  These cells were treated with vehicle, 
Lunasin, or vemurafenib for 24 h.  Representative images for positively-stained melanoma cells in vehicle, 
Lunasin, and vemurafenib-treated samples are shown (Figure 20A). No significant difference in positively 
stained cells (Figure 20B) between vehicle or Lunasin treatment groups (p = 0.09) was observed.  The 
positive control, vemurafenib, induced a significant senescent response in nearly 25% of all cells, and 






Figure 17:  CIC biomarkers are heterogeneously expressed in melanoma cell lines.  Utilizing flow 
cytometry A375 (left) and SKMEL-28 (right) melanoma cell lines were labelled and assessed for 
expression of commonly used CIC identification markers.  Both cell lines had an abundant CD44+/CD24- 
population (A).  Neither cell line had a significant population of cells that express the CD133 CIC 
biomarker (B).  When A375 cells were labelled with anti-CD271 antibody, it was observed that the 
majority of the cells were CD271+; however, in the SKMEL-28 cell line, only a small proportion (28.1%) 
expressed CD271 (C).  Isotype controls were represented by the appropriate host-specific PE- and APC-








Figure 18: Lunasin did not induce an apoptotic response in ALDHhigh melanoma cells.  Annexin V 
binding assays were used to assess apoptotic populations of melanoma cells sorted for high ALDH activity 
and subsequently treated with Lunasin or vehicle for 24 h.  Representative flow cytometry plots for A375 
ALDHhigh cells in each treatment group are shown (A).  No significant decrease in cell viability of 
ALDHhigh subpopulations derived from A375 or SKMEL-28 cells were observed when stained with 
Annexin V/ PI.  Additionally, there was no observed significant increase in apoptotic or necrotic 
populations after Lunasin treatment (B) when compared to control.  It was further confirmed that Lunasin 
did not induce apoptosis by immunoblot analysis for the apoptotic markers active Caspase-3 and cleaved 
PARP, which were absent in both control and Lunasin-treated samples (C).  Significance was determined 
by student’s t-test from three independent experiments with a p-value of < 0.05 representing statistical 









Figure 19:  Lunasin modulated expression of melanocyte differentiation and stem-associated 
markers.  Sorted subpopulations of  ALDHlow and ALDH
high
 cells displayed differential expression of the 
melanocyte-associated transcription factor MITF, with  ALDH
low 
cells expressing higher levels of MITF 
than ALDH
high
 populations in both A375 and SKMEL-28 cell lines (A). MITF and the downstream 
melanocyte differentiation marker Tyrosinase were strongly induced in ALDH
high
 cells treated with Lunasin 
for 24 h (B). Immunoblot analysis revealed that NANOG, a stem-associated marker, was repressed in 
Lunasin-treated ALDH
high
 samples (C). Actin was used as a loading control. 
 
Lunasin may enhance the efficacy of vemurafenib in vemurafenib-resistant melanomas 
 Proliferation (Figure 21A), colony-forming (Figure 21B), and liquid overlay assays (Figure 21C) 
were performed on parental A375 cells and vemurafenib-resistant A375R cells.  In MTS assays, a 
significant decrease in the number of viable A375 cells when 300 nM vemurafenib was combined with 10 
and 100 μM Lunasin (p < 0.05) was observed.  In A375R cells, a significant decrease in viable cell counts 
in combinations of 100 μM Lunasin and several concentrations of vemurafenib (p < 0.05) was observed.  
Similarly, a significant difference in the ability of A375 cells to form colonies in soft agar at concentrations 
of 30 and 100 μM Lunasin alone and 100 μM Lunasin in combination with 300 and 1000 nM vemurafenib 
(p < 0.05) was observed.  While Lunasin did not cause a significant decrease in colony formation in A375R 
cells, it did significantly reduce colony formation when A375R cells were treated in combination with 300 
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nM and 1000 nM vemurafenib (Figure 21B).  Interestingly, the authors observed that when A375R cells 
were grown in anchorage-independent culture conditions (i.e. suspended in soft agar), they were much 
more sensitive to vemurafenib when compared to adherent culture.  Liquid overlay assays were utilized to 
generate multicellular oncospheres and assess their growth characteristics after treatment with 
combinations of Lunasin and vemurafenib.  Lunasin (100 μM) did not significantly decrease the total area 
of the oncospheres in either A375 or A375R cells; vemurafenib-treated cells were significantly smaller in 
total area in both A375 and A375R cells (p < 0.05).  However, when Lunasin was combined with 
vemurafenib, sphere area was significantly decreased in both A375 (p < 0.001) and A375R (p = 0.04) 
tumor spheres (Figure 21C) compared to vemurafenib controls.  For each assay described, DI values were 
calculated based on the effect of each drug on melanoma cell proliferation.  It was observed that Lunasin 
had an additive effect (DI values between 0.9 and 1.1) when used in combination with vemurafenib for all 
of the aforementioned assays.   
 
  
Figure 20: Lunasin did not induce a significant senescent response in A375 ALDHhigh melanoma cells.  
When A375 ALDHhigh cells were treated with vehicle, Lunasin, and vemurafenib, no observable increase in 
senescence between control (2.6%) and Lunasin-treated (4.2%) samples was detected, despite a modest 
increase in cells staining positive for β-Galactosidase activity in the Lunasin-treated cells (A,B).  
Vemurafenib was statistically significant from both groups with nearly 25% of cells staining positive after a 
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24 h treatment.  Representative images for each treatment group are shown at 200x magnification (A) and 
represent data from two independent experiments. Statistical analysis was performed using student’s t-test 
with a p-value of less than 0.05 considered statistically significant. 
 
Figure 21: Combinations of Lunasin and vemurafenib yielded an additive interaction that may 
benefit treatment of chemoresistant populations of melanoma cells.  A375 and A375R (i.e. 
vemurafenib-resistant) cells were treated with combinations of vemurafenib and Lunasin and efficacy was 
assessed by MTS (A), soft agar (B), and liquid overlay assays (C).  C = control, L = Lunasin, V = 
vemurafenib, V + L = combination.  Concentrations of Lunasin are indicated in the respective graph 
legends (A, B). Significant differences between control and treatment groups were determined by student’s 
t-test and were observed for several combination treatments as denoted by asterisks (*).  Results represent 
data taken from three independent experiments and are expressed as mean ± s.d.  Representative images for 
liquid overlay assays were taken at 100x magnification. 
 
 In Annexin V binding assays, a significant decrease in cell viability (PI-A-) was observed in cells 
treated with 1 μM vemurafenib and 1 μM vemurafenib in combination with 100 μM Lunasin after 72 h of 
treatment (Figure 22).  No significant differences in viable (PI-A-), apoptotic (PI-A+/PI+A+), or necrotic  
(PI+A-) populations were observed between treatment groups and control samples at either 24h or 48 h time 
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points.  At 72 h, a significant increase in cells positively stained with PI (PI+A-) was observed in cells 
treated with a combination of Lunasin and vemurafenib when compared to vehicle-treated cells indicating 
that Lunasin may increase necrotic cell death in A375 cells treated with vemurafenib (Figure 22A).  
Representative dot plots for A375 cells treated with vehicle, Lunasin, vemurafenib, and combination 
therapy demonstrate the potential of Lunasin in conjunction with vemurafenib (Figure 22B).  Combined 
with the results from the in vitro proliferation assays, it would seem logical that Lunasin may lend some 
therapeutic benefit as an adjuvant therapy in melanoma patients receiving vemurafenib treatment.  
 
Figure 22: Lunasin in combination with vemurafenib kills A375 melanoma cells.  Annexin V binding 
assays were performed on A375 melanoma cells treated for 24, 48, and 72 h (A).  A significant difference 
was observed in cell viability after 72 h in vemurafenib and combination treatment groups compared to 
control (p < 0.05).  PI-stained cells were significantly increased in combination treatment when compared 
to control samples (p < 0.05).  Data were obtained from three independent experiments and are represented 
as mean percent ± s.d.  Representative dot plots are shown for vehicle, Lunasin, vemurafenib, and 
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combination treatments at the 72 h time point (B). Statistical analysis was performed using the student’s t-
test.  Groups were considered statistically significant when p < 0.05. 
 
3.4 DISCUSSION 
 Consumption of large amounts of soy-derived foods is associated with a lower risk of a number of 
chronic diseases including cancer [180-182]. The anticancer effects of soy components have been attributed 
to secondary metabolites such as isoflavones and specific protein fractions [183, 184]; however, no 
epidemiological evidence directly correlating soy consumption with decreased melanomagenesis has come 
to light.  Lunasin, a peptide present in crude soy protein, has been proposed to be an important 
chemoprevention agent in soy [9]. Lunasin is a 43–44-amino acid polypeptide [16, 18] that is encoded 
within the soybean GM2S-1 gene. The 22-amino acid N-terminal sequence (with no known function) of 
Lunasin is followed by a putative helix domain proposed to target Lunasin to chromatin, and the C-terminal 
end that includes a RGD cell adhesion motif followed by a poly-aspartic acid tail [15, 16]. Lunasin’s 
potential chemopreventive activity has been established by studies which show that Lunasin prevents 
cellular transformation by chemical carcinogens and viral oncogenes [9]. Recent studies have shown that 
Lunasin can inhibit the in vitro and in vivo growth of breast [34, 185], leukemia [186], colon [35, 187], and 
lung cancers [10]. These findings of this dissertation reveal that Lunasin has potential therapeutic effects 
against melanoma in both non-adherent in vitro assays and in vivo xenograft studies.  
The ALDHhigh melanoma cancer cell subpopulation has been reported to harbor the tumor-
initiating and metastatic cells and is enriched in several of the self-renewal genes including NANOG [188, 
189]. A recent study has shown that siRNA-mediated knockdown of ALDH in melanoma cells inhibited in 
vivo tumor development and metastatic properties [106]. Mechanistically, the ALDHhigh melanoma cells 
have been shown to possess higher tumorigenic, invasive, and self-renewal capacities than ALDHlow cells 
and thus, can serve as a potential therapeutic target [103, 111, 188]. These studies implicate high ALDH 
activity as a relevant biomarker for identifying melanoma CICs, and the significant inhibition of ALDH 
activity that was observed with Lunasin phenocopies the antimelanoma/anti-CIC effects observed in cells 
silenced for ALDH. Thus, using Lunasin to reduce this aggressive populations of cells may serve as an 
invaluable tool in melanomas which display cells with CIC-like abilities.  Using surrogate assays for CIC 
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identification, it was demonstrated that sorted cell populations based on the ALDH biomarker were 
sensitive to Lunasin treatment in non-adherent melanosphere formation assays as well as colony formation 
in soft agar.  As presented in these data, Lunasin functionally blocked the self-renewal capacity of isolated 
melanoma CICs. The activity of Lunasin both in vitro and in vivo on melanoma CICs suggests the 
intriguing possibility that Lunasin can target these quiescent and drug-resistant cells and is consistent with a 
recently published study on colon cancer [164].  Using the CIC surface markers CD133 and CD44, the 
authors showed that soy bioactives in combination with the antidiabetic drug, Metformin, reduced 
populations of cells capable of self-renewal by modulating the PTEN/PI3K/FASN axis.  Taken in 
combination with results gathered in this dissertation, these data represent a novel idea that Lunasin and 
other soy derivatives may alleviate patient relapse by decreasing cancer stem cell populations.   
An important and most intriguing aspect of this study is that the potential anticancer effects of 
Lunasin were enduring in vivo.  Despite somewhat modest effects in vitro, it was observed that Lunasin 
had a highly significant effect on tumor growth when cells were transplanted into immunodeficient mice.  
Lunasin-treated mice had a significantly reduced tumor burden in both parental (46%) and ALDHhigh (73%) 
A375 cells when compared to their vehicle-treated counterparts.  In fact, Lunasin has been described to 
have immunomodulatory functions [13, 42] adding another feature to this multifaceted peptide.  In these 
studies, Lunasin was shown to enhance activation of innate immunity.  Lunasin-treated dendritic cells 
expressed higher levels of cytokines and chemokines, and induced expansion of CD4+ T cells [42].  
Additionally, Lunasin-treated mice had improved responses when compared to control mice in models 
which were challenged with OVA-expressing influenza as well as lymphoma [42].  Specific to 
immunotherapy, Lunasin was shown to synergistically enhance NK cell mediated cytotoxicity when used 
in combination with IL-2 or IL-12 in a lymphoma model [13].  These studies open the possibility that 
mouse models with intact innate immunity may provide a substantial boost to the anticancer activity of the 
Lunasin peptide. 
While the study was too small to measure a significant difference between in vivo tumorigenicity 
between ALDHhigh and ALDHlow A375 cells, limiting dilutions assays did provide the intriguing possibility 
that the number of cells in the ALDHhigh compartment may be dependent upon the number of tumor cells 
within the tumor microenvironment (TME).  Data from these serial dilution assays would suggest a 
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differential ability to proliferate and form palpable tumors in ALDHlow and ALDHhigh A375 cells in a 
dilution-dependent manner.  Additionally, samples from tumors initiated by the lowest dilution of cells 
demonstrated that ALDHhigh cells had a higher population of cells remaining in the ALDHhigh compartment 
after tumor formation when compared to samples derived from ALDHlow cells.  It is well known that the 
TME can regulate the stem cell niche through cell-cell contact, secretion of proteins, and hypoxia [190-
192].  Though these data may be a result of the abundance of tumor cells (or lack thereof), it might also 
indicate that A375 cells display high plasticity, and CICs derived from the ALDHhigh compartment may 
revert to a non-stem cell compartment and vice versa.  Indeed, melanoma has been described as a highly 
plastic malignancy [193].  While ALDHlow cells may display a high degree of tumorigenicity in the in vivo 
models used in this study, the authors did not study long-term propagation and self-renewal capacity in 
vivo, a central feature of stem cells, of either ALDHhigh or ALDHlow cells.  Therefore, any conclusive 
evidence as to how these isolated CICs are functioning in vivo in comparison to their non-CIC counterparts 
will need to be explored further.  Until the caveats limiting the CIC hypothesis are further addressed (i.e. 
improved experimental systems or a defined molecular phenotype for CIC identification), it is likely that 
the abundant support for the CIC theory will be met with equally abundant skepticism.   
 With regard to potential mechanisms of action, Lunasin contains a RGD domain and has been 
shown to bind specific integrins that recognize this cell adhesion motif [38]. Integrins are heterodimeric 
cell surface proteins that play critical roles in adhesion to the extracellular matrix, transmitting extracellular 
signals that affect cell migration and the regulation of signaling pathways involved in cell survival and 
proliferation. Recent studies [10, 12, 36, 194] strongly suggest that Lunasin bound to integrins containing 
combinations of the α5, αv, β1, and β3 subunits and modulated the ILK and FAK signaling pathways. 
Additionally, it is becoming clear that there is a strong linkage of integrin-matrix interactions to cancer cell 
initiation and progression (reviewed in  [64]), including the maintenance and survival of CICs through 
integrin-FAK signaling [reviewed in [195]]. Interestingly, the current data indicate that sorted fractions of 
ALDHhigh melanoma cells are more sensitive to Lunasin than the unsorted cell fractions. One possible 
explanation for this differential sensitivity is that when compared to the bulk of tumor cells, the ALDHhigh 
subpopulation of melanoma cells exhibit altered integrin expression profiles.  It is also possible that the 
ALDHhigh melanoma CICs rely more heavily and specifically on ‘outside-in’ signal transduction 
60 
 
mechanisms mediated via integrin networks compared to ALDHlow cells. Such differential integrin 
signaling in CICs could confer an increased sensitivity to Lunasin’s anticancer activity.  In fact, it has been 
reported that metastatic melanomas, compared to primary melanomas, favor the expression of particular 
integrins, including integrin αvβ3 [61], a known Lunasin target [10]. Differential expression of integrins in 
CICs is not only restricted to melanoma but have been reported in CICs from other cancers including 
prostate [196, 197], breast [198], and neuroglia cancers [172]. Given the strong interaction between 
Lunasin and integrins [10, 12, 38], it is tempting to speculate that Lunasin specifically targets CICs by 
modulating integrin signaling circuits that are differentially expressed in melanoma CICs. Although the 
mode of action of Lunasin’s anti-CIC activity remains to be clearly defined, future studies in the Davis lab 
will focus on identifying the specific integrin-mediated signaling modules required for Lunasin sensitivity 
against melanoma CICs.  
 MITF, commonly referred to as a “master controller” gene for melanocyte development strictly 
regulates melanocyte proliferation and differentiation [199].  Recent studies have identified the existence of 
slow-cycling, low MITF-expressing CICs in melanoma cell populations with intrinsic chemoresistant and 
tumorigenic phenotypes [200].  Additionally, this subpopulation of melanoma cells expressed high levels of 
the stem cell-associated markers Oct-4 and Nanog [200]. One of the most significant findings from this 
study is that treatment of melanoma ALDHhigh CICs with Lunasin induced a more differentiated phenotype 
by increasing the expression of MITF as well as the expression of the downstream melanocyte 
differentiation marker, Tyrosinase, an enzyme directly involved in melanin synthesis. Concomitant with the 
Lunasin-induced phenotypic shift, a significant reduction in the expression of NANOG, a transcription 
factor implicated in migration, invasion, self-renewal, and dedifferentiation of melanoma cells [201-203] 
was observed in both A375 and SKMEL-28 cells. This represents a novel activity for Lunasin that has not 
been reported in any cancer model to date. 
 The encouraging functional effects that were observed in melanoma CICs lead to the investigation 
of whether or not Lunasin could be used in conjunction with a clinically relevant therapeutic for the 
treatment of malignant melanoma.  Lunasin in combination with vemurafenib, a selective B-Raf inhibitor, 
was used to demonstrate the potential of Lunasin as an adjuvant therapeutic.  When proliferation and 
colony formation in soft agar were assessed, DI values indicate that Lunasin and vemurafenib did not 
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interact synergistically, but did have an additive effect; the highest DI values were observed using 
combinations using 100 μM Lunasin.  At 100 μM, Lunasin increased the efficacy of vemurafenib in A375 
cells with acquired vemurafenib-resistance to treatment in both adherent (proliferation assays) and non-
adherent formats (soft agar).  Multicellular generation of oncospheres was used to determine the growth 
characteristics when parental and resistant A375 cells were treated with combinations of Lunasin and 
vemurafenib.  In both models, combination treatment with Lunasin and vemurafenib significantly reduced 
the total sphere area when compared to vemurafenib treatment alone suggesting that Lunasin enhanced the 
antiproliferative effects of vemurafenib.  These additive effects may be driven by Lunasin’s interaction 
with integrins and the suppression of activating phosphorylations of downstream signal transducers (i.e. 
FAK).  In fact, research has shown that resistance to vemurafenib may be caused by elevated β1-FAK 
signaling [204].  ERK signaling, which is typically activated downstream of integrin-mediated adhesion, is 
found to be constitutively activated in B-Raf mutated melanomas [205]; consequently, selective targeting 
of ERK or its downstream effectors may provide some therapeutic potential in B-Raf mutated melanomas.  
Combinations of B-Raf and MEK/ERK inhibitors continues to be a field of great interest to researchers 
trying to overcome chemoresistant melanomas [206].  Given the prominent role of integrins in CIC 
maintenance and chemoresistance [207], combining MAPK inhibitors with integrin-targeted therapies 
could potentially offer a novel strategy for reducing tumor burden while also targeting CICs.  
 Taken together, results from the present study and previously published data support the model 
(Figure 23) depicting the potential therapeutic benefits of Lunasin in melanoma.  Effectively reducing pools 
of CICs by driving a movement of cells out of the cancer stem cell-like compartment (i.e. ALDHhigh) and 
into a more differentiated phenotype (i.e. ALDHlow), Lunasin may alleviate patient relapse by diminishing 
pools of cells with the intrinsic abilities generally conserved in hematopoietic stem cells.  By blocking self-
renewal and subsequent expansion of the CIC compartment, Lunasin may ultimately prove to be an 






Figure 23:  Proposed mechanism for Lunasin’s activity in melanoma CICs.  This diagram depicts the 
observed effects and possible therapeutic advantage of Lunasin treatment in cases of malignant melanoma.  
Lunasin decreased the stem-like properties of ALDHhigh CICs isolated from A375 and SKMEL-28 cell 
lines while concurrently decreasing the stem-associated marker NANOG and inducing expression of 
melanocyte differentiation markers MITF and Tyrosinase.  By effectively reducing this stem cell-like 
compartment, Lunasin may alleviate patient relapse caused by the subpopulation of cells with intrinsic 
metastatic potential and chemoresistance.
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CHAPTER 4: LUNASIN SUPPRESSES THE METASTATIC CAPACITY OF MELANOMA 
INITIATING CELLS BY INHIBITING INTEGRIN SIGNAL TRANSDUCTION 
4.1 INTRODUCTION 
 Melanoma is a notoriously aggressive form of skin cancer that represents approximately 80% of 
all skin cancer related deaths, despite accounting for only 5% of diagnosed cases [208, 209].  New classes 
of drugs (i.e. small molecule inhibitors) combating malignant melanomas have yielded mixed results [210-
212].  Although many patients achieve an initial tumor regression, these agents quickly become ineffective, 
and additionally, may promote the spread of a highly aggressive and chemoresistant population of cells 
[213-215].  Studies utilizing immunotherapy (extensively reviewed in [216]) to treat malignant melanomas 
have been found to be an effective treatment option.  However, only a relatively small subset of patients 
achieve a sustained complete response [217-219].   More recently, immunotherapies with substantially 
improved objective responses in melanoma patients have proven the clinical utility of immunotherapy [138, 
220-222].  Nevertheless, adverse safety profiles, chemoresistance, and immune evasion continue to prove 
problematic in many of these newly approved immunotherapies [223-225].  Thus, providing patients with 
additional novel adjuvant therapies to reduce or even prevent metastatic spread will continue to be needed 
for the development for effective treatment strategies.  
 The process of invasion and metastasis is perhaps the most studied hallmark of cancer due to the 
high mortality rates caused by the metastatic dissemination of tumor cells from the primary tumor into 
distant organs.  Malignant melanomas frequently metastasize to the brain, lymph nodes, gastrointestinal 
tract, liver, and most commonly the lungs [226]. Primary tumor formation and subsequent metastatic 
outgrowth is maintained by a subset of cells with innate stem cell-like abilities that enable them to invade 
and colonize surrounding tissues, while preserving a population of highly proliferative bulk tumor cells [66, 
93].  The heterogeneous nature of melanomas make an intriguing model to study metastatic dissemination 
as they have been reported, among many classes of solid tumors, to harbor CIC populations identified by 
several biomarkers including ALDH [103, 106], CD20 [93], CD133 [94], CD271 [95], and ABCB5 [66].   
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 Lunasin is a peptide isolated from soy that has been shown to have chemopreventive and 
chemotherapeutic activity [9, 10, 26, 27, 32, 35, 186, 227, 228]. Lunasin has three domains implicated in its 
anticancer activity; a RGD motif, a helical domain with a sequence conserved in chromatin binding 
proteins, and a poly-aspartic acid tail (Figure 24) [229].  Chapter 3 of this dissertation reported that Lunasin 
significantly reduced a melanoma stem cell population expressing elevated levels of ALDH [228].  
Additionally, it was shown that in vivo tumor growth initiated by this putative CIC population was 
significantly impaired in mice treated with Lunasin [228].   
 
Figure 24: Full amino acid sequence of the Lunasin peptide.  Lunasin is a 44 amino acid peptide with 3 
functional domains attributed with its anticancer activity: 1) a helical regional conserved in chromatin-
binding proteins (blue), 2) a RGD motif recognized by integrins (red), and 3) a poly-D tail involved in 
histone tail binding (green). 
 
 Previously, Lunasin was shown to inhibit metastasis of malignant colon cancer cells and 
additionally, potentiated the antimetastatic effects of oxaliplatin [36]; however, studies linking Lunasin to 
suppressed metastatic dissemination are largely lacking.  With the encouraging effects of Lunasin on breast 
and melanoma CICs [228, 230], it is plausible to speculate that by reducing expansion of the CIC 
compartment, Lunasin would ultimately decrease the ability  of tumor cells to invade, survive, and colonize 
distant tissues.  Mechanistic studies to date support that Lunasin’s anticancer activity may be due to effects 
on histone acetylation and integrin signaling. 
 Preliminary studies of Lunasin suggested that a primary anticancer mechanism was derived from 
its activity as a HAT inhibitor [9].  Both HAT inhibitors and their inverse, histone deacetylase (HDAC) 
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inhibitors, have been shown to have potential clinical utility in malignant melanoma [231, 232]; however, 
some epigenetic modulating agents may also contribute to undesirable effects.  For example, it was recently 
published the HDAC inhibitor, valproic acid, caused breast cancer cells to dedifferentiate toward a 
chemoresistant stem-like state [233].  With regard to Lunasin, it was indeed found that histone acetylation 
patterns are altered in melanoma models; however, it is an open question as to whether or not it is the 
driving mechanism in Lunasin’s chemotherapeutic activity.  Equally, it is proposed that although HAT 
inhibition may cause many anticancer effects in Lunasin treated cancers, inhibition of integrin signaling 
stimulates the effects seen in melanoma as well as NSCLC [10].  The intertwining mechanisms between 
histone acetylation and integrin signal transduction remains unclear.  One major question that remains to be 
answered is whether integrin signaling can modulate epigenetic histone modifications or vice versa? 
 Two key signaling pathways involved in the metastatic cascade are the integrin-FAK axis [195] 
and the downstream PI3K/AKT pathway [234].  FAK is a critical mediator of cell proliferation, 
differentiation, angiogenesis, and invasion as it promotes cytoskeletal remodeling through interactions with 
several proteins including Src kinases [235].  The PI3K/AKT pathway is also found to be aberrantly 
regulated in a variety of cancers including melanoma [236].  Although generally thought of as a central 
protein involved in cell survival and cell cycling, AKT has been shown to bind and regulate FAK 
phosphorylation suggesting an important role in metastatic adhesion [237].  Dual targeting of these 
dysregulated pathways by disrupting upstream (integrin) signaling remains a promising therapeutic 
approach despite the fact that there are few clinical applications using this approach.  Pharmacologic 
targeting of integrins is currently undergoing clinical trials for the treatment of malignant melanomas [68].  
Due to the central role of integrins in several oncogenic signaling pathways [64], blockade of integrin 
signal transduction seems a likely candidate for future drug development.  While the potential clinical 
benefit of integrin antagonists seems hopeful, the future of this class of drug will likely depend upon the 
development of novel first line anticancer drugs as integrin antagonists are generally utilized in 
combination with more traditional chemotherapeutics as antiangiogenic agents  [238-241].   
 The present study significantly extends upon previous work by demonstrating that Lunasin 
inhibits metastasis-associated activities in melanoma CICs both in vitro and in vivo.  Additionally, it is 
proposed that Lunasin is a multifaceted peptide with a complementary array of mechanisms which provides 
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the potential for a significant therapeutic benefit as an adjuvant therapy against malignant melanomas 
compared to single-agent treatment strategies.  By altering histone acetylation patterns as well as inhibiting 
integrin signaling, Lunasin exerts a significant anticancer effect in melanoma models both in vitro and in 
vivo.   
4.2 MATERIALS AND METHODS 
Purification of Lunasin from defatted soy and synthesis of mutated peptides 
 Lunasin was isolated from defatted soy flour as described in Section 2.1 [16].  Mutated peptides 
were synthesized by China Peptides (China) with a purity > 95% as assessed by HPLC/MS.  Full sequences 
are provided (Figure 25) along with validation that these sequences were recognized by the anti-Lunasin 
rabbit polyclonal antibody (Figure 26) used in immunoblot and immunofluorescent assays.  Peptides were 
dissolved in 50 mM sodium phosphate buffer pH = 7.4 (PB), and dialyzed overnight to remove any 
contaminating salts.  Protein concentrations from the resulting peptide solutions were determined using a 
bicinchoninic acid (BCA) assay (Pierce).  Peptide solutions were filter sterilized by passing through a 0.22 
μm filter (Millipore), aliquoted, and stored at -20˚C until use.   
 
Figure 25:  Full sequences of synthesized peptides.  Peptides based on Lunasin’s initial 43 amino acid 
sequence were synthesized by China Peptides to represent altered functional domains.  Mutated amino acid 
sequences for each peptide are underlined in red.  KBP-Lunasin was used in all experimental conditions, 
and varies from the native Lunasin sequence by a single asparagine residue on the C-terminal end. 
 
Figure 26:  Validation of Lunasin antibody recognizing mutated peptides.  200 ng of total peptide were 
electrophoresed in 15% polyacrylamide gels, transferred to a PVDF membrane, and probed for Lunasin 
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using a rabbit polyclonal antibody.  This confirmed that the antibody used in these studies will indeed 
recognize the mutated peptide sequences.  Lunasin is represented by the 5 kDa band; a slight degree of 
oligomerization can be seen as represented by the fainter band above the 5 kDa Lunasin band. 
 
Cell culture and reagents 
 All cell cultures and reagents utilized in Chapter 4 were described in Section 2.2. 
Genome-wide microarray analysis  
 All RNA extractions, cDNA generation, and hybridization protocols were followed as outlined in 
Section 2.16.  RNA integrity values as assessed by the Bioanalyzer are shown in Figure 27. 
 
Figure 27: RNA integrity values assessed on an Agilent Bioanalyzer.  Isolated RNA from parental A375 
cells treated with vehicle (1-3) or Lunasin (4-6) were assessed for RNA degradation and sample integrity 
before generation of the cDNA template for microarray analysis.  A375 ALDHhigh cells were also treated 
with either vehicle (7-9) or Lunasin (10-12), and subsequently assessed on the Bioanalyzer.  RNA integrity 




 Immunofluorescent microscopy was used for colocalization analysis and Lunasin uptake 
experiments as described in Section 2.17. 
Proximity ligation assay (PLA) 
 PLA assays were performed as described in Section 2.18. 
Oncosphere formation assay 
 Generation of melanoma oncospheres was performed as outlines in Section 2.15. 
Flow cytometry 
 Flow cytometry experiments to assess cell cycle and apoptosis have been detailed in Sections 2.6 
and 2.7, respectively. 
Transwell invasion assay 
 In vitro invasion assays were performed on ALDHhigh melanoma cells as described in Section 2.19. 
Murine model of experimental metastasis 
 In vivo metastasis models were utilized to investigate the antimetastatic properties of Lunasin as 
outlined in Section 2.20. 
Histology 
 Tissues resected from primary melanoma lesions were prepared, sectioned, and stained as 
described in Section 2.21. 
Histone Extraction and Immunoblot Analysis 
 Cultured cells were treated with PB or Lunasin (100 μM) for 24 h. Acid extraction of histones was 
performed as described [242].  Briefly, cells were washed in PBS and harvested into 15 mL conical tubes.  
Cells were pelleted by spinning at 300 xg for 10 min and the resulting cell pellet was resuspended in an 
appropriate amount of hypotonic lysis buffer (10 mM Tris–Cl pH 8.0, 1 mM KCl, 1.5 mM MgCl2 and 1 
mM DTT).  Cell pellets were incubated at 37˚ C for 30 min with agitation to promote cell swelling and 
lysis.  Lysates were pelleted by centrifugation at 10,000 xg for 10 min at 4˚ C on a tabletop centrifuge 
(Eppendorf).  The supernatant was discarded and the remaining nuclei were suspended in 0.4 N H2SO4 and 
allowed to sit overnight at 4˚ C with constant agitation.  Samples were centrifuged at 16,000 xg for 10 min 
to remove nuclear debris and the resulting supernatant containing histones was transferred to a fresh 1.5 mL 
69 
 
tube.  A volume of 132 μL of 100 % trichloroacetic acid (TCA) was added to each sample to a final 
concentration of 33% TCA v/v.  Histones were precipitated in TCA overnight at 4˚ C.  The supernatant was 
removed and the histones were pelleted by centrifugation at 16,000 xg for 10 min.  The pellet was washed 
three times with ice-cold acetone to remove any remaining acid with spins at 16,000 xg for 10 min between 
each wash.  After the final wash, the supernatant was removed and the pellet was allowed to air-dry for 30 
min at RT.  The dried pellet was dissolved in 100 – 200 μL of ultrapure water and diluted to a concentration 
of 1 mg/ mL as assessed by BCA method.  Purified histones (10 μg) were prepared, loaded, and 
electrophoresed in 15% gels (Lonza) at 100 V for 120 min.  Transfer to PVDF membranes and antibody 
incubations were performed as described in Section 2.11. 
Statistical Analysis 
 Statistical analysis of data obtained from in vitro and in vivo experiments in this Chapter were 
analyzed for statistical significant as described in Section 2.23. 
 
4.3 RESULTS 
Genome-wide microarray analysis reveals Lunasin-targeted genes and identifies a unique gene 
signature in ALDHhigh melanoma cells compared to parental cells 
 The initial focus in this Chapter was to validate that ALDHhigh melanoma cells harbor the CIC 
population in the A375 cell line.  Additionally, gene expression profiling was utilized as a tool to expose 
potential mechanisms for the selective effects seen when ALDHhigh cells were treated with Lunasin.  The 
initial datasets compared parental A375 cells in vehicle and Lunasin-treated samples (Table 1).  While only 
a modest effect (fold-change is shown in parentheses) on gene expression was observed, some genes of 
interest included MAP2K7 (-1.34), MAPK11 (-1.31), RARα (-1.29), WNT3A (1.28), WNT5A (-1.28), 
RARϒ (-1.27), and FOXP1 (1.52).  MAP2K7 and MAPK11 are components of the MAPK signaling 
pathway which is commonly mutated in cancers [243], thus, reducing expression of these genes may reduce 
oncogenic signaling through MAPK-associated proteins.  Retinoic acid (RA) and its receptors (RARs) are 
centrally involved in stem cell differentiation [161, 244] and have been reported to induce cell cycle arrest 
and apoptosis in melanomas [245-247].  While an exact mechanism for Lunasin’s induction of melanocyte-
associated differentiation markers as well as the phenotype switch out of the CIC compartment has yet to 
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be elucidated, the fact that two RARs were identified in the microarray analysis suggests a potential link 
considering that ALDH metabolizes vitamin A into RA.  To complicate the potential connection between 
Lunasin and RARs, it has been reported that co-repressors and co-activators of RARs have intrinsic HAT 
and HDAC activity, respectively [248].  Yet, there also exists a mechanism by which RARs are 
interconnected to cellular adhesion molecules [249, 250] and more specifically integrins [251].  Given the 
reports that Lunasin can alter histone acetylation patterns [142] as well as antagonize integrin signaling 
[10], the mechanisms for this effect remain unclear.  Wnt/β-catenin signaling is a relatively controversial 
therapeutic target in cancer; several models support the inhibition of the pathway in order to induce a 
therapeutic response [252, 253], while other models support activation of Wnt/β-catenin [254, 255].  Others 
argue that the response may be context dependent [256].  Also of interest, it was found that WNT5A 
antagonized the proliferation induced by Wnt/β-catenin activation [257].  FOXP1 is a member of the FOX 
transcription factor family, and has been shown to be a therapeutic target in tumors in which it is 
overexpressed [258].  In contrast, low levels of FOXP1 expression in neuroblastoma correlates with a poor 
prognosis, and re-expression of the transcription factor significantly reduced tumor cell proliferation and 
diminished tumorigenicity [259].  While these genes have been linked to a functional therapeutic response 
in some cancer cell types, further pathway analysis is necessary to reveal novel mechanisms suggested by 
this initial screen. 
 Next, A375 ALDHhigh cells treated with vehicle or Lunasin (Table 2) were compared in order to 
discriminate any specific genes targeted in this cell population as opposed to the parental A375 cell line.  
Several genes in which Lunasin had a modest effect were identified; many have been found to significantly 
contribute to melanoma progression and metastasis.  Genes of interest identified in this study were FOXP1 
(-1.46), AKT1 (-1.31), KAT2B (-1.30), ERBB2 (-1.28), TGFB3 (-1.25), FOS (1.31), TP73 (1.31), SMAD5 
(1.35), IGF1R (1.38), RAC1 (1.43).  In parental cells, FOXP1 was up-regulated while in CICs treated with 
Lunasin a significant down-regulation of the gene.  AKT represents the major signaling protein of the 
PI3K/AKT pathway and has been discussed previously.  A down-regulation in AKT expression would 
presumably confer an antisurvival signal, which may help explain why A375R cells were sensitized to 
vemurafenib in combination treatments (discussed in Chapter 3, page 48).  Given its involvement in 
integrin signal transduction and regulation of histone acetylation machinery, these changes in expression of 
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AKT signaling components were somewhat expected.  KAT2B encodes for the PCAF protein, and directly 
regulates transcription as it has HAT activity.  Again, these results are not surprising as Lunasin has been 
proposed to alter histone acetylation patterns; however, this is the first report that Lunasin may directly 
change gene expression of HATs.  ERBB2/ERBB3 heterodimers (and its activator NRG1 [-1.26]) in 
melanoma has been shown to modulate AKT activation and promote cell growth, survival, and metastasis 
[260, 261].  The TGF-β/Smad pathway regulates the progression and metastasis of melanoma [262].  The 
fact that SMAD5 is up-regulated while TGFB3 is down-regulated may suggest a mechanism for Smad-
independent TGF-β responses.   
 Finally, gene expression in untreated cells derived from parental A375 cells and ALDHhigh A375 
cells was compared in order to identify a unique gene set that was expressed in ALDHhigh cells, but not in 
the parental line.  Several genes associated with invasion and epithelial to mesenchymal transition (EMT) 
were upregulated in ALDHhigh cells compared to parental cells (Table 3).  Several genes of interest were 
identified including MMP13 (-1.82), BMP4 (1.27), SNAI1 (1.28), TGFB2 (1.31), WNT5A (1.33), SKI 
(1.33), SMAD6 (1.34), BCL2L11 (1.37), ETS1 (1.37), WNT11 (1.37), TLN2 (1.37), BCL2 (1.37), SMAD7 
(1.37), MMP1 (1.39), EGFR (1.39), FN1 (1.44), JUN (1.46), JAG1 (1.59), SNAI2 (1.60), FOS (1.66), 
FOSB (1.80), and BMP2 (1.86).  Several critical mediators of the TGF-β, BMP, and β-catenin signaling 
pathways were identified by analysis of the microarray dataset.  These pathways have been implicated to 
regulate key processes involved in melanoma development and progression [263-265] indicating that the 
increased expression seen in ALDHhigh cells may confer some selective advantage when invading and 
proliferating in distant tissue.  FN1, the gene encoding fibronectin, was upregulated in ALDHhigh cells when 
compared to parental cells, and is implicated in melanoma cell invasion [266]. Additionally, SNAI1 and 
SNAI2, regulators of EMT [267], are both upregulated in ALDHhigh cells compared to parental cells.  
Interestingly, MMP-1 and MMP-13 are inversely affected.  While MMP-1 has been implicated in 
melanoma invasion [268], MMP-13 has also been linked to metastasis [269] and may also mediate cell 
cycling [270].  Finally, the AP-1 transcription factor components, JUN and FOS (and FOSB) were 
upregulated in ALDHhigh cells compared to the parental line.  Despite their well-known connection to 
MAPK signaling [271], these proto-oncogenes have several functions in melanomas including metastatic 
dissemination and chemoresistance [272-274].  These data would indicate that ALDHhigh cells express 
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genes associated with melanoma progression through EMT, invasion, and proliferation which supports the 
function of ALDH as a biomarker for CICs in melanoma. 
 Principle component analysis (PCA) (Figure 28A) shows the disparity between gene signatures of 
parental A375 cells and ALDH-sorted populations.  Additionally, Lunasin-treated ALDHhigh cells appeared 
to deviate from vehicle-treated cells more so than when their parental counterparts were treated with 
Lunasin, despite having a similar trend.  Sources of error were scored using mean F-ratio to assess the 
authenticity of the microarray analysis (Figure 28B).  The greatest difference between groups came from 
the cell type, meaning the highest variance was between parental cells and ALDH-sorted populations.  This 
demonstrates that ALDHhigh cells displayed a significantly altered gene signature from the parental A375 
populations; this may potentially confirm the results discussed previously describing the upregulation of 
several genes associated with EMT, invasion, and stemness in ALDHhigh cells when compared to parental 
populations.  Treatment with Lunasin accounted for the second highest source of variation, followed by 
replicates and human error, respectively.   




Gene Symbol Gene Name Object Type Description Signal p-value 
Phospholamban PLN phospholamban Generic binding 
protein 
Cardiac phospholamban -1.44444 0.0206268 
NF-AT NFATC4 nuclear factor of activated T-cells 4 Transcription 
factor 
 -1.42274 0.00795497 
NF-AT3(NFATC4) NFATC4 nuclear factor of activated T-cells 4 Transcription 
factor 
Nuclear factor of activated T-cells, 
cytoplasmic 4 
-1.42274 0.00795497 
Arrestin 3 ARR3 arrestin 3 retinal (X-arrestin) Generic binding 
protein 
Arrestin-C -1.40384 0.000620583 
Desmin DES desmin Generic binding 
protein 
Desmin -1.39849 0.00816461 
GRAP2 GRAP2 GRB2-related adaptor protein 2 Generic binding 
protein 
GRB2-related adapter protein 2 -1.39079 0.0330518 
SIA7E ST6GALNAC5 ST6 N-acetylgalactosaminide alpha-2,6-
sialyltransferase 5 
Generic enzyme Alpha-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 5 
-1.38735 0.00809087 
Calpain 10 CAPN10 calpain 10 Generic protease Calpain-10 -1.38007 0.0309494 
G3ST3 GAL3ST3 galactose-3-O-sulfotransferase 3 Generic enzyme Galactose-3-O-sulfotransferase 3 -1.35473 0.00908722 
Epiregulin EREG epiregulin Protein Proepiregulin -1.35302 0.0101828 
MKK7 (MAP2K7) MAP2K7 mitogen-activated protein kinase kinase 7 Protein kinase Dual specificity mitogen-activated 




ABO ABO blood group (transferase A, alpha 1-3-N- 
acetylgalactosaminyltransferase; transferase B, 
alpha 1-3galactosyltransferase) 
Generic enzyme Histo-blood group ABO system 
transferase 
-1.33629 0.0348191 
CalDAG-GEFII RASGRP1 RAS guanyl releasing protein 1 Regulators (GDI, 
GAP, GEF) 
RAS guanyl-releasing protein 1 -1.3217 0.0466738 
73 
 
ACACB ACACB acetyl-CoA carboxylase beta Protein Acetyl-CoA carboxylase 2 -1.31886 0.0146277 
ACE1 ACE angiotensin I converting enzyme Generic protease Angiotensin-converting enzyme -1.31409 0.0139762 
p38 MAPK MAPK11 mitogen-activated protein kinase 11 Protein kinase  -1.30969 0.0162317 
p38beta (MAPK11) MAPK11 mitogen-activated protein kinase 11 Protein kinase Mitogen-activated protein kinase 
11 
-1.30969 0.0162317 
BAIAP2 BAIAP2 BAI1 associated protein 2 Generic binding 
protein 
Brain-specific angiogenesis 





HRH2 histamine receptor H2 Generic receptor  -1.29861 0.0393267 
Tissue kallikreins KLK10 kallikrein related peptidase 10 Generic protease  -1.29669 0.0358496 
RARalpha RARA retinoic acid receptor alpha Transcription 
factor 
Retinoic acid receptor alpha -1.28836 0.00247536 
WNT WNT3A Wnt family member 3A Receptor ligand  -1.28404 0.0302277 
WNT3A WNT3A Wnt family member 3A Receptor ligand Protein Wnt-3a -1.28404 0.0302277 
L-type Ca(II) 
channel, alpha 1C 
subunit 
CACNA1C calcium voltage-gated channel subunit alpha1 C Voltage-gated ion 
channel 
Voltage-dependent L-type calcium 
channel subunit alpha-1C 
-1.27809 0.0123255 
WNT WNT5A Wnt family member 5A Receptor ligand  -1.2726 0.00115524 
WNT5A WNT5A Wnt family member 5A Receptor ligand Protein Wnt-5a -1.2726 0.00115524 
RARgamma RARG retinoic acid receptor gamma Transcription factor Retinoic acid receptor gamma -1.2701 0.00193338 
HXK4 GCK glucokinase Generic kinase Glucokinase -1.26848 0.00158031 
Tissue kallikreins KLK12 kallikrein related peptidase 12 Generic protease  -1.26669 0.0488501 
HGF HGF hepatocyte growth factor Receptor ligand Hepatocyte growth factor -1.26587 0.0187103 
NR1 GRIN1 glutamate ionotropic receptor NMDA type subunit 1 Ligand-gated ion 
channel 
Glutamate receptor ionotropic,  
NMDA 1 
-1.26439 0.0494182 
CYP4F2 CYP4F2 cytochrome P450 family 4 subfamily F member 2 Generic enzyme Phylloquinone omega-hydroxylase 
CYP4F2 
-1.26402 0.00367679 
c-Maf MAF MAF bZIP transcription factor Transcription factor Transcription factor Maf -1.26355 0.0364182 
IGH@ IGH immunoglobulin heavy locus Receptor ligand immunoglobulin heavy locus -1.26164 0.0240856 
Synaptotagmin VII SYT7 synaptotagmin 7 Protein Synaptotagmin-7 -1.26021 0.0222702 
Sirtuin6 SIRT6 sirtuin 6 Generic enzyme NAD-dependent protein 
deacetylase sirtuin-6 
-1.25989 0.0426655 
IRF5 IRF5 interferon regulatory factor 5 Transcription factor Interferon regulatory factor 5 -1.25985 0.0210335 
PLC-delta PLCD3 phospholipase C delta 3 Generic 
phospholipase 
 -1.25942 0.0122591 
GRK6 GRK6 G protein-coupled receptor kinase 6 Protein kinase G protein-coupled receptor kinase 
6 
-1.25853 0.0138678 
GLUT2 SLC2A2 solute carrier family 2 member 2 Transporter Solute carrier family 2, facilitated 
glucose transporter member 2 
-1.25405 0.0335012 
PP2A regulatory PPP2R5D protein phosphatase 2 regulatory subunit B'delta Generic binding 
protein 
 -1.21491 0.0285902 
Tissue kallikreins KLK7 kallikrein related peptidase 7 Generic protease  -1.19423 0.0352611 
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Tissue kallikreins KLK6 kallikrein related peptidase 6 Generic protease  -1.18227 0.0432625 
NF-AT NFAT5 nuclear factor of activated T-cells 5, tonicity-
responsive 
Transcription factor  -1.17732 0.0265163 
Tubulin alpha TUBA3C tubulin alpha 3c Generic binding 
protein 
 -1.14922 0.0266541 
Tubulin alpha TUBA3D tubulin alpha 3d Generic binding 
protein 




HTR7 5-hydroxytryptamine receptor 7 Generic receptor  -1.11885 0.0112545 
NF-AT NFATC2 nuclear factor of activated T-cells 2 Transcription factor  1.06543 0.0432984 
PLC-beta PLCB1 phospholipase C beta 1 Generic 
phospholipase 
 1.18758 0.0301776 
MUNC13-1 UNC13A unc-13 homolog A (C. elegans) Generic binding 
protein 
Protein unc-13 homolog A 1.25565 0.0376234 
PARD6 PARD6B par-6 family cell polarity regulator beta Generic binding 
protein 
 1.25711 0.0376021 
P2Y1 P2RY1 purinergic receptor P2Y1 GPCR P2Y purinoceptor 1 1.27086 9.23061E-05 
Heme oxygenase 1 HMOX1 heme oxygenase 1 Generic enzyme Heme oxygenase 1 1.27173 0.000507197 
p130 RBL2 RB transcriptional corepressor like 2 Generic binding 
protein 
Retinoblastoma-like protein 2 1.28053 0.0362018 
CACNA1D CACNA1D calcium voltage-gated channel subunit alpha1 D Voltage-gated ion 
channel 
Voltage-dependent L-type calcium 
channel subunit alpha-1D 
1.29206 0.00864385 
PACAP ADCYAP1 adenylate cyclase activating polypeptide 1 Receptor ligand Pituitary adenylate 
cyclaseactivating polypeptide 
1.31848 0.0327697 
GCL reg GCLM glutamate-cysteine ligase modifier subunit Generic enzyme Glutamate--cysteine ligase 
regulatory subunit 
1.32293 0.00125117 
TLR1 TLR1 toll like receptor 1 Generic receptor Toll-like receptor 1 1.32839 0.0275434 




 1.32991 0.00604937 
Sec8 EXOC4 exocyst complex component 4 Generic binding 
protein 
Exocyst complex component 4 1.33531 0.033613 
AMPK alpha 
subunit 





PLC-beta PLCB4 phospholipase C beta 4 Generic 
phospholipase 
 1.37036 0.00733205 
Carboxypeptidase 
M 
CPM carboxypeptidase M Generic protease Carboxypeptidase M 1.37297 0.0184119 





EGF EGF epidermal growth factor Receptor ligand Pro-epidermal growth factor 1.38549 0.0313874 
PP2A regulatory PPP2R2B protein phosphatase 2 regulatory subunit Bbeta Generic binding 
protein 
 1.39363 0.00776675 





protein with Kazal motifs 
1.40929 0.00514642 
70Z-PEP PTPN22 protein tyrosine phosphatase, non-receptor type 22 Protein 
phosphatase 
Tyrosine-protein phosphatase 
nonreceptor type 22 
1.47127 0.00577936 












Gene Name Object Type Description Signal p-value 
Protein kinase G PRKG1 protein kinase, cGMP-dependent, type I Protein kinase  -1.5701 0.00337114 
FOXP1 FOXP1 forkhead box P1 Transcription factor Forkhead box protein P1 -1.46271 0.0125002 
KCRU CKMT1A creatine kinase, mitochondrial 1A Generic kinase Creatine kinase U-type, mitochondrial -1.45383 0.00150056 
KCRU CKMT1B creatine kinase, mitochondrial 1B Generic kinase Creatine kinase U-type, mitochondrial -1.45383 0.00150056 




 -1.42442 0.00947514 




Caspase recruitment domain-containing 
protein 8 
-1.40269 0.00466734 
Bim BCL2L11 BCL2 like 11 Generic binding 
protein 
Bcl-2-like protein 11 -1.3764 0.0226245 
MSP MST1 macrophage stimulating 1 Receptor ligand Hepatocyte growth factorlike protein -1.3685 0.0243488 
Schwannomin (NF2) NF2 neurofibromin 2 (merlin) Generic binding 
protein 
Merlin -1.36212 0.0331648 
MEK6(MAP2K6) MAP2K6 mitogen-activated protein kinase kinase 
6 
Protein kinase Dual specificity mitogenactivated protein 
kinase kinase 6 
-1.34109 0.0465563 




Rap guanine nucleotide exchange factor 4 -1.33651 0.0162899 
CNTN1 (F3) CNTN1 contactin 1 Generic binding 
protein 
Contactin-1 -1.3314 0.0458024 
Intersectin ITSN1 intersectin 1 Regulators (GDI, 
GAP, GEF) 
Intersectin-1 -1.32506 0.000236297 
NALP2 NLRP2 NLR family pyrin domain containing 2 Generic binding 
protein 
NACHT, LRR and PYD  
domains-containing protein 2 
-1.3211 0.00221173 
GP-IB alpha GP1BA glycoprotein Ib platelet alpha subunit GPCR Platelet glycoprotein Ib alpha chain -1.31542 0.0457474 
GAB2 GAB2 GRB2 associated binding protein 2 Generic binding 
protein 
GRB2-associated-binding protein 2 -1.31488 0.0380525 
CD70(TNFSF7) CD70 CD70 molecule Receptor ligand CD70 antigen -1.30677 0.0111134 
AKT(PKB) AKT1 AKT serine/threonine kinase 1 Protein kinase  -1.30416 0.000226758 
AKT1 AKT1 AKT serine/threonine kinase 1 Protein kinase RAC-alpha serine/threonineprotein kinase -1.30416 0.000226758 
HIVEP2 HIVEP2 human immunodeficiency virus type I 
enhancer binding protein 2 
Transcription factor Transcription factor  
HIVEP2 
-1.29905 0.00355775 
Ephrin-A receptors EPHA3 EPH receptor A3 Generic receptor  -1.29764 0.000542762 





PPARGC1A PPARG coactivator 1 alpha Generic binding 
protein 
Peroxisome proliferatoractivated receptor 
gamma coactivator 1-alpha 
-1.29602 0.0191075 
B-chimaerin CHN2 chimerin 2 Regulators (GDI, 
GAP, GEF) 
Beta-chimaerin -1.29129 0.0233722 
ELF5 ELF5 E74 like ETS transcription factor 5 Transcription factor ETS-related transcription factor Elf-5 -1.29026 0.0487005 
Ephrin-B receptor 1 EPHB1 EPH receptor B1 Receptor with 
enzyme activity 
Ephrin type-B receptor 1 -1.28997 0.0450225 
Ephrin-B receptors EPHB1 EPH receptor B1 Generic receptor  -1.28997 0.0450225 
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 -1.28952 0.00831128 
MSK1 RPS6KA5 ribosomal protein S6 kinase A5 Protein kinase Ribosomal protein S6 kinase alpha-5 -1.28643 0.0290961 
MSK1/2 
(RPS6KA5/4) 
RPS6KA5 ribosomal protein S6 kinase A5 Protein kinase  -1.28643 0.0290961 
MNK1 MKNK1 MAP kinase interacting serine/threonine 
kinase 1 
Protein kinase MAP kinase-interacting serine/threonine-
protein kinase 1 
-1.28634 0.00102042 
ErbB2 ERBB2 erb-b2 receptor tyrosine kinase 2 Receptor with 
enzyme activity 
Receptor tyrosine-protein kinase erbB-2 -1.28262 0.0183775 
IGHG1 IGHG1 immunoglobulin heavy constant gamma 
1 (G1m marker) 
Receptor ligand Ig gamma-1 chain C region -1.27369 0.00748698 
eIF4A EIF4A1 eukaryotic translation initiation factor 
4A1 
Generic enzyme  -1.27351 0.0120587 
CARD7 NLRP1 NLR family pyrin domain containing 1 Generic binding 
protein 
NACHT, LRR and PYD  
domains-containing protein 1 
-1.27181 0.0355684 
DR5(TNFRSF10B) TNFRSF10B tumor necrosis factor receptor 
superfamily member 10b 
Receptor with 
enzyme activity 
Tumor necrosis factor  
receptor superfamily member 10B 
-1.26909 0.000643637 
ADAM17 ADAM17 ADAM metallopeptidase domain 17 Metalloprotease Disintegrin and metalloproteinase 
domaincontaining protein 17 
-1.26776 0.0033431 
CD36 CD36 CD36 molecule Generic receptor Platelet glycoprotein 4 -1.26623 0.018395 
IL4RA IL4R interleukin 4 receptor Generic receptor Interleukin-4 receptor subunit alpha -1.26512 0.0191704 
NKG2A KLRC1 killer cell lectin like receptor C1 Generic receptor NKG2-A/NKG2-B type II integral membrane 
protein 
-1.26289 0.0334868 
GRB10 GRB10 growth factor receptor bound protein 10 Generic binding 
protein 
Growth factor receptorbound protein 10 -1.26127 0.0157259 
FKHR FOXO1 forkhead box O1 Transcription factor Forkhead box protein O1 -1.25939 0.00206426 
Neurotractin NEGR1 neuronal growth regulator 1 Generic binding 
protein 
Neuronal growth regulator 1 -1.25895 0.00424239 
Neuregulin 1 NRG1 neuregulin 1 Receptor ligand Pro-neuregulin-1, membrane-bound isoform -1.25677 0.0236608 
CLIP3 CLIP3 CAP-Gly domain containing linker 
protein 3 
Protein CAP-Gly domain-containing linker protein 3 -1.25409 0.00303439 
HGF HGF hepatocyte growth factor Receptor ligand Hepatocyte growth factor -1.25234 0.0229854 
TGF-beta TGFB3 transforming growth factor beta 3 Receptor ligand  -1.25052 0.00532903 
Ephrin-A receptors EPHA4 EPH receptor A4 Generic receptor  -1.2152 0.0120193 
Adenylate cyclase ADCY7 adenylate cyclase 7 Generic enzyme  -1.192 0.0181893 






AKT(PKB) AKT2 AKT serine/threonine kinase 2 Protein kinase  -1.10513 0.00858131 
MHC class I HLA-E major histocompatibility complex, class 
I, E 
Generic receptor  -1.10479 0.0367323 
HSP90 HSP90AB1 heat shock protein 90kDa alpha family 
class B member 1 
Generic binding 
protein 
 -1.02524 0.0469378 
AKT(PKB) AKT3 AKT serine/threonine kinase 3 Protein kinase  1.08838 0.0379968 
14-3-3 YWHAQ tyrosine 3-monooxygenase/tryptophan 




 1.09529 0.000338352 
14-3-3 YWHAE tyrosine 3-monooxygenase/tryptophan 




 1.1424 0.005047 
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14-3-3 YWHAG tyrosine 3-monooxygenase/tryptophan 




 1.14443 0.0106333 
MRLC MYL12A myosin light chain 12A Generic binding 
protein 
 1.14548 0.00470967 




 1.18192 0.0478546 
HSP90 HSP90AA1 heat shock protein 90kDa alpha family 
class A member 1 
Generic binding 
protein 
 1.21348 0.00543915 
Ephrin-A receptors EPHA5 EPH receptor A5 Generic receptor  1.23325 0.00135816 
MHC class I HLA-G major histocompatibility complex, class 
I, G 
Generic receptor  1.23695 0.0262767 
NGF NGF nerve growth factor Receptor ligand Beta-nerve growth factor 1.25368 0.0133639 
Adenylate cyclase ADCY8 adenylate cyclase 8 (brain) Generic enzyme  1.25427 0.0112251 
Adenylate cyclase 
type VIII 
ADCY8 adenylate cyclase 8 (brain) Generic enzyme Adenylate cyclase type 8 1.25427 0.0112251 
Brca2 BRCA2 BRCA2, DNA repair associated Generic binding 
protein 
Breast cancer type 2 susceptibility protein 1.25438 0.000775725 
ABR ABR active BCR-related Regulators (GDI, 
GAP, GEF) 
Active breakpoint cluster region-related 
protein 
1.25461 0.00190559 
LRRK2 LRRK2 leucine rich repeat kinase 2 Protein kinase Leucine-rich repeat serine/threonine-
protein kinase 2 
1.2566 0.00710897 
SMAD1 SMAD1 SMAD family member 1 Transcription factor Mothers against decapentaplegic homolog 1 1.25784 0.00175723 
RacGAP1 RACGAP1 Rac GTPase activating protein 1 Regulators (GDI, 
GAP, GEF) 
Rac GTPase-activating protein 1 1.26471 0.00486122 
EBP50 SLC9A3R1 SLC9A3 regulator 1 Generic binding 
protein 
Na(+)/H(+) exchange  
regulatory cofactor NHE- 
RF1 
1.26562 0.00298857 
E3b1(ABI-1) ABI1 abl interactor 1 Generic binding 
protein 
Abl interactor 1 1.26599 0.000897763 
Cathepsin B CTSB cathepsin B Generic protease Cathepsin B 1.26656 0.0253929 
P2X7 P2RX7 purinergic receptor P2X 7 Ligand-gated ion 
channel 
P2X purinoceptor 7 1.26689 0.0271523 
CREB1 CREB1 cAMP responsive element binding 
protein 1 
Transcription factor Cyclic AMP-responsive element-binding 
protein 1 
1.26771 0.00371316 
eIF4B EIF4B eukaryotic translation initiation factor 4B Generic binding 
protein 
Eukaryotic translation initiation factor 4B 1.26771 0.0362407 
p18 CDKN2C cyclin dependent kinase inhibitor 2C Generic binding 
protein 
Cyclin-dependent kinase 4 inhibitor C 1.27536 0.00174692 
OATP-A SLCO1A2 solute carrier organic anion transporter 
family member 1A2 
Transporter Solute carrier organic anion  
transporter family member 1A2 
1.2768 0.0127423 




 1.28013 0.028923 
Rictor RICTOR RPTOR independent companion of 
MTOR complex 2 
Generic binding 
protein 
Rapamycin-insensitive companion of mTOR 1.28306 0.00299417 
Perforin PRF1 perforin 1 Transporter Perforin-1 1.28693 0.0356184 
KAP3 KIFAP3 kinesin associated protein 3 Generic binding 
protein 
Kinesin-associated protein 3 1.28759 0.00119856 
ALPL ALPL alkaline phosphatase, liver/bone/kidney Generic phosphatase Alkaline phosphatase, tissue-nonspecific 
isozyme 
1.29131 0.0245732 
Tob1 TOB1 transducer of ERBB2, 1 Generic binding 
protein 
Protein Tob1 1.29203 0.00351566 
CCL2 CCL2 C-C motif chemokine ligand 2 Receptor ligand C-C motif chemokine 2 1.29588 0.0249862 
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Rap guanine nucleotide exchange factor 5 1.29627 0.0364294 
STK4 STK4 serine/threonine kinase 4 Protein kinase Serine/threonine-protein kinase 4 1.2963 0.0067006 
RHAMM HMMR hyaluronan mediated motility receptor Generic receptor Hyaluronan mediated motility receptor 1.29916 0.00116314 
RhoGAP5 ARHGAP5 Rho GTPase activating protein 5 Regulators (GDI, 
GAP, GEF) 
Rho GTPase-activating protein 5 1.29932 0.00320296 
SOD2 SOD2 superoxide dismutase 2, mitochondrial Generic enzyme Superoxide dismutase [Mn], mitochondrial 1.30008 0.000133145 
PARP-1 PARP1 poly(ADP-ribose) polymerase 1 Generic enzyme Poly [ADP-ribose] polymerase 1 1.3017 0.0167984 
MPP5 MPP5 membrane palmitoylated protein 5 Generic binding 
protein 
MAGUK p55 subfamily member 5 1.30188 0.00231735 
APC protein APC WNT signaling pathway regulator Generic binding 
protein 
Adenomatous polyposis coli protein 1.30488 0.0062747 
RAP-1A RAP1A RAP1A, member of RAS oncogene 
family 
RAS - superfamily Ras-related protein Rap-1A 1.30488 0.0416244 
PSAT PSAT1 phosphoserine aminotransferase 1 Generic enzyme Phosphoserine aminotransferase 1.30787 0.000502575 
c-Fos FOS Fos proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor Proto-oncogene c-Fos 1.30873 0.000144963 
p73 TP73 tumor protein p73 Transcription factor Tumor protein p73 1.3132 0.0179451 
14-3-3 YWHAZ tyrosine 3-monooxygenase/tryptophan 




 1.31677 0.0236916 
14-3-3 zeta/delta YWHAZ tyrosine 3-monooxygenase/tryptophan 




14-3-3 protein zeta/delta 1.31677 0.0236916 
mGluR1 GRM1 glutamate metabotropic receptor 1 GPCR Metabotropic glutamate receptor 1 1.31864 0.0051418 
MHC class I HLA-F major histocompatibility complex, class 
I, F 
Generic receptor  1.31998 0.00676518 
IL-1RI IL1R1 interleukin 1 receptor type 1 Generic receptor Interleukin-1 receptor type 1 1.3234 0.00954023 
Syndecan-2 SDC2 syndecan 2 Generic receptor Syndecan-2 1.32432 0.000543997 
IRF1 IRF1 interferon regulatory factor 1 Transcription factor Interferon regulatory factor  
1 
1.32567 0.0148805 




 1.32688 0.0240793 
ATF-1 ATF1 activating transcription factor 1 Transcription factor Cyclic AMP-dependent transcription factor 
ATF-1 
1.33141 0.00862807 




 1.3348 0.00213492 
Caspase-2 CASP2 caspase 2 Generic protease Caspase-2 1.34305 0.00221027 
SMAD5 SMAD5 SMAD family member 5 Transcription factor Mothers against decapentaplegic homolog 5 1.34693 0.012205 




Ras association domaincontaining protein 5 1.3648 0.00616737 
Nucleophosmin NPM1 nucleophosmin (nucleolar 
phosphoprotein B23, numatrin) 
Generic binding 
protein 
Nucleophosmin 1.36901 0.00132591 




Endoplasmin 1.37222 0.0376878 




 1.37222 0.0376878 
RHEB2 RHEB Ras homolog enriched in brain RAS - superfamily GTP-binding protein Rheb 1.37269 0.00391466 
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MHC class I B2M beta-2-microglobulin Generic receptor  1.37655 0.00262384 




Bone morphogenetic protein receptor type-1A 1.37717 0.00542215 
FAP-1 PTPN13 protein tyrosine phosphatase, non-
receptor type 13 
Generic 
phosphatase 
Tyrosine-protein phosphatase non-receptor 
type 13 
1.37852 0.0181538 
IGF-1 receptor IGF1R insulin like growth factor 1 receptor Receptor with 
enzyme activity 
Insulin-like growth factor 1 receptor 1.38488 0.00124826 
Dynorphin A(1-13) PDYN prodynorphin Receptor ligand Dynorphin-A(1-13) 1.38832 0.00114984 
Leu-enkephalin PDYN prodynorphin Receptor ligand Leu-enkephalin 1.38832 0.00114984 
Proenkephalin-B PDYN prodynorphin Receptor ligand Proenkephalin-B 1.38832 0.00114984 
Caspase-8 CASP8 caspase 8 Generic protease Caspase-8 1.39804 0.0119021 
ESR2 ESR2 estrogen receptor 2 Transcription factor Estrogen receptor beta 1.40974 0.0236654 







Rac1 RAC1 ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
RAS - superfamily Ras-related C3 botulinum toxin substrate 1 1.43303 0.00759662 
MRLC MYL12B myosin light chain 12B Generic binding 
protein 
 1.50417 0.000444727 
Adenylate cyclase ADCY1 adenylate cyclase 1 (brain) Generic enzyme  1.52523 2.81187E-06 
Adenylate cyclase 
type I 
ADCY1 adenylate cyclase 1 (brain) Generic enzyme Adenylate cyclase type 1 1.52523 2.81187E-06 
KIR2DL1 KIR2DL1 killer cell immunoglobulin like receptor, 
two Ig domains and long cytoplasmic 
tail 1 
Generic receptor Killer cell immunoglobulinlike receptor 2DL1 1.84246 0.022848 
KIR2DL2 KIR2DL2 killer cell immunoglobulin like receptor, 
two Ig domains and long cytoplasmic 
tail 2 
Generic receptor Killer cell immunoglobulinlike receptor 2DL2 1.84246 0.022848 
KIR2DL3 KIR2DL3 killer cell immunoglobulin like receptor, 
two Ig domains and long cytoplasmic 
tail 3 
Generic receptor Killer cell immunoglobulinlike receptor 2DL3 1.84246 0.022848 
KIR2DL4 KIR2DL4 killer cell immunoglobulin like receptor, 
two Ig domains and long cytoplasmic 
tail 4 
Generic receptor Killer cell immunoglobulinlike receptor 2DL4 1.84246 0.022848 
KIR2DL5 KIR2DL5A killer cell immunoglobulin like receptor, 
two Ig domains and long cytoplasmic 
tail 5A 
Generic receptor Killer cell immunoglobulinlike receptor 2DL5A 1.84246 0.022848 
 
 
Table 3: Parental versus ALDH-high A375 cells (Untreated) 
List Report 




Gene Name Object Type Description 
Signal p-value 
CCL2 CCL2 C-C motif chemokine ligand 2 Receptor ligand C-C motif chemokine 2 -2.36328 1.66572E-05 
p57 CDKN1C cyclin dependent kinase inhibitor 1C Generic binding 
protein 
Cyclin-dependent kinase inhibitor 1C -2.35549 7.53913E-07 
MHC class II HLA-DOA major histocompatibility complex, class 
II, DO alpha 
Generic receptor  -1.88445 1.96402E-05 
MMP-13 MMP13 matrix metallopeptidase 13 Metalloprotease Collagenase 3 -1.81956 0.00133048 
MEF2C MEF2C myocyte enhancer factor 2C Transcription factor Myocyte-specific enhancer factor 2C -1.72111 0.000499586 
TRAF1 TRAF1 TNF receptor associated factor 1 Generic binding 
protein 
TNF receptor-associated factor 1 -1.56675 0.000152341 
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MEK6(MAP2K6) MAP2K6 mitogen-activated protein kinase kinase 
6 
Protein kinase Dual specificity mitogen-activated protein 
kinase kinase 6 
-1.5054 3.59244E-05 
eIF4A EIF4A2 eukaryotic translation initiation factor 
4A2 
Generic enzyme  -1.46238 0.000581214 
MHC class II HLA-DOB major histocompatibility complex, class 
II, DO beta 
Generic receptor  -1.43366 0.0276582 
Osteopontin SPP1 secreted phosphoprotein 1 Receptor ligand Osteopontin -1.37772 1.37342E-05 
GAB1 GAB1 GRB2 associated binding protein 1 Generic binding 
protein 
GRB2-associated-binding protein 1 -1.36772 0.0477614 
Histone H4 HIST1H4A histone cluster 1, H4a Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4B histone cluster 1, H4b Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4C histone cluster 1, H4c Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4D histone cluster 1, H4d Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4E histone cluster 1, H4e Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4F histone cluster 1, H4f Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4H histone cluster 1, H4h Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4I histone cluster 1, H4i Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4J histone cluster 1, H4j Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4K histone cluster 1, H4k Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST1H4L histone cluster 1, H4l Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST2H4A histone cluster 2, H4a Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST2H4B histone cluster 2, H4b Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
Histone H4 HIST4H4 histone cluster 4, H4 Generic binding 
protein 
Histone H4 -1.3674 0.000812007 
CD40(TNFRSF5 
) 
CD40 CD40 molecule Generic receptor Tumor necrosis factor receptor superfamily 
member 5 
-1.36382 0.0110669 




 -1.36311 0.00139958 
PLP1 PLP1 proteolipid protein 1 Generic binding 
protein 
Myelin proteolipid protein -1.35525 0.0103633 
MHC class II HLA-DMB major histocompatibility complex, class 
II, DM beta 
Generic receptor  -1.35184 3.44602E-05 
von Willebrand 
factor 
VWF von Willebrand factor Receptor ligand von Willebrand factor -1.3206 0.0210621 
Fc gamma RII alpha FCGR2A Fc fragment of IgG receptor IIa Generic receptor Low affinity immunoglobulin gamma Fc 
region receptor II-a 
-1.31836 0.00296042 
VDR VDR vitamin D (1,25- dihydroxyvitamin D3) 
receptor 
Transcription factor Vitamin D3 receptor -1.31617 0.00300324 
c-Maf MAF MAF bZIP transcription factor Transcription factor Transcription factor Maf -1.30398 0.021578 
Frizzled FZD4 frizzled class receptor 4 GPCR  -1.30301 0.0233367 
COL1A1 COL1A1 collagen type I alpha 1 Generic binding 
protein 
Collagen alpha-1(I) chain -1.29164 0.0279799 
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Adenylate cyclase ADCY6 adenylate cyclase 6 Generic enzyme  -1.28938 0.00835718 




 -1.28614 0.00403004 




Platelet-derived growth factor receptor beta -1.28614 0.00403004 
Follistatin FST follistatin Generic binding 
protein 
Follistatin -1.2848 0.000024051 




 -1.28221 0.0177006 
CDK6 CDK6 cyclin dependent kinase 6 Protein kinase Cyclin-dependent kinase 6 -1.27706 0.00107739 
MLCK MYLK myosin light chain kinase Protein kinase  -1.2671 0.00395734 
MYLK1 MYLK myosin light chain kinase Protein kinase Myosin light chain kinase, smooth muscle -1.2671 0.00395734 
TAB1 TAB1 TGF-beta activated kinase 1/MAP3K7 
binding protein 1 
Generic binding 
protein 
TGF-beta-activated kinase 1 and 
MAP3K7binding protein 1 
-1.2654 0.00263249 
p38 MAPK MAPK11 mitogen-activated protein kinase 11 Protein kinase  -1.25439 0.0342748 
p38beta  
(MAPK11) 
MAPK11 mitogen-activated protein kinase 11 Protein kinase Mitogen-activated protein kinase 11 -1.25439 0.0342748 
NGF NGF nerve growth factor Receptor ligand Beta-nerve growth factor -1.25013 0.0141866 
MHC class II HLA-DPB1 major histocompatibility complex, class 
II, DP beta 1 
Generic receptor  -1.24615 0.0241933 




 -1.24373 0.0308373 
MHC class II HLA-DMA major histocompatibility complex, class 
II, DM alpha 
Generic receptor  -1.23692 0.00037169 
PKC PRKCZ protein kinase C zeta Protein kinase  -1.22047 0.0013793 
MHC class II HLA-DRA major histocompatibility complex, class 
II, DR alpha 
Generic receptor  -1.214 0.0283084 
MHC class II HLA-DQA1 major histocompatibility complex, class 
II, DQ alpha 1 
Generic receptor  -1.21032 0.00112998 
Adenylate cyclase ADCY1 adenylate cyclase 1 (brain) Generic enzyme  -1.18377 0.00169305 




 -1.17906 0.0275376 
Histone H2 HIST1H2AC histone cluster 1, H2ac Generic binding 
protein 
 -1.17575 0.033901 
p38 MAPK MAPK12 mitogen-activated protein kinase 12 Protein kinase  -1.17095 0.00706191 
MHC class II HLA-DPA1 major histocompatibility complex, class 
II, DP alpha 1 
Generic receptor  -1.16399 0.027006 




 -1.15891 0.0157553 
Histone H2 HIST1H2BH histone cluster 1, H2bh Generic binding 
protein 
 -1.14047 0.0249971 
SOS SOS1 SOS Ras/Rac guanine nucleotide 
exchange factor 1 
Regulators (GDI, 
GAP, GEF) 
 -1.10822 0.0208185 
p90Rsk RPS6KA1 ribosomal protein S6 kinase A1 Protein kinase  -1.09743 0.0387703 
WNT WNT2 Wnt family member 2 Receptor ligand  -1.09671 0.0484961 
Histone H2 HIST2H2AC histone cluster 2, H2ac Generic binding 
protein 
 -1.09121 0.0183897 
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MHC class II HLA-DRB3 major histocompatibility complex, class 
II, DR beta 3 
Generic receptor  -1.08555 0.0133047 
MHC class II HLA-DRB4 major histocompatibility complex, class 
II, DR beta 4 
Generic receptor  -1.08555 0.0133047 
MHC class II HLA-DRB5 major histocompatibility complex, class 
II, DR beta 5 
Generic receptor  -1.08555 0.0133047 
G-protein alpha-i 
family 
GNAI2 G protein subunit alpha i2 G-alpha  -1.07362 0.00354277 
Collagen IV COL4A4 collagen type IV alpha 4 chain Generic binding 
protein 
 -1.05384 0.0498416 




 1.1381 0.0477303 




eIF4A EIF4A1 eukaryotic translation initiation factor 
4A1 
Generic enzyme  1.18902 0.0112779 
PKC PRKCA protein kinase C alpha Protein kinase  1.19457 0.00355992 
Histone H2 HIST1H2BD histone cluster 1, H2bd Generic binding 
protein 
 1.22971 0.00741417 
PKC PRKD3 protein kinase D3 Protein kinase  1.25218 0.0170282 
EDNRA EDNRA endothelin receptor type A GPCR Endothelin-1 receptor 1.25971 0.0455197 
AP-1 FOSL1 FOS like 1, AP-1 transcription factor 
subunit 
Transcription factor  1.26072 0.00083762 
Fra-1 FOSL1 FOS like 1, AP-1 transcription factor 
subunit 
Transcription factor Fos-related antigen 1 1.26072 0.00083762 
KLF5 KLF5 Kruppel like factor 5 Transcription factor Krueppel-like factor 5 1.26959 0.00193235 
Histone H3 H3F3A H3 histone, family 3A Generic binding 
protein 
 1.27027 0.0349977 
Histone H3 H3F3B H3 histone, family 3B (H3.3B) Generic binding 
protein 
 1.27027 0.0349977 
BMP4 BMP4 bone morphogenetic protein 4 Receptor ligand Bone morphogenetic protein 4 1.27237 0.0042337 
G-protein alpha-i 
family 
GNAI1 G protein subunit alpha i1 G-alpha  1.27252 8.97476E-
05 




GCR NR3C1 nuclear receptor subfamily 3 group C 
member 1 
Transcription factor Glucocorticoid receptor 1.27334 1.09912E-
05 
GATA-1 GATA1 GATA binding protein 1 Transcription factor Erythroid transcription factor 1.27414 0.0193385 
SOS SOS2 SOS Ras/Rho guanine nucleotide 
exchange factor 2 
Regulators (GDI, 
GAP, GEF) 
 1.27712 0.00811183 
SNAIL1 SNAI1 snail family transcriptional repressor 1 Transcription factor Zinc finger protein SNAI1 1.27758 0.00712077 
LDLR LDLR low density lipoprotein receptor Generic receptor Low-density lipoprotein receptor 1.27923 0.00008782
1 
C/EBPbeta CEBPB CCAAT/enhancer binding protein beta Transcription factor CCAAT/enhancer-binding protein beta 1.27983 0.00025230
6 
TRAF2 TRAF2 TNF receptor associated factor 2 Generic binding 
protein 
TNF receptor-associated factor 2 1.28784 0.0323403 






Histone H2 HIST1H2BC histone cluster 1, H2bc Generic binding 
protein 
 1.29919 0.0160555 
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Histone H2 HIST1H2BE histone cluster 1, H2be Generic binding 
protein 
 1.29919 0.0160555 
Histone H2 HIST1H2BF histone cluster 1, H2bf Generic binding 
protein 
 1.29919 0.0160555 
Histone H2 HIST1H2BG histone cluster 1, H2bg Generic binding 
protein 
 1.29919 0.0160555 
Histone H2 HIST1H2BI histone cluster 1, H2bi Generic binding 
protein 
 1.29919 0.0160555 
SOX9 SOX9 SRY-box 9 Transcription factor Transcription factor SOX-9 1.30548 0.042592 
Cytochrome c CYCS cytochrome c, somatic Generic enzyme Cytochrome c 1.30676 0.0160318 
VEGF-A VEGFA vascular endothelial growth factor A Receptor ligand Vascular endothelial growth factor A 1.3092 0.00443429 
TGF-beta TGFB2 transforming growth factor beta 2 Receptor ligand  1.31177 0.0495434 
TGF-beta 2 TGFB2 transforming growth factor beta 2 Receptor ligand Transforming growth factor beta-2 1.31177 0.0495434 




 1.31212 0.0031542 
PDGF-A PDGFA platelet derived growth factor subunit A Receptor ligand Platelet-derived growth factor subunit A 1.31216 0.00039450
4 
Alpha-actinin ACTN2 actinin alpha 2 Generic binding 
protein 
 1.31256 0.00387745 




WNT WNT5A Wnt family member 5A Receptor ligand  1.32631 8.78136E-
06 
Ski SKI SKI proto-oncogene Generic binding 
protein 
Ski oncogene 1.33162 0.0187077 
PTHrP PTHLH parathyroid hormone-like hormone Receptor ligand Parathyroid hormone-related protein 1.33186 0.00043387 
p90Rsk RPS6KA2 ribosomal protein S6 kinase A2 Protein kinase  1.33239 0.00884093 
FSRP FSTL3 follistatin like 3 Generic binding 
protein 
Follistatin-related protein 3 1.3342 0.00020716
7 
SMAD6 SMAD6 SMAD family member 6 Transcription factor Mothers against decapentaplegic homolog 6 1.3376 0.00518022 
Bim BCL2L11 BCL2 like 11 Generic binding 
protein 
Bcl-2-like protein 11 1.3653 0.0252576 
AP-1 FOSL2 FOS like 2, AP-1 transcription factor 
subunit 
Transcription factor  1.36594 0.01046 
ETS1 ETS1 ETS proto-oncogene 1, transcription 
factor 
Transcription factor Protein C-ets-1 1.36672 0.00053754 
WNT WNT11 Wnt family member 11 Receptor ligand  1.37035 0.0215301 
Talin TLN2 talin 2 Generic binding 
protein 
 1.37124 0.00143352 
Bcl-2 BCL2 BCL2, apoptosis regulator Generic binding 
protein 
Apoptosis regulator Bcl-2 1.37145 0.00660047 
SMAD7 SMAD7 SMAD family member 7 Transcription factor Mothers against decapentaplegic homolog 7 1.3735 0.0013868 
EGR1 EGR1 early growth response 1 Transcription factor Early growth response protein 1 1.38222 0.000708757 
IL4RA IL4R interleukin 4 receptor Generic receptor Interleukin-4 receptor subunit alpha 1.3835 0.00375447 
MMP-1 MMP1 matrix metallopeptidase 1 Metalloprotease Interstitial collagenase 1.38518 0.000936588 
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EGFR EGFR epidermal growth factor receptor Receptor with 
enzyme activity 
Epidermal growth factor receptor 1.39085 0.0112142 
eIF4E EIF4E eukaryotic translation initiation factor 4E Generic binding 
protein 
Eukaryotic translation initiation factor 4E 1.40812 0.0168678 
SCUBE3 SCUBE3 signal peptide, CUB domain and EGF 
like domain containing 3 
Generic binding 
protein 
Signal peptide, CUB and EGF-like 
domaincontaining protein 3 
1.42369 0.000614548 
TIMP1 TIMP1 TIMP metallopeptidase inhibitor 1 Generic binding 
protein 
Metalloproteinase inhibitor 1 1.42794 1.17491E-06 
Fibronectin FN1 fibronectin 1 Receptor ligand Fibronectin 1.44107 0.000135032 
AP-1 JUN Jun proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor  1.46266 3.33637E-05 
c-Jun JUN Jun proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor Transcription factor AP-1 1.46266 3.33637E-05 
c-Jun/c-Fos JUN Jun proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor  1.46266 3.33637E-05 
Heme oxygenase 1 HMOX1 heme oxygenase 1 Generic enzyme Heme oxygenase 1 1.46526 1.99778E-05 




Triple functional domain protein 1.48572 2.28255E-05 
CYP24A1 CYP24A1 cytochrome P450 family 24 subfamily A 
member 1 
Generic enzyme 1,25-dihydroxyvitamin D(3) 24-hydroxylase, 
mitochondrial 
1.51113 0.0187962 
MAP2K5 (MEK5) MAP2K5 mitogen-activated protein kinase kinase 
5 
Protein kinase Dual specificity mitogen-activated protein 
kinase kinase 5 
1.51502 0.00417811 
Collagen IV COL4A1 collagen type IV alpha 1 chain Generic binding 
protein 
 1.51599 0.000878077 
FKHR FOXO1 forkhead box O1 Transcription factor Forkhead box protein O1 1.54368 2.99464E-05 
SHP-2 PTPN11 protein tyrosine phosphatase, non-
receptor type 11 
Protein phosphatase Tyrosine-protein phosphatase non-receptor 
type 11 
1.55187 0.02919 
Histone H2 HIST1H2AG histone cluster 1, H2ag Generic binding 
protein 
 1.58172 0.00195219 
Histone H2 HIST1H2AI histone cluster 1, H2ai Generic binding 
protein 
 1.58172 0.00195219 
Histone H2 HIST1H2AK histone cluster 1, H2ak Generic binding 
protein 
 1.58172 0.00195219 
Histone H2 HIST1H2AL histone cluster 1, H2al Generic binding 
protein 
 1.58172 0.00195219 
Histone H2 HIST1H2AM histone cluster 1, H2am Generic binding 
protein 
 1.58172 0.00195219 
Jagged1 JAG1 jagged 1 Receptor ligand Protein jagged-1 1.58718 1.62228E-06 
SLUG SNAI2 snail family transcriptional repressor 2 Transcription factor Zinc finger protein SNAI2 1.59851 3.98516E-05 
PAI1 SERPINE1 serpin family E member 1 Receptor ligand Plasminogen activator inhibitor 1 1.60385 5.49105E-05 
Neurofibromin NF1 neurofibromin 1 Regulators (GDI, 
GAP, GEF) 
Neurofibromin 1.65278 0.0100313 
AP-1 FOS Fos proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor  1.6562 0.00330321 
c-Fos FOS Fos proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor Proto-oncogene c-Fos 1.6562 0.00330321 
c-Jun/c-Fos FOS Fos proto-oncogene, AP-1 transcription 
factor subunit 
Transcription factor  1.6562 0.00330321 
ID2 ID2 inhibitor of DNA binding 2, HLH protein Transcription factor DNA-binding protein inhibitor ID-2 1.70344 1.43712E-05 
Amphiregulin AREG amphiregulin Receptor ligand Amphiregulin 1.71147 3.82709E-07 
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 1.74553 0.00216841 




 1.78839 0.00171406 
AP-1 FOSB FosB proto-oncogene, AP-1 
transcription factor subunit 
Transcription factor  1.80026 0.000011886 
FosB FOSB FosB proto-oncogene, AP-1 
transcription factor subunit 
Transcription factor Protein fosB 1.80026 0.000011886 
EGR2 (Krox20) EGR2 early growth response 2 Transcription factor E3 SUMO-protein ligase EGR2 1.85416 7.39307E-05 
BMP2 BMP2 bone morphogenetic protein 2 Receptor ligand Bone morphogenetic protein 2 1.85652 4.92344E-05 
COX-2 (PTGS2) PTGS2 prostaglandin-endoperoxide synthase 2 Generic enzyme Prostaglandin G/H synthase 2 2.59037 7.57152E-07 
 
 
Figure 28: Principle component analysis and sources of variation resulting from genome-wide 
microarray analysis.  Parental A375 cells (red) were compared to ALDHhigh A375 cells (blue).  The 
response to Lunasin treatment in A375 (purple) and A375 ALDHhigh cells (green) was also compared (A).  
The largest source of variation between the experimental groups was cell type (parental vs ALDH) 
followed by treatment (vehicle vs Lunasin).  Technical replicates and human error accounted for 
comparatively little variation with F-ratios of 1.22 and 1.00, respectively (B). 
 
Lunasin uptake correlates with expression of αV integrin subunits 
 Lunasin internalization is thought to be dependent upon endocytic mechanisms involving integrins 
[38].  A375 cells, which overexpress the integrin αVβ3, were treated with vehicle or 100 μM Lunasin, and 
analyzed for colocalization of integrin subunits and Lunasin at several time points ranging from 4 to 24 h.  
It was observed that Lunasin is abundantly internalized in A375 cells, and present both in the cytoplasm 
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and the nucleus.  Interestingly, cell morphology was slightly altered at later time points in Lunasin-treated 
cells; a decrease in cell size as well as localization of integrins around the nucleus was observed in treated 
cells when compared to cells in control wells (Figure 29).  
B16-F10 CIC populations were reduced with Lunasin treatment 
 Previously, it was shown Lunasin reduced ALDH-expressing populations of cells in A375 and 
SK-MEL-28 melanoma cell lines (Chapter 3, Figure 11) concomitant with a decreased ability of these cells 
to form oncospheres (Chapter 3, Figure 12) when plated in anchorage-independent culture conditions in 
serum-free media [228].  To determine if this is the case with a murine model of melanoma, these 
experiments were repeated using the aggressive mouse-derived melanoma line B16-F10 (Figure 30).  
Treatment with 100 μM Lunasin reduced oncosphere formation by 29% (p = 0.005).  Representative 
images taken at 7 days post-treatment show the inhibitory effect of Lunasin on oncosphere formation 
(Figure 30A).  Additionally, a decrease in the ALDHhigh population when cells were treated with 100 μM 
Lunasin for 24 h was observed.  Treatment reduced the mean percentage of ALDH-positive B16-F10 cells 
from 8% in the control samples to 1.9% in the Lunasin-treated samples (p = 0.029).  The 4-fold decrease in 
ALDHhigh cells is depicted in a representative series of flow cytometry dot-plots (Figure 30C) showing 
DEAB, Control, and Lunasin-treated samples.  Three populations with varying degrees of ALDH activity 
exist within parental B16-F10 cells (Figure 30C); an ALDH-negative population represented at the left of 
each dot-plot, an ALDHlow population that displays a baseline expression of ALDH activity (i.e. these cells 
are ALDH-positive, but do not significantly shift in fluorescence intensity when exposed to ALDEFLUOR 
reagent in the absence of DEAB) represented by the population of cells clustered at a slightly higher 
intensity than the ALDH-negative population, and an ALDHhigh population (at least a one-log shift in 
fluorescence intensity over DEAB controls) represented by the cells in the gated compartment on the right 





Figure 29: Lunasin is readily internalized in A375 melanoma cells.  A375 cells treated with Lunasin for 
up to 24 h internalized Lunasin, which was found to colocalize with integrin αV subunits.  Additionally, 
nuclear localization of Lunasin was observed after 4 h, and Lunasin persisted in cells up to 24 h post-
treatment. Florescence intensity of clustered integrin subunits was higher around the nucleus in Lunasin-
treated cells when compared to vehicle-treated cells where integrin αV subunits appeared on the periphery 
of A375 cells.  These results demonstrate that Lunasin was readily internalized in A375 cells, and may 
support a mechanism in which Lunasin is internalized with integrin αV subunits.  Representative images 
from three independent experiments were used, and were taken at 40x magnification.  (Blue = dapi, green = 




Figure 30: Lunasin disrupted oncosphere formation and reduces ALDHhigh populations.  B16-F10 
ALDHhigh cells were plated in low adherent culture in stem cell media and allowed to form floating 
oncospheres.  When media was amended with 100 μM Lunasin, a significant decrease in oncosphere 
formation compared to control samples was observed (A, B).  V = vehicle, L = Lunasin.  ALDH activity 
was measured as described in Section 2.5.  When B16-F10 cells were treated with Lunasin, a significant 
reduction in cells displaying the ALDHhigh phenotype was observed (C,D).  Figures represent data obtained 
from three independent experiments and are shown as mean ± s.d.  Statistical significance (p < 0.05) was 
determined by student’s t-test and denoted by an asterisk (*).  
 
Lunasin inhibits invasion of ALDHhigh melanoma stem cells in vitro 
 A375 and B16-F10 cells were sorted to isolate populations with elevated ALDH activity.  These 
cells were pretreated with 100 μM Lunasin for 24 h, and subsequently replated in the upper chamber of 
transwell inserts containing serum-free DMEM/F12 media amended with PB or Lunasin.  After adding 
media containing 10% FBS to the lower chamber, plates were incubated for 24 h, and the cells invading 
through the Matrigel basement membrane were counted.  Invasion of A375 and B16-F10 ALDHhigh was 
significantly inhibited in Lunasin-treated wells compared to vehicle-treated wells resulting in a 57% (p = 
0.02) and 60% (p = 0.04) decrease in invading cells, respectively (Figure 31A).  Representative images 
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showing the Toluidine-stained invading cells from the bottom of the inserts illustrate the antimetastatic 
effects of Lunasin in vitro (Figure 31B).   
 
Figure 31: CIC invasion was suppressed in Lunasin-treated cells.  In vitro invasion assays demonstrate 
that Lunasin-treated A375 and B16-F10 ALDHhigh cells had less invasive capacity than cells treated with 
vehicle (A).  A375 and B16-F10 ALDHhigh cells were plated in the upper compartment of a Boyden 
chamber, and allowed to migrate through a Matrigel-coated insert (8 μm pore size) toward a 
chemoattractant as described in Section 2.19.  Invading cells were stained with toluidine blue and 
representative images are shown at 20x magnification (B).  Five fields from each insert were counted and 
the mean number of stained cells per field in Lunasin-treated wells was normalized to the mean number of 
invading cells in vehicle-treated wells.  The normalized values were expressed as percent (%) control.  Data 
from three independent experiments are shown as mean ± s.d.  Statistical significance was determined by 
student’s t-test and is denoted by an asterisks.   
 
Lunasin abrogates pulmonary metastasis in vivo 
 To test whether Lunasin’s antimetastatic effects would persist in vivo, a syngeneic mouse model 
using the B16-F10 cell line was employed.   This system was shown to represent an excellent model to test 
Lunasin’s efficacy in inhibiting tumor growth in xenograft experiments [275].  When 2.5x105 B16-F10 
cells were intravenously injected into C57Bl/6 mice, pulmonary seeding and subsequent tumor 
establishment occurred within 18 days.  Throughout the experiment, mice were dosed daily with vehicle or 
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Lunasin (30 mg/ kg) by i.p. injection.  Upon experimental endpoint, it was observed that Lunasin-treated 
mice had significantly reduced metastatic outgrowths when compared to control mice (Figure 32).  Mice in 
the control group averaged 45 (± 22) observable pulmonary lesions compared to only 9.5 (± 8) in Lunasin-
treated mice (Figure 32A).  These results were consistent with data obtained when observable microscopic 
lesions from randomized lung sections of control and Lunasin-treated mice were counted and measured 
(Figure 32B).  Representative images of lungs resected from metastasis-bearing mice in control (Figure 
32C) and Lunasin (Figure 32D) treatment groups are shown.  In addition, macrometastases were present in 
the lungs of all control mice (n = 10); however, lungs from 2 mice in the Lunasin group (n = 10) had no 
observable macrometastases.   
 Hematoxylin and eosin (H&E) stained lung sections also showed an observable difference in the 
average area of micrometastases between treatment groups.  Control mice had an average lesion area of 
31.6 mm2 compared to 10.3 mm2 in the Lunasin group (Figure 32B).  Micrometastases formed in the lungs 
of vehicle treated mice (Figure 32E) were larger and more abundant than in mice treated with Lunasin 
(Figure 32F).  Cellular morphology was similar between lesions derived from both control and Lunasin-
treated mice.  A subsequent graphic (Figure 33) which includes all pulmonary tissues resected from all 
mice in each treatment group (n = 20) is also provided.  The total number of observable macrometastases 
found on each set of lungs is provided in the bottom left corner of each image (Figure 33). 
 The decreased size and number of micrometastases present in Lunasin-treated animals led to the 
investigation of whether Lunasin has a significant effect on cell cycling in melanoma cell lines.  Although 
Lunasin has been shown to have an antiproliferative effect in NSCLC, no significant effect on cell cycle or 
cell viability (despite a modest increase in the G1 population) was observed when A375 or B16-F10 cell 
were treated with 100 μM Lunasin (Figure 34A-B).  Vemurafenib was used as a positive control and 




Figure 32: Lunasin reduced pulmonary metastases in vivo.  B16-F10 melanoma cells were injected i.v. 
into female C57BL/6 mice.  Lunasin-treated mice had less incidence of macrometastases (A) as well as 
significantly reduced average lesion area (B) as measured using ImageJ software.  Representative images of 
pulmonary tissues resected from control (C) and Lunasin (D) treated mice are shown.  H&E stained 
sections demonstrate the significant difference between average lesion area in vehicle (E) and Lunasin (F) 
treated mice.  Stained sections were imaged at 10x (left) and 40x (right), scale bar = 1 mm.  Graphs 
represent data plotted as mean ± s.e.m.  Means were determined to be statistically significant by student’s t-
test and significance is denoted by an asterisk. 
 
Lunasin antagonizes integrin signaling through FAK/AKT/ERK and inhibits histone acetylation 
 It was next investigated whether the effects of Lunasin on human and murine melanoma cells is 
related to the known effects of Lunasin on integrin signaling.  Immunoblot analysis showed that A375 and 
B16-F10 melanoma lines treated with Lunasin for 24 h had decreased phosphorylation patterns of FAK, 
AKT, and ERK.  When compared to ALDHlow cells, A375 ALDHhigh cells exhibited decreased AKT and 
ERK phosphorylation in Lunasin-treated cells (Figure 35A); both ALDHlow and ALDHhigh showed 
decreased FAK phosphorylation when treated with 100 μM Lunasin.  Integrin β1 engagement has been 
shown to activate auto-phosphorylation of FAK at Y397 [276, 277], thus, binding of Lunasin to the α-
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subunit (via Lunasin’s RGD motif) and the subsequent inhibition of β1 engagement with downstream signal 
transducers may cause the observed decreased in phosphorylation patterns.  Because β1 subunits dimerize 
with a plethora of α subunits (reviewed in [278]), the baseline phosphorylation may be due to the 
expression of various integrin heterodimers (e.g. α1β1) in melanoma cells.  Similarly, the β1 integrin subunit 
has been shown to phosphorylate AKT at S473 [279], suggesting a analogous mechanism to FAK 
activation. 
 In order to validate the effects of Lunasin on integrin signaling in CICs, PLA assays were used to 
investigate the interactions between integrin β subunits and the intracellular signal transducers ILK and 
pFAK (Y397).  Firstly, it was observed that Lunasin interacts with the integrin αV subunit of A375 
ALDHhigh cells (Figure 35B).  This interaction suppressed downstream interactions between β1 and β3 
integrin subunits with ILK and pFAK by approximately 40- 50% (Figure 35B and 35C).  These results are 
consistent with those seen in NSCLC models [10], and further confirm that the effects of Lunasin on 
melanoma CICs are, in part, due to altered integrin signaling pathways. 
 Immunoblot analysis for several phosphorylation sites corresponding to activation of FAK and 
AKT were conducted on A375 and B16-F10 ALDHhigh cells.  Phosphorylation of FAK at tyrosine residues 
Y397 and Y925 was inhibited when ALDHhigh cells were treated with Lunasin for 24 h (Figure 36A).  It 
was also observed that PI3K/AKT signaling was reduced in Lunasin-treated cells.  Lunasin treatment 
decreased phosphorylation of AKT at S473 and T308 as well as phosphorylated ERK1/2 at T202/Y204 
(Figure 36B).   
 Because Lunasin has been reported to have activity as a HAT inhibitor, it was also investigated if 
any histone acetylation marks may have been changed in Lunasin-treated cells.  Histones were isolated by 
acid extraction, and acetylation marks in H3 and H4 histone were assessed by immunoblot analysis.  It was 
previously reported that several acetylation marks were altered when NSCLC cells were incubated with 
Lunasin [10].  Interestingly, an observable change in a different set of acetylation marks in melanoma cells 
treated with Lunasin.  Lunasin treatment reduced histone acetylation at H3K9 and H4K12, while no 
difference was seen in acetylation of H4K8 and H3K14 (Figure 37).  The present data suggest that Lunasin 
modulates histone acetylation in melanoma cells resulting in decreased acetylation marks, which may lend 
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itself to the anticancer effects of Lunasin.  These results are consistent with previously published reports 
supporting a mechanism in which Lunasin disrupts histone acetylation at H3 and H4 histone tails [9, 10]. 
 
Figure 33:  Lungs resected from experimental metastasis in vivo model.  Lungs were resected from 
mice receiving vehicle (A) or Lunasin (B) treatment after implantation of B16-F10 cells.  Lunasin-treated 
mice displayed significantly less tumor burden in pulmonary tissues when compared to vehicle-treated 
mice.  The number of macrometastatic lesions observed for each set of lungs is shown in the bottom left of 
each image. 
 
 Interestingly, ALDHhigh and ALDHlow A375 cells had somewhat contrasting integrin expression 
profiles; ALDHhigh cells expressed integrin subunits αV and β3 more abundantly than ALDHlow cells when 
grown in anchorage independent culture, while ALDHlow cells seemed to express higher levels of α5 and β1 
integrin subunits (Figure 38).  These data may suggest a mechanism for the increased disruption of 
integrin-associated signaling in cells derived from ALDHhigh CICs when compared to cells from the non-
CIC compartment (i.e. ALDHlow). 
The RGD-domain is essential for Lunasin uptake and disrupting oncosphere formation 
 Immunoblot analyses implicated suppression of integrin signaling and effects on histone 
acetylation as being important for Lunasin action.  To investigate whether these mechanisms are required 
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for Lunasin activity, peptides were synthesized in which the RGD domain or poly-D tail were mutated in 
order to disrupt Lunasin’s interaction between integrins or histones, respectively.  The generation of 
oncospheres was utilized as a surrogate assay to identify the effect of Lunasin on CIC clonogenicity.  No 
difference in the ability of A375 ALDHhigh cells to form oncospheres between vehicle-treated cells and cells 
treated with RAD-mutated peptide was observed.  Conversely, cells treated with native Lunasin (p < 0.001) 
and the scrambled tail peptide (p = 0.0013) had a significantly reduced ability to form oncospheres in 
anchorage-independent culture (Figure 39).  These data suggest that the RGD domain, which interacts with 
integrins, is necessary for preventing sphere formation by CICs.   
 
Figure 34:  Cell cycle was not significantly affected by Lunasin.  A375 (A) and B16-F10 (B) ALDHhigh 
cells were treated with 100 μM Lunasin, and stained with PI for analysis of cell cycle.  No significant 
difference in populations in G1, S-phase, or G2/M was observed with Lunasin treatment compared to 
control in either cell line.  A representative image shows the cell cycle curve for control, Lunasin, and 
vemurafenib (positive control) as analyzed using FlowJo cell cycle analysis software.  Data were obtained 
from three independent experiments and shown as mean ± s.d.  Statistical significance was determined by 
student’s t-test (p < 0.05), and significant values are denoted by an asterisk (*).   
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 An endocytic mechanism by which Lunasin is internalized has been reported in human 
macrophages [38].  Since the RGD domain appears to be necessary for Lunasin’s disruption of oncosphere 
formation, it was next asked whether or not the RGD domain was essential for Lunasin’s internalization.  
A375 cells, which express the RGD-recognizing integrin subunits αV and α5, were treated with 100 μM 
native Lunasin (Figure 40A) or RAD-Lunasin (Figure 40B) for 5, 10, 30, and 60 min.  Cells were fixed and 
probed for Lunasin using a rabbit polyclonal antibody which was confirmed to recognize the mutated 
peptide sequence.  Although Lunasin was detected intracellularly in cells treated with both native and 
RAD-mutated peptides, fluorescent intensity was much higher in cells treated with native Lunasin 
compared to RAD-Lunasin.  Interestingly, RAD-Lunasin never localized in the nucleus, while the native 
peptide was observed in the nucleus after 10-30 m.  These data support the notion that Lunasin’s 
internalization is integrin-dependent, and may explain why the RGD domain is an integral part of Lunasin’s 
anticancer activity. 
 
Figure 35: Lunasin suppressed integrin signal transduction.  ALDHhigh and ALDHlow cells derived from 
the A375 melanoma cell line were treated with 100 μM Lunasin in low adherent culture for 24 h, and the 
resulting lysates were probed for integrin-associated signaling proteins (A).  Reductions in phosphorylation 
patterns of FAK, AKT, and ERK in ALDHhigh cells were observed in Lunasin-treated ALDHhigh cells, while 
only a modest effect was observed on FAK phosphorylation in ALDHlow cells (A).  Actin was used as a 
reference protein.  Relative protein expression (normalized to control) is shown above corresponding 
bands.  Additionally, PLA assays were utilized to validate that Lunasin was targeting integrin signal 
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transduction (B).  A significant decrease (~40 – 50%) in fluorescence signals per cell were observed when 
interactions between integrins and ILK/pFAK were detected in vehicle and Lunasin-treated cells (C).  
These results suggest Lunasin decreased the interactions between integrin β subunits and the intracellular 





Figure 36: Lunasin inhibited phosphorylation of FAK, AKT, and ERK.  ALDHhigh cells derived from 
human A375 and murine B16-F10 melanomas were treated with Lunasin for 24 h, and the resulting cell 
lysates were subjected to SDS-PAGE and probed for integrin-associated signaling pathways.  Lunasin 
inhibited activating phosphorylations of FAK (A), AKT (B), and ERK (B) at several amino acid residues.  
Immunoblot analysis of integrin-associated pathways were performed in two independent experiments.  






Figure 37: Lunasin modulates histone acetylation.   It was observed that Lunasin treatment caused a 
decrease in histone acetylation at H3K9 and H4K12, which suggests epigenetic modification may play a 
role in Lunasin’s effects on melanoma CICs.  Histone acetylation was assessed by immunoblot and relative 
protein expression (shown above corresponding bands) was taken from analysis of two independent 
experiments. 
 
Figure 38:  Differential expression of integrin subunits by melanoma CICs.  A375 ALDHlow and 
ALDHhigh cells were isolated by FACS, and lysates were subjected to SDS-PAGE.  Integrin expression 
profiles show that ALDHhigh cells express higher levels of αV and β3 subunits when compared to ALDHlow 
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cells.  ALDHlow cells showed higher abundance of integrin α5 and β1 subunits when compared to samples 
from ALDHhigh cells.  
 
 
Figure 39: Lunasin’s RGD motif is essential for disrupting oncosphere formation.  Mutated peptides 
based on Lunasin’s activity domains were synthesized and used to treat A375 ALDHhigh cells in low 
adherent culture.  Vehicle-treated cells readily formed oncospheres, but native Lunasin disrupted 
oncosphere formation (A).  When the RGD sequence was mutated to RAD, Lunasin lost its ability to 
inhibit oncosphere formation, while a peptide containing a scrambled tail retained the ability to inhibit 
oncosphere generation (A).  Representative images taken at 10x (left) and 20x (right) demonstrate the 
ability of the peptide to inhibit oncosphere formation (B).  Averages from three independent experiments 
were plotted at mean ± s.d.  Statistical significance was determined by student’s t-test and denoted by an 






Figure 40:  Lunasin uptake is an integrin-dependent process.  RGD (A) and RAD (B) Lunasin peptides 
were incubated with A375 cells for various time points up to 1 h.  While some RAD-Lunasin was detected, 
cells treated with RGD-Lunasin (native) showed significantly more abundant intracellular Lunasin as 
illustrated by a significantly increased fluorescent signal (C).  Additionally, it was observed that native 
Lunasin with an intact RGD motif was localized in the nucleus of A375 cells after just 10 min, while RAD-
Lunasin was only detected in the cytoplasm at up to 1 h after treatment.  Images represent data obtained 
from two independent experiments, and is plotted as average fluorescence per cell ± s.d. Statistical 
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significance was determined by student’s t-test (p < 0.05).  An asterisk (*) denotes significance between 
RGD and RAD peptides at the respective time points. 
 
4.4 DISCUSSION 
 The findings that Lunasin reduced metastatic dissemination in vivo and invasion through Matrigel 
in vitro, support the unique hypothesis that RGD peptides may help alleviate patient relapse in malignant 
melanomas.  Chapter 4 shows that mechanisms previously described for Lunasin’s anticancer effects 
persist in melanoma models, and perhaps most importantly, are exacerbated in isolated CIC populations.  
Uptake and internalization of Lunasin in A375 cells was shown to be integrin-dependent and correlated 
with the expression of the integrin αV subunit.  Colocalization of Lunasin with integrin subunits was 
observed at several time points varying from 4 h to 24 h, and localization of Lunasin in both the cytoplasm 
and nucleus was observed for all time points.  These data are in agreement with previously reported studies 
on Lunasin’s interaction and uptake with specific integrin subunits [12, 38].  Interestingly, a morphological 
difference between A375 cells treated with Lunasin and vehicle was observed.  Intracellular localization of 
integrin αV in Lunasin-treated cells was observed, while integrin αV was found only on the periphery of 
vehicle-treated cells.  These data indicate that Lunasin was readily internalized in A375 cells, and support 
the previously described endocytic mechanism reported in human macrophages [38]. 
 The Davis lab has previously published results using human melanoma cell lines showing that 
Lunasin efficiently reduced pools of CICs based on the ALDH biomarker, and resulted in disrupted  
oncosphere formation when ALDHhigh cells were plated in stem cell media in anchorage-independent 
culture conditions [228] (described in Chapter 3, page 43).  Additionally, it was found that Lunasin induced 
expression of melanocyte-associated differentiation markers MITF and Tyrosinase (described in Chapter 3, 
page 46).  Low-MITF expressing populations in melanomas have been described to harbor a slow cycling 
stem-like population with intrinsic chemoresistant and tumorigenic properties [200].  It was recently 
reported that MITF regulates melanoma invasion through Rac/Rho GTPases [280], which supports 
previous evidence showing MITF is explicitly involved in melanoma progression [281, 282].  This is a 
particularly interesting discovery given the regulation of Rac1 by integrins [283].   
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 In the present study, a significant decrease in B16-F10 oncosphere generation was observed when 
cells were treated with 100 μM Lunasin concomitant with a significant decrease in the ALDH-positive 
population of cells, which has been reported to bear the CIC fraction responsible for tumor formation and 
metastasis [103].  When the in vitro invasive potential of A375 and B16-F10 ALDHhigh cells was measured, 
Lunasin-treated cells were significantly less capable of invading through the basement membrane when 
compared to vehicle-treated cells).  These data are in agreement with Lunasin’s effect on depleting 
ALDHhigh populations [228], which may be responsible for metastatic dissemination [103, 106, 228]. 
 When C57Bl/6 mice were subjected to an experimental metastasis model of melanoma using B16-
F10 cells, Lunasin treatment significantly suppressed the ability of these cells to invade and proliferate in 
the lungs.  Two mice in the Lunasin-treated group displayed no sign of macrometastases suggesting that 
Lunasin was an effective treatment for reducing or abolishing metastatic burden altogether.  It was 
demonstrated that Lunasin inhibited subcutaneous tumor growth of murine models of melanoma and 
NSCLC [275].  Utilizing immunocompetent preclinical models of cancer allows researchers to explore the 
complex relationship between host immunity and tumor microenvironment; this especially holds true given 
the immunogenic nature of melanomas [136, 284].  It has been found that Lunasin has robust immune 
boosting effects, and may improve vaccine efficacy by promoting dendritic cell maturation [41, 42].  
Furthermore, Lunasin synergistically enhanced the cytotoxic effect of NK cells when combined with 
cytokine therapy [13].   The exciting possibility that Lunasin not only directly affects cells by reducing 
integrin signaling or histone acetylation, but can also “prime” the innate immune system to repress cancer 
cell proliferation illustrates the extremely promising benefits of the peptide that deserve further study. 
 As described in Chapter 3 [228], Lunasin has a selective effect on melanoma CICs compared to 
bulk tumor cells.  It was questioned whether these selective effects would persist when integrin signal 
transduction was evaluated.  Phosphorylations of FAK, AKT, and ERK, intracellular kinases downstream 
of integrins, were significantly reduced when A375 and B16-F10 cells were treated with Lunasin; A more 
robust effect was observed in the ALDHhigh cells when compared to the ALDHlow cells.  These mechanisms 
have been described in several cancer models including breast [227], colon [36], and lung cancer [10]; 
however, the Davis lab is the first to report that CICs are more sensitive to Lunasin’s integrin antagonism in 
melanoma.  Given the explicit involvement of FAK and AKT in carcinogenesis, progression, and 
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metastasis [195, 234], these results are promising especially taken in conjunction with the finding that 
Lunasin decreased CIC pools.   
 Lunasin sensitivity of A375 ALDHhigh and ALDHlow cells correlates with differential expression of 
specific integrin subunits when cultured as spheres in low-adherent conditions.  ALDHhigh cells expressed 
relatively higher amounts of αV and β3 integrin subunits, while ALDHlow cells expressed comparatively 
higher levels of α5 and β1 integrin subunits.  The complexities of integrin signal transduction mechanisms 
remain somewhat of a mystery; however, new research has revealed disparities in signaling coordinated 
though αvβ3 integrins and α5β1 [285, 286].  In fact, expression of specific integrins in stem cell-like cancer 
cells has been reported in other cancer models including prostate [196] and breast [198], which may reveal 
a potential weakness of CICs that provides a potential therapeutic target to specifically inhibit CIC 
expansion.   
 Histone acetylation by HATs (Reviewed in [287]) results in chromatin remodeling to allow for the 
initiation of transcription; efficient histone acetylation is necessary for replicative machinery to initiate 
transcription of target genes.  Thus, targeting HATs appears an attractive means to reduce cancer cell 
proliferation.  Lunasin’s activity as a HAT inhibitor has been described [20].  Histone acetylation in A375 
and B16F10 ALDHhigh cells was affected with Lunasin treatment; however, Lunasin induced different 
acetylation patterns in melanoma when compared to previously reported results in NSCLC [10].  Recently, 
it was shown that HAT inhibition preferentially induced apoptosis and inhibited stem-associated markers in 
a NSCLC model [288].  While an induction of apoptosis in melanoma was not observed, many of the 
results described in Chapters 3 and 4 parallel those obtained in this study, suggesting a potential link 
between suppression of CIC invasion and Lunasin’s epigenetic mechanisms. 
 The present study suggests that inhibition of integrin signaling is the primary mechanism 
mediating Lunasin’s effects in melanoma stem cells.  When the RGD domain of Lunasin was mutated, 
Lunasin lost its ability to disrupt oncosphere formation, a surrogate assay for stem cell identification and 
propagation.  Mutating the poly-aspartic acid tail seemingly had no effect on oncosphere formation.  This 
result implies that the poly aspartic acid tail is not required for inhibiting CIC clonogenicity; however, 
functional assays utilizing siRNA-mediated knockdown of both integrins and histone acetylation would 
provide a more suitable system to test this hypothesis.  Though supporting evidence shows that stem cells 
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can be maintained through integrin signaling [289], further research must be conducted to unequivocally 
determine that integrin antagonism is the sole mechanism for Lunasin’s reduction of the CIC compartment, 
especially given that CICs may also be maintained by histone acetylation [290].  This is particularly 
interesting considering that when p300, a HAT whose activity is antagonized by Lunasin [33], was knocked 
out in embryonic stem (ES) cells, Nanog expression was markedly reduced yet, self-renewal capacity (a 
function measured by oncosphere formation) was not significantly affected [291].  These results 
corroborate findings from a previous study [228] (described in Chapter 3, page 47) showing Lunasin 
treatment resulted in a significant reduction in Nanog levels; however, Lunasin treatment also robustly 
inhibited sphere formation, suggesting oncosphere formation may be integrin-dependent and independent 
of histone acetylation.  Crosstalk between integrin signaling and histone acetylation is relatively 
unexplored; though, evidence that integrin β1 engagement with ECM proteins may regulate H3 acetylation 
patterns has been described [292].  The complex signaling circuits between extracellular cues transduced 
through integrins, and intracellular events leading to changes in histone acetylation patterns is slowly 
unraveling; however, several key pieces of the puzzle remain.  Lunasin may serve as a key tool to bridge 
the gap between these two interesting and highly complex signaling pathways. 
 In summary, the present study found that Lunasin has robust antimetastatic properties in vitro and 
in vivo.  CICs, characterized by elevated ALDH activity, showed a greater disruption in integrin signaling 
induced by Lunasin treatment when compared to non-CICs as assessed by downstream activating 
phosphorylations of FAK and AKT.  In agreement with the studies described in Chapter 3, it was shown 
that B16-F10 cells exhibited Lunasin-dependent depletion of ALDHhigh populations, and disruption of 
oncosphere formation.  While Lunasin also altered histone acetylation patterns, Lunasin’s effects in 
melanoma appear to be largely an integrin-dependent process.  The present study extends upon the novel 
therapeutic approach that using Lunasin to reduce pools of CICs will ultimately lead to decreased invasion 
and subsequent metastatic outgrowths.  By modulating integrin signaling through FAK and PI3K/AKT 
pathways as well as altering histone acetylation patterns, Lunasin’s complex and multifaceted anticancer 
activities suggest a potential therapeutic utility against malignant diseases in which recurrence due to CICs 
is likely.  Given the results presented in this dissertation as well as those from others, a sufficient body of 
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evidence has been presented to examine the clinical utility of Lunasin as an antimetastatic agent in patients 




CHAPTER 5: DISCUSSION AND CONCLUSIONS 
5.1 Restatement of Specific Aims 
Specific Aim 1: Identify the mechanisms in which Lunasin targets CICs 
Sub Aim A. Assess the ability of Lunasin to reduce populations expressing CIC and stem-
associated markers 
Sub Aim B. Characterize the effects of Lunasin on CICs through analysis of proliferative, 
apoptotic, and differentiation markers 
Specific Aim 2: Evaluate the interaction between Lunasin and integrin subunits 
Sub Aim A. Specify the explicit integrin subunits interacting with Lunasin and identify the 
downstream mediators of integrin signal transduction 
Sub Aim B. Mutate the Lunasin peptide to discriminate the effects caused by histone 
acetyltransferase inhibition and integrin antagonism 
Sub Aim C. Genome-wide microarray analysis to discover Lunasin associated gene targets 
Specific Aim 3: Investigate the antimetastatic effects of Lunasin 
5.2 Summary of Findings and Impact of the Work 
 The overall aim of this dissertation was to investigate the therapeutic benefit that Lunasin may 
achieve in malignant melanomas, and identify the potential mechanisms driving its anticancer properties.  
Initially, it was demonstrated that Lunasin suppressed melanoma cell growth in 3D in vitro assays as well 
as in vivo.  In Chapter 3, these studies were expanded to describe the selective effects of Lunasin on CICs, 
identified by elevated ALDH activity. It was shown that Lunasin efficiently reduced ALDH-high 
populations, a subset of cells that harbor the stem cell-like population, and consequently inhibited the 
functional characteristics and self-renewal capabilities of these cells.  Mechanistically, Lunasin drastically 
decreased integrin signaling through FAK, AKT, and ERK while also inducing a differentiated phenotype 
with reduced expression of stem-associated markers.  Data presented in Chapter 4, investigated the 
antimetastatic effects of Lunasin on melanoma CICs, and elucidated the potential mechanisms underlying 
106 
 
Lunasin’s antimetastatic activity.  Given the significant involvement of CICs and integrin signaling in 
metastatic dissemination, this work aims to explain how Lunasin may be useful clinically in patients with 
malignant diseases.  This dissertation advances the potential utility of the novel therapeutic Lunasin which 
is largely unexplored and additionally, provides a compelling argument for the development of Lunasin, 
not only in melanoma, but malignant diseases in which CICs can produce refractory tumors. 
 The first aim of this work was to define the selective effects of Lunasin on CICs by assessing 
proliferation, apoptosis, and differentiation markers, and additionally, show that Lunasin induced a 
movement of cells out of the CIC compartment (defined by elevated ALDH activity) and into the non-stem 
compartment (i.e. ALDHlow).  The human melanoma cell lines A375 and SKMEL-28 had subpopulations of 
cells with both ALDHhigh and ALDHlow activity.  In both cell lines, Lunasin induced a shift of cells from the 
ALDHhigh compartment to the ALDHlow compartment without decreasing cell viability or cell cycling.  This 
phenotype switch was concomitant with an induction of melanocyte-associated differentiation markers 
MITF and its downstream target Tyrosinase.  A significant decrease in the stem-associated transcription 
factor NANOG was observed when melanoma cell lines were treated with Lunasin.  NANOG has been 
shown to control stemness and self-renewal properties of physiological stem cells as well as CICs [293].  
Perhaps the most interesting discovery from these initial studies is the fact that CICs were more sensitive to 
Lunasin when compared to parental cells in vitro.  This exacerbated effect on melanoma CICs persisted in 
vivo when nude mice were subcutaneously injected with parental and ALDHhigh A375 cells.  Lunasin’s 
safety profile was also quite promising; no cytotoxicity was observed in mice receiving i.p. injections of 
Lunasin at 30 mg/kg.  Liver and kidney functions were not significantly impaired, nor was a significant 
difference in CBC counts observed between mice receiving vehicle and Lunasin-treated mice. 
 To follow up the studies presented in Chapter 3, Chapter 4 questioned whether Lunasin’s effects 
on CICs were driven by the inhibition of integrin signaling; thus, the second aim of this dissertation was to 
describe the downstream effectors of integrin signal transduction which may be affected by Lunasin.  
Additionally, the work in Chapter 4 investigated the effects elicited by Lunasin on integrin antagonism and 
alterations in histone acetylation patterns.  It was revealed that Lunasin’s effects in melanoma cells was 
primarily integrin-driven, and integrin signal transduction through FAK, PI3K-AKT, and ERK was 
significantly suppressed when melanoma cells were treated with Lunasin.  The final sub-aim was to utilize 
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a genome-wide microarray screen in order to help reveal selective targets of Lunasin in CICs, but also to 
define a unique gene signatures between ALDHhigh melanoma cells and parental cells.  The datasets 
generated from the microarray analysis revealed the upregulation of EMT-associated genes in ALDHhigh 
populations along with several genes linked to invasion and metastasis.  Although Lunasin had a modest 
effect on both parental and ALDHhigh cells treated for 72 h, ALDH-sorted cells had nearly twice as many 
genes up- or down-regulated when compared to parental cells, which may indicate why isolated CIC were 
more sensitive to Lunasin.  Furthermore, this study validated the use of ALDH as a viable biomarkers for 
stem-like cells in melanoma models; ALDHhigh cells had increased expression of several genes associated 
with EMT and melanoma invasion. 
 Given the results presented in Chapter 3 and Chapter 4 describing the robust effects of Lunasin on 
depleting CIC pools and suppression of integrin signaling, it was hypothesized that Lunasin would have 
significant antimetastatic effects.  Therefore, the final aim of this dissertation was to investigate the 
proposed antimetastatic effects using an experimental metastasis model.  Boyden chamber assays using 
Matrigel coated inserts provided evidence that in vitro invasion was repressed when A375 and B16-F10 
ALDHhigh melanoma cells were pretreated with Lunasin.  Subsequently, a syngeneic murine model of 
metastasis was utilized to demonstrate that Lunasin’s antimetastatic effects were enduring in vivo.  A 
significant decrease in pulmonary colonization of B16-F10 cells was observed in Lunasin-treated mice 
when compared to mice receiving vehicle treatment.   
 Completion of these studies contributed significantly to the field of Lunasin research in several 
ways.  The Davis laboratory is the first to report on the anticancer effects of Lunasin in a melanoma model, 
and additionally, the first to report that CICs may be more sensitive to Lunasin’s inhibition of integrin 
signaling.  The present study also showed that functionally, the RGD domain of the Lunasin peptide is 
essential for Lunasin uptake as well as its disruption of oncospheres generated from isolated CICs.  This 
dissertation provides substantial evidence supporting that Lunasin has robust antiproliferative effects in 
subcutaneous xenograft models of melanoma as well as considerable antimetastatic effects in a syngeneic 
mouse model of experimental metastasis; studies which are largely lacking in the field of Lunasin research.  
Moreover, this work has created a foundation upon which future studies of Lunasin can draw from in 
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addition to provided concepts which could be further expanded upon.  These studies support the already 
solid body of evidence supporting the development of the Lunasin peptide as an anticancer therapeutic.  
5.3: Strengths and Weaknesses of the Dissertation 
 This dissertation has several strengths that have contributed significantly to understanding the 
mechanisms involved in the anticancer activities of Lunasin.  Using Lunasin to treat isolated CICs based on 
the ALDH biomarker is a novel strategy for the treatment of malignant disease in which CICs have been 
described.  Furthermore, the present study compared ALDHhigh samples to parental samples in order to 
differentiate the specific signaling pathways mediating Lunasin-sensitivity.  Evidence was provided which 
supports previous studies involving Lunasin’s interactions and uptake with specific integrin subunits, as 
well as expands upon the idea that Lunasin drives alterations in intracellular signaling cascades involving 
FAK, AKT, and ERK.  Not only do these studies define specific mechanisms implicated in Lunasin’s 
activity as a chemotherapeutic, but also support the concept that targeting CICs may provide an innovative 
intervention strategy for malignant diseases. 
 Another strength of the dissertation is the use of several preclinical in vivo murine models of 
cancer to demonstrate the ability of Lunasin to inhibit cancer progression in a living system.  
Immunocompromised mice were utilized to show that Lunasin robustly inhibits human melanoma 
proliferation in subcutaneous xenograft models of melanoma.  An immunocompetent syngeneic mouse 
model was also utilized to demonstrate that Lunasin significantly suppressed metastatic dissemination to 
pulmonary tissues of mice injected with the highly metastatic B16-F10 cell line.  Both 
immunocompromised and immunocompetent mouse models have distinct advantages and disadvantages.  
By using both types of murine models, this dissertation demonstrates that Lunasin has robust anticancer 
effects regardless of host immune status, or species from which the cancer cells are derived.   
 Although preclinical murine models can mimic human diseases, there are several distinct 
differences between model organisms and humans.  Firstly, subcutaneous xenografts do not recapitulate the 
correct microenvironment from which a human tumor will arise.  Although the human condition cannot be 
exactly recapitulated in murine models, certain cellular processes such as angiogenesis or proliferation can 
somewhat be observed within the tumor microenvironment; however, these model are lacking the 
interactions typically reserved between tumor stroma and surrounding tissues.  Additionally, these studies 
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cannot accurately mimic the de novo formation of tumor cells; nor do subcutaneous tumors readily progress 
to malignant disease, therefore, limiting subcutaneous models to essentially measuring in vivo tumor 
proliferation, but not progression. 
 Experimental metastasis models have the advantage of being quick, easy, and reproducible.  Yet, 
injecting tumor cells intravenously does not account for the early cellular changes involved in metastatic 
dissemination.  Because these cells are already in systemic circulation, this model avoids important 
processes involved in metastasis including invasion of surrounding tissues and extravasation.  While 
melanomas commonly metastasize to the lungs, experimental metastasis models are generally confined to 
producing pulmonary lesions and do not allow for colonization of other common metastatic sites such as 
the brain, bone, or lymph nodes. 
 The lack of positive controls for several in vitro assays is another source of potential error.  In 
order to determine if the assay(s) is working correctly, positive controls must be included in the analysis of 
apoptosis, proliferation, and invasion.  For Annexin V binding assays and immunoblot analysis of 
apoptosis-associated proteins, a positive control (e.g. staurosporin) should have been included.  
Additionally, the inclusion of an agent known to inhibit proliferation of melanoma cells (e.g. vemurafenib) 
should have been included in the tetrazolium-based proliferation assays.  Many of these controls were used 
in prior experiments to demonstrate that the assays were performing as expected; however, were not 
included in the representative experiments shown in this dissertation.  The absence of such controls lowers 
the potential impact of such studies, and should be included in any future studies.  Furthermore, many 
assays utilizing PB (the vehicle in which Lunasin is dissolved) as a control would benefit from the addition 
of an RGD tripeptide control.  The simple addition of this tripeptide as a control would potentially explain 
if perhaps Lunasin’s activity is significantly higher due to mechanisms other than those associated with its 
RGD domain.  Several experiments in which immunoblot analysis revealed a significant impact on 
integrin-associated signal transduction would have benefitted from the inclusion of several concentrations 
of Lunasin; the addition of multiple treatment groups would demonstrate whether or not the observed 
effects were dose-dependent.  Furthermore, several techniques could have been used to definitively 
demonstrate that mutated peptides were interacting with integrin subunits including knockdown of integrins 
and subsequent Lunasin internalization, saturation binding assays, or competition binding assays.  The 
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addition of such an assay would strengthen the discussion on whether or not the RGD motif is necessary to 
Lunasin’s activity in melanoma cells. 
 Perhaps the most glaring weakness of this dissertation is the use of cell lines without employing 
any primary melanoma cultures.  Several disadvantages to using cell lines include: 1) the continual passage 
in culture can alter cellular phenotypes, 2) without genotyping the status of several critical genes involved 
in specific models of cancer (e.g. B-Raf) can be ambiguous, 3) cross-contamination and mycoplasma, and 
4) they do not accurately mimic primary cultures.  Although many of these problems can be avoided 
through simple testing procedures, purchasing from approved vendors, and using proper controls in 
experiments, using cell lines can be especially problematic when studying CIC populations.   
 While the experimental system used to identify changes in gene expression in the genome-wide 
microarray analysis was robust and technically sound, it is necessary to validate these results by qRT-PCR 
as well as determine the subsequent changes in protein levels.  Conversely, the inclusion of several 
technical replicates, sample integrity, and stringent analysis minimized any artifacts or false discoveries 
resulting from the array. 
 It was observed that ALDHlow cells derived from A375 and SKMEL-28 cell lines tended to 
“dedifferentiate” into ALDHhigh cells when grown in culture (described in Chapter 3).  This is counter to 
some studies in which ALDH-sorted cells were isolated from primary melanomas; ALDHhigh cells could 
differentiate into ALDHlow cells, but ALDHlow cells did not generate ALDHhigh populations.  Whether this is 
a condition of using cells that have been propagated in culture, plasticity in ALDHlow melanoma cells, or a 
“rebound” effect initiated by cells trying to recapitulate the balance of heterogeneous populations in 
parental cell lines remains unclear. 
5.4: Future Studies 
 The questions answered in this work, while significant to the field of Lunasin, created several new 
questions that will need to be investigated to obtain a more thorough understanding of the novel 
mechanisms described in CICs as well as the role they play in tumorigenesis and metastasis.  Listed below 
are several of these questions: 
1. What is the connection (if any) between integrin signaling and histone acetylation? 
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 While this study linked several of Lunasin’s effects in melanoma to integrin signaling, a 
significant change in histone acetylation patterns was also observed.  Without functional studies which 
manipulate integrin signaling and measure the resulting histone acetylation patterns (or vice versa), it is 
impossible to determine unequivocally that these effects are only driven by integrin signaling networks.  
Using peptides with mutated activity domains, it was shown that uptake and localization of Lunasin 
intracellularly was associated with the interaction between the RGD domain and integrins.  In RAD-
Lunasin-treated samples, a minimal fluorescent signal was observed when probing for Lunasin.  However, 
some Lunasin in the cytoplasm was observed, which may suggest an alternative mechanism for Lunasin 
internalization. 
2. What are the pharmacokinetic properties of Lunasin? 
 Lunasin has been shown to be bioavailable in men consuming applicable amounts of soy protein; 
however, kinetic profiling of Lunasin in vivo has been a rather unexplored field.  Obtaining metabolomics 
data in a relevant system is paramount to developing any therapeutic.  Because this study used 
comparatively high concentrations of Lunasin in vitro, many questions arise to the practicality and 
correlation to achievable concentrations in vivo.  While the authors digress that Lunasin’s kinetic properties 
are unknown, several biologics including peptide therapeutics and monoclonal antibodies are dosed at 
similar ranges to the in vivo studies in this work which utilized Lunasin at a concentration of 30 mg/kg.  
More importantly, robust anticancer effects were achieved using this dosing regimen while also observing 
minimal dose-limiting toxicity. 
3. What therapeutics could be used in conjunction with Lunasin to achieve a synergistic 
response? 
 Novel, first-line therapeutics to battle cancer are essential to the development and evolution of 
chemotherapy; however, several institutions are focusing on combination therapies to combat diseases 
traditionally treated with single agents; malignant melanomas are often treated with temozolomide as the 
only agent of the chemotherapeutic arm.  While these strategies may alleviate some primary and secondary 
tumor growth, they simply are not effective in the long-term treatment of recurrent malignant diseases.  
Combination therapy allows for several advantages over traditional single agent approaches including less 
dose-associated toxicity, minimizing chemoresistance, and modulation of several oncogenic pathways.  
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Initial studies in the Davis laboratory have focused on utilizing molecules which affected histone 
acetylation in combination with Lunasin in order to induce a synergistic response in cancer cells.  While 
little positive data were obtained from these studies, they seem to support the hypothesis that Lunasin’s 
anticancer effects are primarily integrin-driven.  Indeed, combinations of vemurafenib and Lunasin resulted 
in an additive/ slightly synergistic interaction.  Because Lunasin does not induce apoptosis or inhibit 
proliferation in vitro, the authors do not foresee using the peptide as a stand-alone therapeutic; a real-world 
application of Lunasin as an adjuvant therapy seems much more likely.  
4. Does Lunasin target EMT-associated genes? 
 It was demonstrated that Lunasin repressed the invasive phenotype of melanoma CICs; however 
proteins associated with EMT were not explored in this study.  Since the experimental metastasis model 
used in this dissertation does not accurately mimic EMT and extravasation, it would be interesting to 
explore the modulation of EMT-associated genes that are potentially targeted by Lunasin.  For example, 
assessing the effect of Lunasin on Notch, TGF-β, Wnt/β-Catenin, and BMP signaling may provide a critical 
perspective in further describing mechanisms associated with Lunasin’s antimetastatic properties. 
5. How does Lunasin modulate the expression of differentiation-associated biomarkers? 
 A novel component of this study was revealing the activity of Lunasin on the induction of 
melanocyte-associated differentiation markers.  Several proteins can regulate MITF expression including 
AKT yet, a major unanswered question to this dissertation is how Lunasin induced MITF.  What upstream 
pathway(s) was associated with the observed effects on MITF protein expression?  Answering these 
questions would unravel the mechanisms behind Lunasin’s function as a differentiation-inducing agent, and 
perhaps the mechanisms behind the suppression of self-renewal capacity of CICs.  While it was shown that 
Lunasin treatment suppressed Nanog levels, it was not conclusively answered how Lunasin was inhibiting 
Nanog expression, and whether this effect was a result of altered integrin signaling, histone acetylation, or 
some other mechanism. 
6. Can Lunasin prevent UV-mediated melanomagenesis? 
 As several studies have shown, Lunasin has significant chemopreventive activity in chemical and 
viral oncogene-induced carcinogenesis [27].  In the case of melanoma, the greatest risk factor is ultraviolet 
(UV) exposure.  Examining the literature on Lunasin revealed that there have been no studies investigating 
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whether Lunasin’s chemopreventive activity would apply to a UV-induced model of carcinogenesis.  The 
data presented in this dissertation would indicate that Lunasin has significant antimelanoma effects, yet, 
this work did not test human melanocytes for any functional effects stemming from Lunasin treatment.  It 
would be interesting to see if the protective effects of Lunasin exist in melanocytes, or if the results 
observed in this work are due to dysregulated oncogenic signaling in melanoma cells.  Although several 
studies in NSCLC parallel these results, it would be interesting to assess whether these effects are tissue-
specific especially when considering the induction of melanocyte-specific transcription factors such as 
MITF.  
5.5: Final Summary and Conclusions 
 The overall aim of this work was to examine the mechanisms involved in the anticancer effects of 
the Lunasin peptide.  The work in Chapter 3 uncovered a novel function of Lunasin in that it can selectively 
target CICs based on the ALDH biomarker.  Additionally, it was demonstrated that Lunasin depleted pools 
of cells displaying elevated ALDH activity, a subpopulation which has been reported to harbor the stem 
cell-like population occurring in several malignant diseases.  These studies were extended upon by using in 
vivo xenograft studies to demonstrate that Lunasin has robust antiproliferative effects in preclinical 
melanoma models, and exhibited an excellent safety profile with no significant cytotoxicity.  Work 
completed in Chapter 4 confirmed that CICs were more sensitive to the antagonism of integrin signaling by 
Lunasin; however, Lunasin treatment also resulted in alterations of histone acetylation patterns.  
Mechanistically, the work presented in this dissertation showed that the RGD domain is necessary for rapid 
uptake of Lunasin as well as for inhibiting the self-renewal capacity of CICs.  Combining the concepts that 
Lunasin depleted pools of CICs and antagonizes integrin signaling, this study investigated the 
antimetastatic effects of Lunasin in vitro and in vivo.  Lunasin significantly reduced invasive potential of 
ALDHhigh CICs in vitro, and suppressed colonization of the lungs by B16-F10 cells in an experimental 
metastasis model.  Taken together, this dissertation highlights several mechanisms associated with 
Lunasin’s effects, and examines its potential clinical utility as an adjuvant therapy to minimize patient 
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AA Amino acid 
ABCB5 ATP-binding cassette sub-family B member 5 
AEBSF 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 
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ALT Alanine transaminase 
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BCL-2 B-cell lymphoma 2 
BMP2 Bone morphogenetic protein 4 
BMP4 Bone morphogenetic protein 4 
BRAF V-Raf murine sarcoma viral oncogene homolog B 
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CD20 Cluster of differentiation 20 (B-lymphocyte antigen 20) 
CD271 Cluster of differentiation 271 (low-affinity nerve growth factor receptor) 
CDK Cyclin-dependent kinase 
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EMT Epithelial to mesenchymal transition 
ERBB2 Erb-b2 receptor tyrosine kinase 2 
ERK Extracellular signal–regulated kinases 
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FACS Fluorescence-assisted cell sorting 
FAK Focal adhesion kinase 
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FN1 Fibronectin 1 
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GFP Green fluorescent protein 
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NOD/SCID Nonobese diabetic/severe combined immunodeficiency 
NSAID Non-steroidal anti-inflammatory drug 
NSCLC Non-small cell lung cancer 
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PBS Phosphate-buffered saline 





PI Propidium iodide 
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PLA Proximity ligation assay 
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RIN RNA integrity number 
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SEER Surveillance, Epidemiology, and End Results 
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T Threonine 
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TGF-β Transforming growth factor beta 
TGF-β3 Transforming growth factor beta 3 
TME Tumor microenvironment 
TNF Tumor necrosis factor 
TP73 Tumor protein p73 
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UV Ultraviolet 
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